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The aim of this thesis is to investigate the role of interleukin-13 (IL-13), a Th2
cytokine, in the induction of minimal change nephrotic syndrome (MCNS) using a
novel IL-13 overexpression rat model. Chapter 1 is a comprehensive literature review
on our current understanding of i) the different aspects of IL-13 including its
physiological functions and pathological roles in different disease conditions, ii) the
characteristics and pathogenesis of MCNS, and iii) recent advances in podocyte
biology and its association with nephrotic syndrome. Chapter 2 is the “Materials &
Methods” section which outlines the principles of all the experimental procedures
used in this study. The complete protocols of all these experimental procedures are
described in detail in the “Appendix” section. Chapter 3 is a study on the effect of IL-
13 on the development of proteinuria and other clinico-pathological features of
MCNS. Rats overexpressing IL-13 developed varying degrees of proteinuria,
hypoalbuminemia and hypercholesterolemia with 17% of the IL-13 transfected rats
developing frank nephrotic syndrome. No significant pathological changes were
found in the glomeruli except for partial effacement of podocyte foot processes. Both
the clinical and pathological features found in the IL-13 transfected rats resembled
human MCNS. In chapter 4, we explored the mechanism of proteinuria in this IL-13
overexpression rat model by studying the effect of elevated level of serum IL-13 on
podocytes. Both the glomerular gene and protein expression of nephrin, podocin and
dystroglycan, which are podocyte-associated proteins important in maintaining the
glomerular filtration barrier, were found to be significantly decreased in the IL-13
transfected rats when compared to the control rats. This was paralleled by an increase
in the glomerular gene and protein expression of IL-4Ra, one of the IL-13 receptor
subunits, suggesting that IL-13 may act directly on the podocytes and cause the
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xdownregulation of these podocyte-associated proteins. Chapter 5 is an examination on
the association of proteinuria with the glomerular expression of B7-1, a co-
stimulatory signaling molecule on antigen presenting cells which has been implicated
in nephrotic syndrome. Both the gene and protein expression of B7-1 were found to
be significantly increased in the nephrotic rats when compared to the control rats. The
glomerular gene expression of B7-1 also correlated significantly with the serum levels
of IL-13 in the IL-13 transfected rats. Chapter 6 is a follow-up study focusing on the
effect of IL-13 on the cholesterol metabolic pathway. The gene expression of
enzymes and proteins involved in the metabolism of cholesterol were examined in
both in-vivo and in-vitro conditions. The gene expression of HMG-CoA reductase, the
rate limiting enzyme in the cholesterol synthetic pathway, was found to be
upregulated in the liver of the IL-13 transfected rats as well as in hepatocyte cell
culture incubated with recombinant IL-13. Chapter 7 is a summary and conclusion on
the results of this study. The role of IL-13 on the development of MCNS was re-
examined based on our initial hypothesis and results obtained from our IL-13
overexpression rat model. The similarities and differences between human MCNS and
our rat model were discussed.
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ACAT Acyl-CoA cholesterol acyltransferase
Apo-B Apolipoprotein-B
BSA Bovine serum albumin
CD2AP CD2 associated protein
cDNA Complementary DNA
CERP Cholesterol efflux regulatory protein
CNF Congenital nephrotic syndrome of the Finnish type
CoA Coenzyme A
Cp Crossing point
CTLA-4 Cytotoxic T-lymphocyte-associated antigen-4
CYP7A1 Cytochrome P450, family 7, subfamily a, polypeptide 1
ddH2O Double distilled water
DEPC Diethylpyrocarbonate




ELISA Enzyme linked immunosorbent assay
F-actin Filamentous actin
FBS Fetal bovine serum
FITC Fluorescein isothiocyanate
Frat-1 Frequently rearranged in advanced T cell lymphoma-1
FSGS Focal segmental glomerulosclerosis
FXR Farnesoid X receptor
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GBM Glomerular basement membrane
GM-CSF Granulocyte macrophage – colony stimulating factor
GN Glomerulonephritis
HBSS Hank’s balanced salt solution
HDL High-density lipoprotein







IL-4Ra Interleukin-4 receptor alpha
IL-13Ra1 Interleukin-13 receptor alpha 1
IL-13Ra2 Interleukin-13 receptor alpha 2
JAK Janus tyrosine kinase
LB Luria-Bertani
LCAT Lecithin cholesterol acyltransferase
LDL Low-density lipoprotein
LDLR Low-density lipoprotein receptor
LM Light microscopy
LPS Lipopolysaccharides
LXR Liver X receptor
mAB Monoclonal antibody
MCNS Minimal change nephrotic syndrome
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MHC Major histocompatibility complex
M-MLV Moloney murine leukemia virus
mRNA Messenger RNA
Ms Mouse
NEPH1 Nephrin homolog 1





PAGE Polyacrylamide gel electrophoresis
PAN Puromycin aminonucleoside
PAS Periodic acid-Schiff
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PCR Polymerase chain reaction
P-cadherin Proto-cadherin
PE Phycoerythrin
PI3K Phosphoinositide 3-OH kinase
PMA Phorbol myristate acetate
PMSF Phenylmethylsulfonyl fluoride
r Coefficient of correlation









RT-PCR Reverse transcription – Polymerase chain reaction
SD Standard deviation
SDS Sodium dodecylsulphate
SEM Standard error mean
SH2 Src homology 2
SNP Single nucleotide polymorphism
SRB-1 Scavenger receptor B-1
SREBP Sterol regulatory element binding protein
SRNS Steroid-resistant nephrotic syndrome
SSNS Steroid-sensitive nephrotic syndrome
STAT Signal transducer and activator of transcription
Taq Thermus aquaticus
TBE Tris borate EDTA
TBS Tris buffered saline
TCR T cell receptor
TE Tris-EDTA
TEM Transmission electron microscopy




TNF-a Tumor necrosis factor-alpha
Tyk Tyrosine kinase
VEGF Vascular endothelial growth factor
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VLDL Very low-density lipoprotein
VLDLR Very low-density lipoprotein receptor
VPF Vascular permeability factor
WT-1 Wilms’ tumor - 1
ZO-1 Zonula occludens-1
DocumentsPDFComplete










EU/mg Enzyme units per milligram
g Gram
g Gravity
g/24hr Gram per 24 hour
g/100g Gram per 100 gram








mg/24hr Milligram per 24 hour
mg/100g Milligram per 100 gram
mg/dL Milligram per decilitre
mg/ml Milligram per millilitre
ml Millilitre
ml/24hr Millilitre per 24 hour
DocumentsPDFComplete







mmol/L Millimole per litre









pg/ml Picogram per millilitre
pmole Picomole
rpm Revolutions per minute
s Second
U Unit
U/ml Unit per milliliter
U/ml Unit per microlitre
mg Microgram
mg/ml Microgram per millilitre
mg/ml Microgram per microlitre
ml Microlitre
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1.1.1 Source of IL-13
Interleukin-13 (IL-13) is a lymphokine produced by the Th2 subset of helper T cells.
IL-13 is not normally detectable in naïve human systems, but IL-13 production can be
induced in response to immunological challenge (McKenzie, Culpepper, de Waal
Malefyt et al, 1993; Minty et al, 1993). Although IL-13 is produced primarily by the
Th2 subset, it is also expressed by Th0 cell clones, Th1 cell clones and CD8+ T cell
clones (de Waal Malefyt et al, 1995). Mast cells (Burd et al, 1995) and natural killer
cells (Hoshino et al, 1999) have also been shown to secrete IL-13 upon stimulation
recently. In Hodgkin lymphoma, IL-13 is found to be secreted by, and stimulatory for
the growth of Reed-Sternberg cells (Kapp et al, 1999).
1.1.2 Gene and protein structure of IL-13
Human IL-13 gene is located on chromosome 5q31 (NCBI LocusLink Locus ID
3596). Mouse IL-13 gene is located on the syntenic region of chromosome 11 29.0cM
(NCBI LocusLink Locus ID 16163). Rat IL-13 gene is located at chromosome 10q22
(NCBI LocusLink Locus ID 116553). All these genes have four exons and three
introns and span approximately 4.6 kb, 4.3 kb and 3.8 kb for the human, mouse and
rat IL-13 gene respectively. The IL-13 gene is closely linked to the genes encoding
IL-4, IL-5, IL-3 and GM-CSF in humans (McKenzie, Li, Largaespada et al, 1993),
suggesting that IL-13 is another member of this cytokine gene family that may have
arisen by gene duplication. Indeed, the IL-13 gene maps approximately 12 kb
upstream of the IL-4 gene in the mouse and the human (Smirnov et al, 1995). The
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2coding region of rat IL-13 cDNA displays 74% and 87% sequence identity with the
coding regions of human and mouse IL-13 cDNA respectively. The deduced amino
acid sequence of rat IL-13 reveals 63% and 79% homology with the human and
mouse proteins respectively (Lakkis & Cruet, 1993) (Table 1.1). IL-13 is secreted as a
monomeric peptide of approximately 10 kDa. It contains 4 anti-parallel alpha helical
proteins similar to IL-4. This molecular mass increases with glycosylation, resulting
in a range of protein species with Mr of 14000-40000 (McKenzie, Culpepper, de Waal
Malefyt et al, 1993).
Table 1.1 Interspecies IL-13 sequence identity
Nucleotide identity
Amino acid identity Human Rat Mouse
Human --- 74% 66%
Rat 63% --- 87%
Mouse 58% 79% ---
(Adopted from: McKenzie ANJ, Matthews DJ. IL-13. In: Cytokine reference: A
compendium of cytokines and other mediators of host defense. Edited by Oppenheim
JJ, Feldmann M. Academic Press, San Diego, 2001, pp204.)
1.1.3 IL-13 receptors
There are two membrane-bound IL-13 binding proteins, IL-13 receptor alpha 1 (IL-
13Ra1) and IL-13 receptor alpha 2 (IL-13Ra2). The IL-13Ra1 protein has a
moderate affinity for IL-13 and requires the presence of IL-4 receptor alpha (IL-4Ra)
to form a high-affinity receptor complex (Hilton et al, 1996). IL-4Ra alone does not
bind IL-13 (Zurawski et al, 1995). Signaling through the IL-4Ra/IL-13Ra1 complex
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3initiates a JAK/STAT signaling cascade resulting in the activation of STAT6 (Lin et
al, 1995) and STAT3 (Orchansky et al, 1999). The cytoplasmic domains of IL-
4Ra/IL-13Ra1 complex, which is mainly expressed in non-hematopoietic cells,
interact with tyrosine kinases (Tyk) of the Janus kinase (JAK) family including JAK1
and JAK2 but not JAK3 (Murata et al, 1998). Phosphorylation of the JAK tyrosine
kinase leads to the recruitment and tyrosine phosphorylation of STAT6 (Nelms et al,
1999). Phosphorylated STAT6 then migrates into the nucleus and binds to consensus
sequences in the promoters of genes regulated by IL-4 and IL-13 (Pernis & Rothman,
2002). Transcription factors c-fos, c-jun, and c-myc have been shown to be
upregulated by IL-13 (Doucet et al, 1998). In contrast, IL-13Ra2 alone is a high-
affinity receptor for IL-13 but there is little evidence that this protein has signal
transduction properties (Orchansky et al, 1997). Instead, there is increasing evidence
showing that IL-13Ra2 is a decoy receptor for IL-13 (Yasunaga et al, 2003;
Yoshikawa et al, 2003) and acts to downregulate the effect of IL-13. Both IL-13Ra1
and IL-13Ra2 are members of the class I cytokine receptor family. They contain an
N-terminal immunoglobulin-like domain followed by a class I cytokine receptor
region including a WSXWS motif near the transmembrane domain. The human and
mouse IL-13Ra1 proteins have a cytoplasmic region capable of signal transduction
and contain Box 1 and Box 2 motifs. The main structural difference between the two
IL-13 receptors is that the IL-13Ra1 chain has a longer intracellular domain than IL-
13Ra2 (Hilton et al, 1996; Caput et al, 1996). IL-13 receptors are expressed on
human B cells, basophils, eosinophils, mast cells, endothelial cells, fibroblasts,
monocytes, macrophages, respiratory epithelial cells, and smooth muscle cells.
However, functional IL-13 receptor has not been demonstrated on human or mouse T
cells (Hershey, 2003).
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41.1.4 IL-13 and the immune system
IL-13 was first recognized for its effects on B cells and monocytes, where it
upregulated surface MHC class II antigen expression, promoted IgE class switching
and inhibited inflammatory cytokine production. Recombinant IL-13 stimulates the
proliferation of anti-IgM or anti-CD40 activated human B lymphocytes and induces
IL-4 independent IgG4 and IgE synthesis. It also induces the differentiation of human
monocytes into dendritic-like cells and upregulates the surface expression of MHC
class II antigens and the low-affinity receptor for IgE (CD23 or FceRII) on these cells
(McKenzie, Culpepper, de Waal Malefyt et al, 1993; Punnonen et al, 1993; Cocks et
al, 1993). Functional IL-13 receptors have not been demonstrated on human or mouse
T cells. Thus unlike IL-4, IL-13 does not appear to be important in the initial
differentiation of CD4+ T cells into Th2-type cells (Hershey, 2003). However, IL-13
is important in the modulation of Th2 cell development. Studies using IL-13 deficient
mice have identified impaired Th2 cell development in the absence of IL-13
(McKenzie, Emson, Bell et al, 1998). IL-13 has been shown to have anti-
inflammatory functions on monocytes and macrophages. IL-13 inhibits the production
of inflammatory cytokines such as IL-1b, IL-6, TNF-a and IL-8 by
lipopolysaccharides (LPS)-stimulated monocytes (Minty et al, 1993). In addition, by
inhibiting IL-12, IL-13 may also act to skew the T helper populations away from a
Th1 phenotype and towards a Th2 phenotype (Zurawski and de Vries, 1994).
It should be noted that IL-4 and IL-13 are closely related cytokines, as both of them
belong to the Th2 subset. They share many biological and immunoregulatory
functions on B lymphocytes, monocytes, dendritic cells and fibroblasts. Their genes
are closely linked in human, mouse and rat genomes, and there is sequence homology
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5between IL-13 and IL-4 proteins (Chomarat & Banchereau, 1998). The IL-4 and IL-
13 receptors are multimeric and share at least one common chain called IL-4Ra. Both
cytoplasmic tails of IL-4 and IL-13 receptor subunits associate with tyrosine kinases
of the Janus family. Activation of JAKs initiates a series of downstream signal
transduction events which leads to phosphorylation of STAT6, a transcription factor
that regulate genes’ expression (Kelly-Welch et al, 2003). This explains the striking
overlap of IL-4 and IL-13 induced biological activities such as regulation of antibody
production and inflammation.
1.1.5 Pathological role of IL-13
Apart from its effects on the haematopoietic cells of the immune system, IL-13 also
plays a role in a number of pathological conditions in the body. Studies on IL-13 have
been focused on its close relationship to asthma and allergic diseases. It has also been
involved in tissue fibrosis, tumor immunosurveillance, Hodgkin lymphoma and
resistance to parasites (Wynn, 2003).
IL-13, asthma and allergic diseases
Asthma is a complex inflammatory disease of the lung characterized by airway
hyperresponsiveness, subepithelial fibrosis, eosinophilic inflammation, mucus
hypersecretion and elevated IgE levels. It is believed to be a result of inappropriate
immune responses to common aeroallergens in genetically susceptible individuals.
There is mounting evidence that IL-13, independent from other Th2 cytokines, is the
central mediator of allergic asthma (Wills-Karp & Chiaramonte, 2003). Genetic
polymorphisms of the IL-13 gene have been linked to asthmatic phenotypes in
different populations throughout the world (Vercelli, 2002). IL-13 expression also
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6correlates strongly with the occurrence of allergic asthma and atopy and the
associated expression of IgE (Ghaffar et al, 1997; van der Pouw Kraan et al, 1998).
Recent studies using mouse models of experimental airway hypersensitivity have
demonstrated that IL-13 plays a central role in these responses, independent of IgE
and eosinophilia. Blocking of IL-13 activity has been shown to reverse airway
hyperresponsiveness and mucus production in allergen-challenged mice (Grunig et al,
1998; Wills-Karp et al, 1998).
IL-13 and resistance to gastrointestinal nematodes
Resistance to most gastrointestinal nematodes is mediated by Th2 cytokine responses,
where IL-13 plays a dominant role (Bancroft et al, 1998). Helminth parasites induce
strong Th2 responses that contribute to the mast cell, eosinophil, giant cell, IgE/IgA,
and mucus responses, which are critical for host resistance to infection (Finkelman et
al, 1997). IL-13 was shown to be important in the expulsion of N. brasiliensis by
itself, and of T. muris and H. polygyrus with the help of another Th2 cytokine, IL-4,
in rodents (Urban et al, 1998; Grencis, 2001). Administration of recombinant IL-13 to
IL-13 deficient mice or SCID mice resulted in improved expulsion of N. brasiliensis
from helminth-infected animals (Barner et al, 1998; McKenzie, Bancroft, Grencis et
al, 1998).
IL-13 and tissue fibrosis
IL-13 is a potent mediator of tissue fibrosis in both schistosomiasis and asthma, which
indicates that it is a key regulator of the extracellular matrix. Overexpression of IL-13
in the murine lung induces a dramatic fibrotic response in the airway wall (Zhu et al,
1999), concomitant with increases in matrix proteases such as matrix
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7metalloproteinase (MMP) and cathepsins which are thought to be important in
regulating matrix deposition (Zheng et al, 2000). Indirectly, neutralization of IL-13 by
soluble anti-IL-13Ra2 immunoglobulin was also shown to prevent parasite-induced
fibrosis in Schistosoma mansoni infection. The exact mechanism of how IL-13
induces tissue fibrosis is not clear, but upregulation of pro-fibrotic molecules such as
TGF-b by IL-13 has been proposed (Wen et al, 2002; Lee et al, 2001).
IL-13 and tumor immunosurveillance
An immune deviation towards Th2 leads to suppression of Th1 development (Sergio,
2000). Since the major mediators of anti-tumor immunity are CD4+ Th1 cells and
CD8+ cytotoxic T lymphocytes (Terabe et al, 2004), a shift towards Th2 production,
which includes IL-13, may be able to suppress tumor immunosurveillance. It has been
demonstrated that loss of natural killer (NK) T cells in CD1 knockout mice resulted in
decreased IL-13 production and increased resistance to recurrence. Thus NK T cells
and IL-13, possibly produced by NK T cells and signaling through the IL-4R-STAT6
pathway, are necessary for downregulation of tumor immunosurveillance (Terabe et
al, 2000). As such, inhibitors of IL-13 might be effective as cancer
immunotherapeutics by boosting type-1 associated anti-tumor defenses.
IL-13 and Hodgkin lymphoma
IL-13 expression is a feature of classical Hodgkin lymphoma. IL-13 and the IL-13
specific receptor chain IL-13Ra1 are frequently expressed in classical Hodgkin
lymphoma derived cell lines (Kapp et al, 1999) and in Reed-Sternberg (RS) cells from
biopsies of Hodgkin lymphoma tissue (Skinnider et al, 2001). IL-13 is found to be an
important autocrine growth factor in the stimulation of Hodgkin lymphoma and RS
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8cell growth. Neutralization of IL-13 in cultures of classical Hodgkin lymphoma
derived cell lines HDLM-2 and L-1236 leads to a dose-dependent inhibition of
proliferation, and is associated with increased apoptosis of L-1236 cells. IL-13
neutralization also decreased activation of STAT6, which is an important mediator of
IL-13 function. STAT6 is phosphorylated in RS cells of primary Hodgkin lymphoma
samples, supporting the hypothesis that IL-13 signaling occurs in these malignant
cells in-vivo (Skinnider, Kapp & Mak, 2001; Skinnider et al, 2002). Recently, the
soluble IL-13Ra2 decoy receptor has been shown to inhibit Hodgkin lymphoma
growth in-vitro and in-vivo (Trieu et al, 2004).
1.1.6 Transgenic model of IL-13
IL-13 transgenic mice, regulated by the human T cell promoter, showed elevated
serum levels of IgE but normal levels of other immunoglobulin isotypes.
Overexpression of IL-13 also perturbed the development of thymocytes but did not
affect significantly the composition of peripheral T cell populations (Emson et al,
1998). In contrast, IL-13 transgenic mice, regulated by the lung Clara cell promoter,
displayed an asthmatic phenotype which included mucous metaplasia, subepithelial
fibrosis, enhanced accumulation of tissue hyaluronic acid and upregulation of mucin
gene expression (Zhu et al, 2001). Further studies showed that this airway
inflammation and tissue fibrosis were largely mediated by monocyte chemotactic
protein 1 (MCP-1) through the binding of chemokine receptor 2 (CCR2) and was
associated with activated TGF-b1 (Elias et al, 2003). Interestingly, increased
expression of TGF-b1 was also observed in IL-4 transgenic mice which showed
glomerular hypertrophy and progressive mesangial sclerosis (Ruger et al, 1999).
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91.1.7 In-vivo administration of recombinant IL-13
Administration of recombinant IL-13 to naïve mice using an osmotic pump caused
monocytosis and splenomegaly. Histological examination of the spleen revealed
increased numbers of hematopoietic precursors such as erythroblasts and
megakaryocytes (Lai et al, 1996). Other studies have also demonstrated that in-vivo
administration of recombinant IL-13 can downregulate TNF-a production, but
enhance IL-6 expression (Di Santo et al, 1997).
1.1.8 Knockout model of IL-13
Knockout mice deficient in IL-13 showed lower basal levels of serum IgE,
impairment in the development of Th2 cells and reduced production of Th2 cytokines
from peripheral T cells (McKenzie, Emson, Bell et al, 1998). These mice were also
impaired in their ability to expel the parasitic gastrointestinal nematodes
Nippostrongylus brasiliensis and Trichuris muris (Bancroft et al, 1998).
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1.2.1 Definition of nephrotic syndrome
Nephrotic syndrome is a set of symptoms related to kidney dysfunction, and not a
disease, in and of itself. It can be caused by many different underlying diseases that
affect the kidneys and is characterized by proteinuria, hypoalbuminemia, oedema and
hypercholesterolemia. In humans, nephrotic-range proteinuria is usually defined as
the excretion of more than 3.5 gram of protein per 24 hours. The decrease in serum
albumin level is secondary to loss of protein in the urine. The underlying mechanism
in the majority of patients with nephrotic syndrome is a permeability defect in the
glomerular filtration barrier that allows the loss of protein from the plasma into the
urine. However, reduction in serum albumin concentration may also be due to a shift
in the fraction of total albumin mass from the plasma to the interstitial fluid resulting
from a diffuse abnormality in capillary permeability.
1.2.2 Classification and etiology of nephrotic syndrome
The causes of nephrotic syndrome can be divided into primary or secondary. In
primary nephrotic syndrome, the etiology is unknown. On the other hand, secondary
nephrotic syndrome is associated with diseases such as systemic lupus erythematosus,
Henoch-Schonlein purpura and diabetes mellitus. Nephrotic syndrome can also be
categorized histologically into minimal change disease, focal segmental
glomerulosclerosis (FSGS), membranous glomerulonephritis (GN), mesangial
proliferative GN and membranoproliferative GN.
In children, the major cause of primary nephrotic syndrome is minimal change
disease, and it occurs frequently between 18 months and 4 years of age, whereas in
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adults, the most common form of glomerulopathy causing nephrotic syndrome is
membranous GN, followed by FSGS. In the United States, the overall prevalence of
nephrotic syndrome in childhood is approximately 2-5 cases per 100,000 children.
The cumulative prevalence rate is approximately 15.5/100,000, and is more common
in boys than girls.
Idiopathic nephrotic syndrome in children is generally divided into steroid-sensitive
and steroid-resistant nephrotic syndrome, depending on the patient’s response to
steroid therapy. Most patients show a favorable outcome to this treatment, although
they may be subject to more or less frequent relapses of the disease. However, 10-
20% of patients fails to respond and may develop end-stage renal failure (Chesney,
1999).
There are two major histological varieties of the idiopathic nephrotic syndrome in
children – minimal change disease and FSGS. In minimal-change disease, no
structural lesions are seen in the glomeruli by light microscopy. In contrast, FSGS is
characterized by glomerular scarring that is focal (found only in some glomeruli) and
segmental (found only in some glomerular lobules). Minimal change disease and
FSGS can be viewed as two extremes of one spectrum and represent different stages
in the evolution of a single disease. Minimal-change disease is the more benign
variety and is usually sensitive to glucocorticoids, alkylating agents, and cyclosporine,
whereas FSGS is prognostically more sinister, less responsive to these therapies, and
frequently progresses to end stage renal failure (Ritz, 1994).
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With the decline in acute post-infectious glomerulonephritis in children in Singapore
over the past 15 years due to improving socioeconomic conditions (Yap et al, 1990),
idiopathic nephrotic syndrome is now the most common cause of significant
morbidity amongst childhood glomerulonephrities. In a study on the pattern of
glomerulonephritis in Singapore children (Table 1.2), the nephrotic syndrome formed
the major indication (67%) for a renal biopsy (Yap et al, 1989). The 2 most common
causes of childhood nephrotic syndrome are minimal change disease and focal
segmental glomerulosclerosis (FSGS). Up to 70% of children with minimal change
nephrotic syndrome (MCNS) will have multiple relapses, of which at least half will
require long-term steroid therapy or courses of cytotoxic drugs, with their attendant
adverse effects on growth and puberty, cataract formation, and risk of malignancy. On
the other hand, FSGS, which presents in early childhood, tends to follow a rather
“malignant” course, with rapid progression to end-stage renal disease, and a need for
the expensive options of dialysis and transplantation.
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Focal global sclerosis 20
Focal segmental glomerulosclerosis 17
Diffuse mesangial proliferative glomerulonephritis 11
Focal mesangial proliferative glomerulonephritis 9
Membranous glomerulonephritis 7
Diffuse endocapillary glomerulonephritis 4
Diffuse sclerosing glomerulonephritis 4
Diffuse mesangial sclerosis 4
Diffuse crescentic glomerulonephritis 2
(Adopted from: Yap HK, Murugasu B, Saw AH, Chiang GSC, Tay JSH, Wong HB,
Tan CL, Lim CH. Pattern of glomerulonephritis in Singapore children – a renal
biopsy perspective. Ann Acad Med Singapore 1989; 18(1):35-39.)
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In a large multi-centre study of primary nephrotic syndrome in children conducted by
The International Study of Kidney Diseases in Children (ISKDC) between 1967 and
1974, MCNS was found to be the most common lesion (Table 1.3). MCNS causes
approximately 90% of the nephrotic syndrome in young children, 50% in older
children, and 20% in adults.
Table 1.3 Distribution of patients by histopathology in children primary
nephrotic syndrome
Categories No. of Patients %
Minimal change nephrotic syndrome 398 76.4
Membranoproliferative glomerulonephritis 39 7.5
Focal & segmental glomerulonephritis 36 6.9
Proliferative glomerulonephritis 12 2.3
Pure diffuse mesangial proliferation 12 2.3
Focal & global glomerulosclerosis 9 1.7
Membranous glomerulopathy 8 1.5
Chronic glomerulonephritis 3 0.6
Unclassified 4 0.8
Total 521 100
(Adopted from: Nephrotic syndrome in children: Prediction of histopathology from
clinical and laboratory characteristics at the time of diagnosis. A report of the
International Study of Kidney Disease in Children. Kidney Int 1978; 13:159-165.)
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MCNS has, by definition, no abnormalities apparent on analysis of kidney biopsy
specimens by light microscopy. Humoral components of the immune system, such as
immunoglobulins and complement, are absent on immunofluorescent analysis of
cortical kidney sections in most cases. Some patients with MCNS have mesangial
deposition of IgM and prominent mesangial hypercellularity on renal biopsy (Cohen
et al, 1978). It is controversial whether the presence of IgM deposition is a separate
clinicopathologic entity or a variant of MCNS. Most of the previous studies showed
that the IgM electron dense deposits were vague and ill-defined (Hsu et al, 1984;
Hirszel et al, 1984), and this had led to the speculation that the presence of mesangial
IgM is an epiphenomenon rather than an active immunologic process, and is probably
the result of passive IgM entrapment due to disturbed mesangial macromolecular
transport in nephrotic patients (Nadasdy et al, 1994). On the other hand, MCNS
patients presenting with mesangial IgM deposits were found to show poorer response
to corticosteroid therapy (Bhasin et al, 1978; Allen et al, 1982) and a higher tendency
to develop FSGS (Zeis et al, 2001) when compared with MCNS patients whose
biopsies are negative for IgM.
The most consistent and significant pathological change observed in MCNS is
effacement of the podocyte foot processes in electron microscopy, a finding seen with
many forms of glomerular pathology that are associated with nephrotic-range
proteinuria. These ultrastructural abnormalities typically resolve with corticosteroid-
induced clinical remissions.
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1.3 Pathogenesis of minimal change nephrotic syndrome
1.3.1 Minimal change nephrotic syndrome and the immune system
Although the pathogenesis of MCNS is still unknown, it has long been believed to be
a disease of immune dysregulation. Back in 1974, Shalhoub postulated that the
abnormal expansion of a clone of T cells might result in the production of a
lymphokine toxic to the glomerular basement membrane (GBM), resulting in
increased glomerular permeability to protein (Shalhoub, 1974). Evidence of
involvement of the immune system in MCNS comes from the observations that: i)
Serum IgG and IgA levels are often reduced in nephrotic patients with MCNS; ii)
Minimal change disease frequently remits with measles infection, which is known to
suppress cell-mediated immunity; iii) Patients are highly susceptible to pneumococcal
infections, despite minimal losses of IgG in urine; iv) Patients response well to
treatment with immunosuppressive drugs such as corticosteroid and
cyclophosphamide; v) Symptoms of MCNS and FSGS, which have been observed in
patients with Hodgkin disease, non-Hodgkin lymphoma, lymphocytic leukaemia and
mycosis fungoides, disappear after successful treatment of the tumor.
1.3.2 Circulating factors
The absence of infiltrating lymphocytes in light microscopy and the recurrence of
nephrotic syndrome after transplantation in both steroid-sensitive nephrotic syndrome
(Mauer et al, 1979) and FSGS (Ingulli and Tejani, 1991) suggest that a circulating
pathogenetic factor is responsible for inducing proteinuria in both MCNS and FSGS.
Several groups have also demonstrated that supernatants of concanavalin-A
stimulated lymphocytes derived from nephrotic patients were able to change
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glomerular permeability and increase albuminuria when injected into rats (Boulton-
Jones et al, 1983; Garin & Boggs, 1987; Tanaka et al, 1992).
Circulating factors and MCNS
Over the years, a lot of effort has been made to search for the circulating factor(s) or
the causative agent in MCNS. Sobel and colleagues (Lagrue et al, 1975) first
described and characterized a soluble lymphokine secreted by concanavalin-A
stimulated human lymphocytes of nephrotic patients, which they called vascular
permeability factor (VPF) due to its ability to increase the permeability of guinea pig
skin capillaries. It has a molecular weight of 12 kDa, a sedimentation rate of 1.8S and
a pI of 6.4 upon isoelectric focusing (Sobel et al, 1977). Numerous reports then
emerged in the following years describing increased levels of VPF in serum and
supernatants of concanavalin-A stimulated lymphocytes from children with steroid-
sensitive nephrotic syndrome (Tomizawa et al, 1985; Yoshizawa et al, 1989). Soluble
factor produced from hybridomas derived from T cells of patients with MCNS has
also been shown to cause proteinuria when injected into rats (Koyama et al, 1991).
Furthermore, some studies have shown that cyclosporin was able to inhibit the
production of VPF in a dose-dependent manner in-vitro (Maruyama et al, 1992). This
indicated that the reduction of proteinuria by cyclosporin in MCNS might be due to
the inhibition of VPF production, and further confirm the role of VPF in increasing
glomerular permeability in MCNS. However, measurement of VPF activity was based
on an indirect method which measured the degree of extravasation of systemically
injected blue dye in guinea pig skin rather than the level of VPF itself. Progress on the
study of VPF has been slow because no lymphokine factor has so far been identified
as equivalent to VPF.
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A number of lymphocyte derived factors such as vascular endothelial growth factor
(VEGF) and heparanase have been proposed as the possible candidate molecule of
VPF. VEGF is able to alter the permeability of endothelial cell monolayer
(Hippenstiel et al, 1998). Increased glomerular mRNA expression of VEGF has been
demonstrated in minimal change nephropathy when compared to control (Bailey et al,
1999). Heparanase has also been shown to modulate the permeability of the GBM in
steroid-sensitive nephrotic syndrome (Sewell & Short, 1993; Holt et al, 2005) by its
ability to degrade heparan sulfate glycosaminoglycan, a major component of the
GBM. Haemopexin, a 100 kDa vasoactive factor, has been investigated and
characterized from patients with steroid-sensitive nephrotic syndrome. This plasma
factor, which displays kallikrein-like activity, is able to induce proteinuria in rats,
probably by its ability to reduce glomerular sialoglycoproteins (Cheung et al, 1996).
However, its interaction with the immune system has yet to be determined.
Increased expression of individual cytokines has also been described in MCNS. Sahali
and co-workers have demonstrated that the DNA binding activity of NF-kB, a
transcription factor which regulates the expression of cytokines, was upregulated
during relapses of MCNS. This was associated with downregulation of the regulatory
protein IkBa which inactivates NF-kB when they bind with each other (Sahali et al,
2001). Increased production of IL-4 (Cho et al, 1999) and IL-8 (Garin et al, 1994)
have been detected in mitogen-stimulated PBMC derived from children with steroid-
sensitive nephrotic syndrome. Increased expression of IL-4 mRNA was associated
with decreased IFN-g mRNA in some children while IL-8 was shown in-vitro to
increase sulphation of the GBM, a process that leads to alteration in the charge
selectivity of the GBM seen in MCNS. Matsumoto and colleagues added IL-12, IL-15
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and IL-18 to the list of candidate cytokines, by demonstrating their ability to
significantly induce the release of VPF from concanavalin-A stimulated lymphocytes
obtained from MCNS patients. They also showed a significantly increased
spontaneous and LPS-stimulated release of IL-12 and IL-18 in peripheral blood
monocyte cultures from MCNS patients when compared to normal control. This
increased LPS-stimulated production of IL-12 and IL-18 occurred during relapses,
returned to normal during remission, and also correlated significantly with the levels
of VPF released in the same culture (Matsumoto & Kanmatsuse, 1999; Matsumoto et
al, 1999; Matsumoto & Kanmatsuse, 2001).
Circulating factors and FSGS
Compared to MCNS, the circulating factors in FSGS are much better characterized.
The presence of circulating factor in FSGS is perhaps best illustrated by the
Buffalo/Mna rats which spontaneously develop glomerular changes with a
histological pattern similar to the human disease. The recurrence of proteinuria after
transplantation in Buffalo/Mna and the remission of lesions in Buffalo/Mna kidneys
transplanted into normal hosts strongly suggest that Buffalo/Mna rats express
circulating albuminuric factors, which may be relevant to the relapse of nephrotic
syndrome in humans (Le Berre et al, 2002). In fact, some patients with FSGS showed
recurrence of nephrotic syndrome in the immediate post-transplant period and protein
was detected in the very first urine sample of these patients (Dantal et al, 1991). This
was further supported by the fact that remission was seen in some patients with FSGS
after plasmapheresis (Artero et al, 1994) or by protein adsorption using protein A
Sepharose (Dantal et al, 1994). Savin and colleagues (Savin et al, 1996) have isolated
a 50 kDa circulating factor that binds to protein A in patients with recurrent FSGS
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after transplantation. This factor was found to be associated with increased glomerular
permeability to albumin.
1.3.3 Bias to Th2 cytokines and involvement of IL-13
A bias to Th2 cytokines, such as IL-4 and IL-13, in MCNS has been proposed by
some authors in recent years (Stachowski et al, 2000; Mathieson, 2003; Le Berre et
al, 2005). IL-4 activity and mRNA expression in mitogen stimulated peripheral blood
lymphocytes obtained from active MCNS patients have been shown to be upregulated
when compared to age-matched healthy normal controls (Cho et al, 1999). This was
also associated with a significantly higher expression of CD23, the type II IgE
receptor (FceRII), on B cells in these patients. Genetic polymorphism in the promoter
region of the IL-4 gene and STAT6 gene was also found to be associated with MCNS
in Japanese children (Kobayashi et al, 2003).
Our previous study examined the Th1 and Th2 cytokine profiles in children with
steroid-sensitive nephrotic syndrome (SSNS) (Yap et al, 1999). The mRNA
expression of Th1 (IL-2, IFN-g) and Th2 (IL-4, IL-13) cytokines from CD4+ and
CD8+ T cells of patients with SSNS in relapse and remission was studied. Both cross-
sectional and paired data showed increased CD4+ and CD8+ IL-13 mRNA expression
in patients with nephrotic relapse as compared to remission, normal and patient
controls (p<0.008). This was also associated with increased cytoplasmic IL-13
expression in PMA/ionomycin-activated CD3+ cells (6.66±3.39%) from patients with
nephrotic relapse compared to remission (2.59±1.35%) (p<0.001). However, there
was no difference in CD4+ or CD8+ IL-2, IFN-g and IL-4 mRNA expression in all
the study groups. Our studies have also shown that upregulation of lymphocyte IL-13
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was not only associated with increased serum IgE levels (Cheung et al, 2004), but
also with downregulation of both monocyte IL-8 and IL-12 gene expression in
children with SSNS in relapse as compared to remission (Chen et al, 2003). In our
preliminary study using the technique of differential display reverse transcription
polymerase chain reaction (DDRT-PCR), we have demonstrated the presence of up to
5 differentially upregulated monocyte genes in children with SSNS in relapse
compared with remission (own observation, results not published). Hence although
IL-13 normally downregulates pro-inflammatory monokine production, it could still
be a vital mediator acting on monocytes to produce factor(s) that are important in the
pathogenesis of the nephrotic syndrome.
Genetic polymorphism of the IL-13 gene has been shown to be a predisposing factor
in the development of MCNS. The frequency of the GG homozygote at position
(4257G/A) of the IL-13 gene was found to be significantly lower in Indonesian
children with MCNS when compared to the control group (Acharya et al, 2005). Our
study also showed that genetic polymorphisms in the 3’ untranslated region (3’UTR)
of the IL-13 gene correlated with long-term outcome of MCNS, rather than disease
susceptibility, in Singapore Chinese children (Wei et al, 2005). Moreover, PBMC IL-
13 mRNA expression in patients with haplotype AAT (relapsing nephrotic syndrome)
was significantly higher than those with haplotype GCC (long-term remission).
Involvement of IL-13 in nephrotic syndrome is further supported by its association
with atopy and Hodgkin disease. The close relationship between atopy and idiopathic
nephrotic syndrome, as demonstrated by our group and other workers, suggests a
common immune pathway (Yap et al, 1983; Lin et al, 1990). Stimuli, such as
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allergens, may activate common immune mechanisms, which subsequently result in
proteinuria in children with MCNS. Previous studies have suggested that both IL-4
and IL-13 independently enhance the production of IgE in non-atopic donors, while
IFN-g inhibits the event (Punnonen et al, 1993). We have evaluated serum IgE levels
as well as intracellular cytokine (IFN-g, IL-4, IL-13) production among paediatric
patients with SSNS (Cheung et al, 2004). Paired analysis showed that the total serum
IgE level was found to be significantly higher in children with SSNS in relapse
(550±391 U/ml), compared to remission (226±156 U/ml) or normal controls
(185±139 U/ml) (p<0.001). Moreover, the elevated serum total IgE levels found in
patients in nephrotic relapse correlated significantly with the increase in CD3+ IL-13
producing cells (r=0.782, p<0.001). Our finding of an increased IL-13 gene
expression from both CD4+ and CD8+ cells in nephrotic children in relapse, was
consistent with Kimata’s study where IL-13 was shown to be important for the
spontaneous production of IgE and IgG4 by PBMC in nephrotic syndrome.
Importantly, this activity was specifically blocked by anti-IL-13 antibody (Kimata et
al, 1995). Kimata et al contrasted this finding to that in atopic individuals where IL-4
was the controlling cytokine. Moreover, in the nephrotic patients in his study, IL-13
binding was increased not only on B cells, but also on monocytes and NK cells. The
association between Hodgkin disease and MCNS has been described decades ago. As
discussed in the previous section, IL-13 expression has been shown to be upregulated
in RS cells found in Hodgkin lymphoma. IL-13 is secreted by RS cells and stimulates
the growth of the tumor by an autocrine mechanism (Kapp et al, 1999). Symptoms of
nephrotic syndrome disappear after successful treatment of the tumor. This
corroborates our findings that increased IL-13 gene expression may be important in
the pathogenesis of MCNS.
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1.4 Genetic aspects of nephrotic syndrome
1.4.1 Hereditary diseases manifested with nephrotic syndrome
Alport’s syndrome, Nail-patella syndrome, Denys-Drash syndrome and Frasier
syndrome are well characterized hereditary form of glomerulopathy. Alport’s
syndrome is caused by mutation of the genes COL4A3, COL4A4 and COL4A5 which
encodes for the  a-chain subunits of collagen IV (Heikkilä et al, 2000). Nail-patella
syndrome is caused by mutations in the LMX1B gene which encodes a transcription
factor of the Lin-11, Isl-1, Mec-3 (LIM)-domain family (Dreyer et al, 1998; Iannotti
et al, 1997). Denys-Drash and Frasier syndrome are caused by mutations in the
Wilm’s tumor gene WT1 which encodes a DNA binding transcription factor that
controls the expression of a wide variety of target proteins (Englert, 1998). Mutations
in COL4A3, COL4A4, COL4A5 and LMX1B alter the composition of collagen a-
chains in type IV collagen deposited in the GBM and therefore change its structural
integrity and its ability to act as the filtration barrier (Miner & Sanes, 1996; Cosgrove
et al, 1996). Mutation of LMX1B also leads to a strong reduction in the glomerular
expression of two podocyte proteins, podocin and CD2AP (Miner et al, 2002).
1.4.2 Nephrin and congenital nephrotic syndrome
Mutation of the gene NPHSI, which codes the glomerular protein nephrin, causes
congenital nephrotic syndrome of the Finnish type (CNF) (Kestila et al, 1998). This
disease is characterized by autosomal recessive inheritance and the development of
severe nephrosis in-utero (Rapola, 1987). Two mutations, termed Fin-major (deletion
of nucleotides 121-122 causing a frameshift) and Fin-minor (a C-T substitution at the
nucleotide causing protein truncation at amino acid 1109) account for over 90% of the
NPHS1 mutations found in the Finnish population (Kestila et al, 1998; Patrakka et al,
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2000). A large number of mutations has now been described in both Finnish and non-
Finnish patients (Lenkkeri et al, 1999; Aya et al, 2000), and these include missense as
well as nonsense and splicing mutations. Nephrin is expressed predominantly in the
podocyte, and is localized exclusively to the glomerular slit diaphragm (Holthofer et
al, 1999; Holzman et al, 1999). It is hypothesized that nephrin molecules from
neighboring foot processes form homoduplexes to create the slit diaphragm structure,
which is absent or abnormal in patients with mutations in both nephrin alleles
(Ruotsalainen et al, 1999).
1.4.3 Podocin and steroid-resistant nephrotic syndrome
Mutations of the gene NPHS2, which encodes the glomerular protein podocin, was
found in an autosomal recessive form of steroid-resistant nephrotic syndrome (Boute
et al, 2000). This autosomal recessive form of nephrotic syndrome is characterized by
early onset, resistance to steroid therapy and rapid progression to end-stage kidney
failure. Most affected children showed an FSGS pattern on renal biopsy, though some
showed minimal change disease (Pollak, 2002). Podocin has been localized to the slit
diaphragm and has now been shown to interact directly with nephrin (Schwarz et al,
2001; Huber et al, 2001; Roselli et al, 2002). A substantial number of the reported
mutations encode truncated proteins, suggesting that disease results from a loss of
function of NPHS2 (Fuchshuber et al, 2001; Caridi et al, 2001). Since then, podocin is
found to be responsible for disease in a sizable fraction of both familial and
nonfamilial instances of childhood-onset recessive FSGS. Fuchshuber et al found
NPHS2 mutations in 46% of such families. Recent studies suggest that NPHS2
mutations underlie disease in 20-30% of children with sporadic steroid-resistant
nephrotic syndrome (Caridi et al, 2001; Karle et al, 2002).
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1.4.4 a-Actinin-4 and familial FSGS
Heterozygous missense mutations in ACTN4, encoding a-actinin-4, cause a dominant
form of familial FSGS (Kaplan et al, 2000). This autosomal dominant disease is
characterized by adult onset, non-nephrotic proteinuria and slowly progressive renal
insufficiency in a significant fraction of patients. a-Actinin-4, a widely expressed
protein, is the only one of the four a-actinin isoforms significantly expressed in the
podocyte (Kaplan et al, 2000). The identified ACTN4 mutations are all missense, and
increase the affinity of the encoded protein to filamentous actin (F-actin) (Kaplan et
al, 2000). By contributing to the organization of the actin cytoskeleton and anchoring
it to the plasma membrane, a-actinin is thought to be important in the maintenance of
cell shape, adhesion, and movement. The FSGS-associated ACTN4 mutations may
alter podocyte foot process function by altering its mechanical properties (Pollak MR,
2002).
1.4.5 Animal models of nephrotic syndrome
Many more protein molecules have been found to be implicated in idiopathic
nephrotic syndrome in transgenic and knockout animal models. Mice lacking NEPH1
(Donoviel et al, 2001) or haploinsufficiency for CD2AP (Shih et al, 1999) developed
severe nephrosis and showed effacement of podocyte foot processes. Both NEPH1
and CD2AP are expressed by podocytes and are structural components of the slit
diaphragm complex. Inactivation or deletion of other genes Mpv17 (Reuter et al,
1998), Rho GDI-a (Togawa et al, 1999) and Fyn (Yu et al, 2001) was found to cause
FSGS in mouse models. Conversely, overexpression of TGF-b1 (Kopp et al, 1996),
Frat 1 (Jonkers et al, 1999) and bovine growth hormone (Yang et al, 1993) in mice
also led to progressive renal disease characterized by FSGS-like glomerular lesions.
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It is interesting to note that most of the mutated genes mentioned above are closely
related to the podocyte. The podocyte, also known as glomerular visceral epithelial
cell, is a large polygonal cell with extensive cytoplasm found covering the outer
aspect of the GBM. It forms part of the filtration barrier in the glomeruli of the kidney
which also includes the GBM and the fenestrated endothelium lining the inner aspect
of the GBM. The filtration barrier in the glomerulus regulates the outflow of solutes
from the blood capillaries to the urinary space. WT1 is mainly expressed in both
parietal and visceral epithelial cells in the glomeruli and plays a critical role in
maintaining the differentiation of podocytes (Reddy & Licht, 1996; Dreyer et al,
1998; Heikkilä et al, 2000). Nephrin and podocin are important structural components
of the slit diaphragm complex while a-actinin-4 is closely linked with the actin
cytoskeleton of the podocyte foot processes. In view of the strategic anatomical
position of the podocyte in the glomerular filtration barrier, it is not hard to
understand that mutation of genes associated with podocytes could lead to proteinuria
in conditions mentioned above.
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1.5.1 Podocyte and the glomerular filtration barrier
The glomerulus is the filter of the nephron and is located within the Bowman's
capsule found at the cortical area of the kidney. Blood is transported into the
Bowman's capsule via the afferent arteriole, and leaving via the efferent arteriole. The
glomerulus resembles a twisted mass of capillaries through which the blood passes.
Four resident cell types are found in the glomerulus: endothelial cells, mesangial cells,
parietal epithelial cells and visceral epithelial cells (podocytes). The endothelial cells
form a porous layer known as the fenestrated endothelium, lining the luminal side of
the GBM. The mesangial cells and the extracellular substances they secrete form into
a matrix called the mesangium which gives support to the capillary mass. The
podocytes are large polygonal cells with extensive cytoplasmic processes covering the
outer aspect of the GBM. The parietal epithelial cells form the epithelium of the
Bowman’s capsule facing the urinary space. The fenestrated endothelium, the GBM
and the podocytes together form the filtration barrier in the glomerulus that regulates
the outflow of solutes from the blood capillaries to the urinary space. The cytoplasmic
extension of podocytes forms into secondary foot processes and further extends into
individual tertiary foot processes. These individual foot processes are seen slightly
embedded onto the GBM with slit pores forming in between. Adjacent tertiary foot
processes are linked together by an electron dense membrane-like material called slit
diaphragm which can only be seen by transmission electron microscopy. The slit
diaphragm is a complex structure that is believed to regulate the flow of protein out to
the urinary space from the blood capillaries. One podocyte generally serves more than
one capillary. (Figure 1.1 & 1.2)
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Figure 1.1 Cross section of the glomerular capillary wall. The glomerular
filtration barrier is composed of 3 layers: the inner endothelium, the GBM and the
outer podocyte and its foot processes. Individual foot processes are seen resting on the
















Figure 1.2 High power view of the podocyte tertiary foot processes. Individual
podocyte tertiary foot processes are resting on the GBM with slit pores in between
and linked together by the electron dense slit diaphragm. The GBM appears as
homogeneous matrix material. The endothelial cells line the inner layer of the barrier













1.5.2 Charge and size selectivity of the glomerular filtration barrier
The glomerular filtration barrier is believed to have distinct charge and size selectivity
to protein molecules. The charge barrier is mainly contributed by the negative
residues on the GBM and the podocytes. The GBM is made up of heparan sulfate
proteoglycans such as perlecan and agrin which contain negatively charged heparan
sulfate polysaccharide side chains (Groffen et al, 1999). The podocyte is covered by a
highly glycosylated layer of sialoprotein known as podocalyxin which contains
negatively charged sialic acid residues (Kerjaschki et al, 1984). These polyanionic
sites are thought to oppose the movement of the negatively charged albumin
molecules out from the blood capillaries. The size selectivity has been attributed to
either the GBM or the slit diaphragm. The GBM is made up of a meshwork of type IV
collagen, laminin, fibronectin, entactin and heparan sulfate proteoglycans and is
believed to act as a molecular sieve to protein molecules (Shikata et al, 1990). The slit
diaphragm forms part of the filtration barrier and is responsible for about half of the
total hydraulic resistance. It appears to be the main barrier for molecules larger than
albumin, thus representing the main determinant of size selectivity (Drumond &
Deen, 1994).
1.5.3 Molecular structure of podocyte foot processes
With recent advances in podocyte cell biology, it is clear that the podocyte foot
processes contain an actin-based cytoskeleton supported by a wide variety of linking
molecules (Pavenstädt et al, 2003). The actin cytoskeleton of podocyte foot processes
is formed by the polymerized form of actin, called F-actin, which is a highly dynamic
structure with a polar orientation. F-actin binds with myosin and forms into
microfilament bundles which are interconnected by  a-actinin-4, a form of actinin-4
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specifically expressed by podocytes. The loop-shaped microfilament bundles run
along the longitudinal axis of the foot processes connecting the sole of the foot
processes and the major process (Drenckhahn & Franke, 1988; Mundel & Kriz,
1995). The actin bundles are linked to the slit diaphragm membrane by the adaptor
protein complex consisting of ZO-1, catenins, CD2AP, FAT and podocin (Reiser et
al, 2000; Li et al, 2000). The slit diaphragm membrane itself, which connects adjacent
podocyte foot processes resting on the GBM, is also a complex structure known to
consist of nephrin, and P-cadherin (Asanuma & Mundel, 2003). The actin bundles are
linked to the GBM by integrins and dystroglycans at the basal aspect of the tertiary
foot processes. The integrin complex consists of the cytoplasmic adaptor proteins,
vinculin, paxillin and talin, and of the transmembrane a3/b1 integrin dimers, which
bind to the a3, a4 and a5 chains of collagen IV as well as to laminin 11, a
heterotrimer composed of a5/b2/g1 laminin chains (Kreidberg & Symons, 2000). The
dystroglycan complex is made up of the cytoplasmic adaptor protein utrophin, of the
transmembranous b-dystroglycan subunit, and of the extracellular a-dystroglycan
subunit which bind to agrin and laminin a5 chains in the GBM matrix (Durbeej et al,
1998). Dystroglycans and integrins are believed to co-ordinate the formation of a
polygonal network of laminin in basement membranes (Schwarzbauer, 1999). In
summary, these protein molecules are important in maintaining the cell shape and the
3-dimensional architecture of the podocyte foot processes as well as their attachment
onto the GBM. Therefore, a better understanding of the molecular aspect of the
podocyte foot processes may be helpful in understanding the disease processes in the
glomerulus. (Figure 1.3)
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Figure 1.3 Schematic drawing of the molecular equipment in podocyte foot
processes. Cas=p130Cas, Cat=catenins, CD=CD2-associated protein, Ez=ezrin,
FAK=focal adhesion kinase, ILK=integrin-linked kinase, M=myosin, N=NHERF2,
NSCC=non-selective cation channel, PC=podocalyxin, S=synaptopodin, TPV=talin,
paxillin, vinculin, U=utrophin, Z=ZO-1. (Adopted from: Endlich K, Kriz W, Witzgall
R. Update in podocyte biology. Curr Opin Nephrol Hypertens 2001; 10:331-340.)
Collagen IV (a3, a4, a5)
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The slit diaphragm is a modified adherens junction (Reiser et al, 2000) that connects
adjacent podocyte foot processes in the glomeruli. It helps to maintain the structure of
the interdigitating foot processes overlying the GBM and the formation of the slit
pore. Nephrin is the main component protein of the slit diaphragm. This is best
illustrated by the absence of slit diaphragm between adjacent podocyte foot processes
in patients with congenital nephrotic syndrome of the Finnish type, a disease which is
caused by mutations of the nephrin gene NPHS1 (Kestila et al, 1998). In-vitro study
of podocyte cell lines showed that nephrin is localized at cell-cell contacts (Schiwek
et al, 2004) and promotes cell-cell adhesion through homophilic interaction
(Khoshnoodi et al, 2003). Using electron tomography, Wartiovaara and colleagues
(Wartiovaara et al, 2004) further demonstrated that nephrin exists as globular cross
strands about 35 nm in length emanating from both sides of the slit, and interact with
each other by their free distal end. These globular cross strands form a network of
winding molecular strands with pores the same size as or smaller than albumin
molecules. P-cadherin is another important structural component of the slit
diaphragm. P-cadherin is a transmembrane protein which associates with each other
by homophilic interaction through their extracellular domains between adjacent
podocyte foot processes and links with b-catenin inside the podocyte foot processes
by its cytoplasmic b-catenin binding domain (Reiser et al, 2000). With the
tremendous progress in the study of podocyte biology in recent years, we now know
that the slit diaphragm complex, in addition to nephrin and P-cadherin, is made up of
several other protein molecules including CD2AP, podocin, FAT, ZO-1, catenins and
NEPH1 (Asanuma & Mundel, 2003). These are adaptor proteins which help to
maintain the structural integrity of the slit diaphragm and the slit pore through their
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association with the cytoplasmic domain of the nephrin and P-cadherin molecules.
The adaptor proteins also link the slit diaphragm to the actin cytoskeleton which may
have significant pathological impact as explained later. Apart from maintaining the
structural integrity of the glomerular filtration barrier, the slit diaphragm complex
may also serve as a signaling platform to regulate podocyte function (Huber &
Benzing, 2005). In a recent study, both nephrin and CD2AP were found to interact
with the p85 regulatory subunit of phosphoinositide 3-OH kinase (PI3K). This leads
to recruitment of PI3K to the plasma membrane, where, in association with podocin,
they stimulate PI3K-dependent AKT signaling in podocytes. The nephrin-induced
AKT mediates phosphorylation of several target proteins in podocytes including Bad,
and the phosphorylation and inactivation of Bad by 14-3-3 protects podocytes from
detachment-induced cell death (Huber, Hartleben, Kim et al, 2003). Nephrin is also
found to be tyrosine-phosphorylated by the Src family kinase Fyn (Verma et al,
2003). Fyn phosphorylates the cytoplasmic domain of nephrin and leads to increased
interaction between nephrin and podocin (Li et al, 2004).
1.5.5 The podocyte in idiopathic nephrotic syndrome
Podocyte damage plays a central role in the pathogenesis of many glomerulopathies
(Smoyer & Mundel, 1998). As mentioned in section 1.4, several genetic disorders of
the podocyte have been described. Immunologic change is responsible for the
development of membranous nephropathy, MCNS and primary FSGS (Masutani et al,
2004; van den Berg & Weening, 2004). Hyperglycaemia leads to the formation of
advanced glycation end-products which act on its receptor on the podocyte membrane
in diabetic nephropathy (Wendt et al, 2003). Direct stimulation of the podocyte by
human immunodeficiency virus (HIV) infection can lead to collapsing FSGS
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(Barisoni et al, 1999). Haemodynamic change to the podocytes in glomerular
hypertension is important in secondary glomerulosclerosis (Kretzler et al, 1994).
In MCNS and FSGS, there is mounting evidence suggesting that the podocyte is
central in the pathogenesis of this nephrotic syndrome. In fact, the only histological
change in MCNS is the extensive effacement of podocyte foot processes with loss of
the slit diaphragm and disappearance of the slit pores when viewed under electron
microscopy (Figure 1.4). Animal studies have shown that detachment of podocytes
from the GBM is coincident with the onset of massive proteinuria in both adriamycin
nephropathy and puromycin nephropathy (Whiteside et al, 1989). Podocyte injury,
including foot process effacement, pseudocyst formation, and cytoplasmic
accumulation of lysosomal granules and lipid droplets, was also shown to contribute
to the progress of FSGS in rats (Gassler et al, 2001). In humans, podocytes are
frequently detected in the urine of patients with FSGS and MCNS (Masanori et al,
2001). Podocytes are terminally differentiated cells and have limited capacity to
divide and regenerate to replace those that have been lost. Loss of podocytes will
facilitate the progress of glomerular diseases and this could explain why some
glomerular lesions, such as FSGS, are irreversible (Kriz et al, 1998).
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Figure 1.4 Effacement of podocyte tertiary foot processes. 3 partial glomerular
capillary loops are seen in this picture. Note that no individual tertiary foot processes,
slit pores or slit diaphragm are seen. The podocyte foot processes have fused together
and formed a continuous layer covering the GBM (arrows). (Minimal change disease
in human, TEM Magnification = x7800)
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1.5.6 Mechanism of proteinuria
Early studies on the mechanism of albumin leakage in the glomeruli focused on the
charge selectivity of the glomerular filtration barrier. Treatment of glomeruli with
polycations, such as protamine sulfate and cationized ferritin, targeted to neutralize
the polyanionic sites on podocytes, resulted in flattening and retraction of podocyte
foot processes and dislocation of the slit diaphragm (Kerjaschki, 1978; Andrews,
1978). These changes were very similar to glomerular changes observed in puromycin
nephropathy which is characterized by heavy proteinuria. In fact, it was later found
that sialic acid content of podocalyxin was reduced from 4.5% to 1.5% in rats of
puromycin nephropathy (Kerjaschki et al, 1985). Furthermore, enzymatic removal of
the alpha 2-->6-linked sialic acid by bacterial sialidase from the glomerulus was
shown to cause proteinuria and renal failure in mice in a dose dependent manner
(Gelberg et al, 1996). Lastly, mice deficient in podocalyxin was found to have
impaired kidney development and died perinatally with anuric renal failure.
Podocytes from these mice failed to form the slit pores on the GBM and exhibited
tight and adherens junctions instead (Doyonnas et al, 2001). The electrostatic
repelling force derived from the anionic sialic acid residues present in podocalyxin is
important both in opposing the movement of negatively charged protein molecules as
well as in maintaining the integrity of the slit pore between the interdigitating
podocyte foot processes. It is clear that treatment of glomeruli with polycations
always leads to effacement of podocyte foot processes. However, it is still
controversial whether the subsequent leakage of protein (Vehaskari et al, 1982) is due
to the loss of electrostatic repelling force against the protein molecules or is a
consequence of the effacement of the foot processes. Recent studies on the molecular
structure of podocytes have broadened our understanding on the role of podocalyxin
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in the glomerular filtration barrier. In addition to its charge selectivity function,
podocalyxin may also contribute to the filtration barrier function of podocytes in an
alternative way. The highly conserved intracellular carboxyl terminal of podocalyxin
was shown to link with the actin cytoskeleton through 2 adaptor proteins: Na(+)/H(+)
exchange regulatory factor-2 (NHERF-2) (Li et al, 2002) and ezrin (Orlando et al,
2001). NHERF-2 and ezrin co-localized with podocalyxin along the apical plasma
membrane of podocytes and help to maintain the apical localization of podocalyxin
(Takeda, 2003). Podocalyxin has also been found recently to activate RhoA and
modulate the distribution of the actin cytoskeleton through NHERF2 and ezrin
(Schmieder et al, 2004). The interaction of the podocalyxin/NHERF2/ezrin complex
with the actin cytoskeleton was found to be disrupted in PAN-, protamine sulfate- or
sialidase-treated rats, which showed a dramatic loss of foot processes, comparable to
that seen in the nephrotic syndrome (Takeda et al, 2001).
Although the mechanism of how podocyte foot process effacement leads to
proteinuria is still unknown, maintenance of the in-vivo 3-dimensional architecture of
the podocyte foot processes seems to be crucial to the proper function of the filtration
barrier in the glomerulus. Podocytes are highly dynamic cells. They are able to
respond to stimuli in the microenvironment within the glomeruli in different forms of
glomerulonephritis (Andrews, 1988; Smoyer & Mundel, 1998). These include
retraction of foot processes, effacement of foot processes and detachment of foot
processes from the underlying GBM. These changes in the shape and architecture of
the podocyte have been shown to associate with alterations in the actin cytoskeleton.
Rearrangement of the actin cytoskeleton has been shown to induce process formation
during differentiation in a conditionally immortalized mouse podocyte cell line
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(Mundel et al, 1997). Disaggregation of the actin cytoskeleton (Whiteside et al, 1993)
and induction of a-actinin (Smoyer et al, 1997) in podocytes were also found to
precede the onset of proteinuria and effacement of podocyte foot processes. The actin
cytoskeleton of the podocyte foot processes is important in maintaining the cell shape,
cell polarity and structural integrity of the podocyte (Endlich et al, 2001). Structural
changes of the podocyte initiated by rearrangement of the actin cytoskeleton may
result in disruption of the filtration barrier, alter the glomerular permeability and
eventually lead to proteinuria.
Recently, mutations of genes coding for some important structural proteins of the
podocyte such as nephrin, podocin and a-actinin-4 have been found to link with both
sporadic and familial steroid-resistant nephrotic syndrome (Pollak, 2002). This
suggests that the morphological changes observed in podocytes in the proteinuric state
could be a result of the loss of function in these structural proteins. Nephrin and
podocin are the component proteins of the slit diaphragm complex while a-actinin-4
is closely associated with the actin cytoskeleton. This further demonstrates that the
integrity of the slit diaphragm complex and the actin cytoskeleton is critical in the
function of the glomerular filtration barrier by maintaining the cell morphology of the
podocyte. In summary, changes in the expression of protein molecules associated with
the slit diaphragm or the actin cytoskeleton may alter glomerular permeability in
several ways:
1) Direct damage to the slit diaphragm
The critical role of the slit diaphragm in regulating glomerular permeability
implies that any changes in its structural component may alter the normal function
of the filtration barrier. Thus, changes in the expression of its component proteins,
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such as nephrin, may directly lead to structural changes in the slit diaphragm,
altering its size selective characteristic, resulting in a loss of function as a physical
barrier to protein molecules.
2) Structural changes of the filtration barrier
Since the slit diaphragm helps to maintain the in-vivo 3-dimensional architecture
of the podocytes, changes in the expression of protein molecules associated with
the slit diaphragm may result in changes of the podocyte cell shape or even loss of
the slit pore. This will affect the spatial distribution and structural integrity of the
filtration barrier and subsequently loss of function. For example, nephrin has been
shown to redistribute both in puromycin nephropathy (Luimula, Ahola, Wang et
al, 2000) and in patients with primary acquired nephrotic syndrome (Doublier et
al, 2001). Downregulation in the expression of ZO-1, a structural component of
the slit diaphragm complex, was found to be associated with increased glomerular
permeability (Kawachi et al, 1997).
3) Rearrangement of the actin cytoskeleton.
Modulation of the actin cytoskeleton has been associated with the onset of
proteinuria. For example, mutations of a-actinin-4, an actin bundling binding
protein, were associated with an autosomal dominant form of familial FSGS
(Kaplan et al, 2000). This implies that mutation of proteins that are closely
associated with actin may impair the proper organization of the actin cytoskeleton,
initiating changes in the shape and form of the podocyte foot processes. The actin
cytoskeleton is also linked to the slit diaphragm by adaptor proteins such as
CD2AP and FAT cadherins (Lehtonen et al, 2002; Tanoue & Takeichi, 2005);
therefore, mutations in proteins associated with the slit diaphragm may also
interfere with the organization of the actin cytoskeleton. Rearrangement of the
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actin skeleton causes changes in podocyte cell shape, which again may affect the
structural integrity of the filtration barrier and alter glomerular permeability.
4) Dissociation of the podocyte foot process from the GBM
The podocyte foot processes are linked to the GBM via a3b1 integrin and
dystroglycans (Adler, 1992). Detachment of podocytes from the GBM has been
associated with massive proteinuria (Whiteside et al, 1989). Therefore, cell matrix
contacts of the podocyte foot processes may be crucial in the maintenance of the
glomerular capillary wall substructure and hence of barrier function. Alteration in
the expression of integrins or dystroglycans or their linking molecules will
inevitably affect the binding of podocyte foot processes to the GBM and modify
glomerular permeability.
1.5.7 Podocyte specific/associated protein molecules implicated in nephrotic
syndrome
Nephrin
Rat nephrin is encoded by the NPHS1 gene mapping to chromosome 1, and consists
of 1252 amino acids. It is a putative transmembrane protein of the immunoglobulin
family of cell adhesion molecules specifically expressed in renal glomeruli. Amino
acid sequences of rat and human nephrin are highly homologous (82.2% identity).
The domain structure of nephrin is also highly conserved between rats and humans
(Kawachi et al, 2000). In humans, mutation of the NPHS1 gene, which code for
nephrin, caused a severe form of glomerular disease known as congenital nephrotic
syndrome of the Finnish type (CNF). CNF is an autosomal recessive inherited
disorder which results in an absence of nephrin and podocyte slit diaphragms along
with massive proteinuria in utero and nephrosis at birth (Kestila et al, 1998). Nephrin
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is localized to the slit pore of the glomerular epithelial cell by immunoelectron
microscopy (Holzman et al, 1999; Ruotsalainen et al, 1999). The importance of the
slit diaphragm and its component, nephrin, in regulating glomerular permeability, was
best demonstrated in some of the animal models of nephropathy. Mice homozygous
for inactivated NPHS1 developed massive proteinuria and oedema immediately after
birth and died within 24 hours. The kidney of null mice showed enlarged Bowman’s
spaces, dilated tubuli, effacement of podocyte foot processes and absence of the slit
diaphragm similar to those found in patients with CNF (Putaala et al, 2001). mAB 5-
1-6, which acts against the slit diaphragm and induces severe proteinuria when
injected into rats, was shown to recognize the extracellular domain of nephrin
(Topham et al, 1999). This was also supported by the fact that nephrin and mAB 5-1-
6 antigen have identical glomerular localization patterns on immunofluorescence in
rat kidney. Recently, nephrin has been shown to redistribute from the filtration slits to
the podocyte membrane in puromycin nephropathy of the rats (Luimula, Ahola, Wang
et al, 2000) and in patients with primary acquired nephrotic syndrome (Doublier et al,
2001). The expression of nephrin-specific RNA was also shown to be downregulated
in the rat model of puromycin nephropathy and its expression was also inversely
proportional to the severity of proteinuria (Kawachi et al, 2000; Luimula, Ahola,
Wang et al, 2000). Nephrin, thus, plays a crucial role in the development and function
of the glomerular filtration barrier, and appears to be an important molecule in the
causation of proteinuria.
Podocin
Podocin was first identified as a product of the gene mutated in patients with
autosomal recessive steroid-resistant nephrotic syndrome, characterized by early
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childhood onset of proteinuria, rapid progression to end-stage renal disease and
FSGS. The gene, NPHS2, coding for podocin was identified by positional cloning and
mapped to 1q25-31 in humans (Boute et al, 2000). Podocin is a membrane-integrated
protein that belongs to the stomatin protein family. It consists of a single hairpin-like
integral membrane protein with intracellular NH2- and COOH- termini (Roselli et al,
2002). Rat podocin is encoded by the NPHS2 gene mapping to chromosome 13q21,
and consists of 383 amino acids. Amino acid sequences of rat and human podocin are
highly homologous (84.3% identity). The domain structure of rat and human podocin
is also highly conserved (Kawachi et al, 2003). Podocin is exclusively expressed in
the podocytes of fetal and mature glomeruli. By immunoelectron microscopy, podocin
is localized to the podocyte foot process membrane, at the insertion site of the slit
diaphragm (Roselli et al, 2002). Podocin accumulates in an oligomeric form in lipid
rafts of the slit diaphragm. Podocin associates via its COOH-terminal domain with
CD2AP, a cytoplasmic binding partner of nephrin, and with nephrin itself (Schwarz et
al, 2001). NPHS2-/- knockout mice developed proteinuria during the antenatal period
and died a few days after birth from renal failure caused by massive proteinuria.
Electron microscopy revealed extensive effacement of podocyte foot processes and
the lack of a slit diaphragm in the remaining foot process junctions (Roselli et al,
2004).
Dystroglycan
a- and b-dystroglycan (Dystrophin-associated glycoprotein) are ubiquitously
expressed in various tissues. In humans, they are translated from a single mRNA, a
5.8 kb transcript derived from the Dag1 gene located at chromosome 3p21, as a 97
kDa protein which is proteolytically cleaved into two closely associated peptides. Rat
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dystroglycan 1 is encoded by the Dag 1 gene mapping to chromosome 8q32, and
consists of 893 amino acids (GeneBank accession no. XM_343483). Dystroglycan is
an important member of the dystrophin-glycoprotein complex. The dystrophin-
glycoprotein complex, which comprises a- and b-dystroglycan, sarcoglycans, and
utrophin/dystrophin, links the cytoskeleton to agrin and laminin in the basal lamina in
muscle and epithelial cells. In a recent study, mRNA expression of dystroglycan was
found in kidney cortex, isolated glomeruli, cultured podocytes and mesangial cells.
Immunofluorescence examination using antibodies against a- and b-dystroglycan
revealed a granular podocyte-like staining pattern along the glomerular capillary wall
(Raats et al, 2000). Agrin was also identified as a major heparan sulfate proteoglycan
in the GBM and was found to be a high-affinity binding partner of dystroglycan
(Gesemann et al, 1998). These results suggest that dystroglycan is present in the
GBM and their ultrastructural localization supports the concept that these molecules
are involved in linking the podocyte cytoskeleton to the GBM. In another study,
glomerular expression of dystroglycans was shown to be reduced in minimal change
nephrosis by immunoelectron microscopy (Regele et al, 2000). This result further
suggests that dystroglycan may be involved in the pathogenesis of foot process
flattening, leading to nephrotic syndrome as seen in minimal change nephrosis.
a-Actinin-4
a-Actinin-4 is a novel nonmuscle isoform of actinin-4 that is found to be upregulated
upon enhanced cell movement. It is an actin-bundling protein that plays an important
role in cell motility and cancer invasion (Honda et al, 1998). Mutations of the gene
ACTN4 encoding a-actinin-4 were associated with an autosomal dominant form of
FSGS in several families. In-vitro study showed that mutant a-actinin-4 binds F-actin
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more strongly than wild-type a-actinin-4 (Kaplan et al, 2000). The mutant form of a-
actinin-4 forms large aggregates, appears less dynamic and degrades more rapidly
when compared with the wild-type a-actinin-4 (Yao et al, 2004). Transgenic mice
which carry a mutation in ACTN4 expressed in a podocyte specific manner also
developed significant albuminuria, associated with a downregulation of nephrin gene
and protein in the kidney (Michaud et al, 2003). Mice deficient in a-actinin-4 showed
progressive proteinuria, various degrees of podocyte foot process effacement and died
within a few months (Kos et al, 2003).
CD2AP
CD2-associated protein (CD2AP) was first linked with nephrotic syndrome by Shih
and co-workers in 1999 when they described CD2AP knockout mice which died of
kidney failure at the age of 6-7 weeks. Examination of the glomeruli revealed
podocyte foot processes effacement, mesangial cell hyperplasia and extracellular
matrix deposition (Shih et al, 1999). In the immune system, CD2AP is an 80 kDa
adaptor protein that is critical for stabilizing contacts between T cells and antigen
presenting cells (Dustin et al, 1998). In the kidney, CD2AP is localized to the slit
diaphragm and binds to the C-terminal domain of nephrin (Shih et al, 2001). CD2AP
was found to colocalize with F-actin in the podocyte foot processes (Welsch et al,
2001). It also interacts with the actin cytoskeleton through its carboxyl terminus
(Lehtonen et al, 2002) and is involved in endosomal sorting and/or trafficking by its
association with dynamic actin on vesicles in podocytes (Welsch et al, 2005).
Recently, mice with CD2AP haploinsufficiency (CD2AP +/- heterozygous mice) were
found to develop glomerular changes similar to human FSGS at the age of 9 months.
Surprisingly, 2 patients with idiopathic FSGS were also found to have a mutation in
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CD2AP that ablated expression of one allele (Kim et al, 2003). Thus, CD2AP is also a
slit diaphragm associated molecule that is critical in maintaining the integrity of the
glomerular filtration barrier.
NEPH1
NEPH1 is a recently discovered protein structurally related to nephrin. Like nephrin,
it belongs to the immunoglobulin superfamily and is highly expressed in the kidneys
of human and mice. Knockout mice of NEPH1 showed high perinatal lethality rate
and developed proteinuria ranging from 300 to 2,000 mg/dL together with effacement
of podocyte foot processes (Donoviel et al, 2001). NEPH1 is localized to the
basolateral area of podocyte foot processes close to the insertion site of the slit
diaphragm as seen by immunoelectron microscopy (Barletta et al, 2003). NEPH1
forms homodimers with each other and interact with nephrin through their
extracellular domains to form heterodimers (Liu, Kaw, Kurfis et al, 2003; Gerke et al,
2003).  NEPH1 has also been found to interact with the C-terminal domain of podocin
(Sellin et al, 2003). These findings demonstrate that NEPH1 is another important
molecule in maintaining the integrity of the slit diaphragm and the interaction
between NEPH1 with nephrin and podocin may be important in modulating
glomerular permeability.
FAT
FAT cadherins form a distinct subfamily of the cadherin gene superfamily which is
important in cell-cell adhesion and maintenance of cell architecture. The FAT
cadherins contain an extraordinarily large extracellular region comprising of 34
tandem cadherin-like extracellular domains (Mahoney et al, 1991). FAT is found to
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be a component of the glomerular slit diaphragm. mRNA expression of FAT was
detected in total RNA extracted from isolated rat glomeruli. FAT is highly expressed
in podocytes. Immunofluorescence staining of FAT also showed a distribution along
the glomerular capillary wall. Double immunostaining technique and double
immunogold electron microscopy demonstrated that FAT is colocalized with ZO-1
and the 5-1-6 antigen which are closely associated with the slit diaphragm (Inoue et
al, 2001). Recently, FAT1, one of the mammalian homologs of FAT, was found to be
an important regulator of actin dynamics and cell-cell interactions through its binding
with Ena/vasodilator-stimulated phosphoproteins (Ena/VASP) proteins (Tanoue &
Takeichi, 2005).
1.5.8 Podocytes and IL-13
Expression of mRNA for the IL-13 receptor subunits: IL-4Ra, IL-13Ra1 and IL-
13Ra2 have been demonstrated in isolated glomeruli and in cultures of human and rat
podocyte by RT-PCR. Protein expression of IL-4Ra and IL-13Ra2 has also been
detected by immunohistochemistry in human kidney biopsies and podocyte cultures
(van den Berg et al, 2000). IL-13 is able to act on podocytes in culture to inhibit the
production of vascular endothelial growth factor (VEGF) (Parry et al, 2001) and dose-
dependently decrease the transepithelial electrical resistance to approximately 40% of
baseline values (van den Berg et al, 2000). On the other hand, IL-13 promotes the
production of basolateral proton and lysosomal proteinase procathepsin L by cultured
podocytes which may promote proteolysis at the basolateral surface of podocyte (van
den Berg et al, 2002). Incubation of podocyte cultures with IL-13 resulted in
phosphorylation of STAT6 (van den Berg et al, 2000), which has been shown to be
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the downstream signaling pathway of the activated heterodimeric receptor complex of
IL-13 composed of IL-4Ra and IL-13Ra1 (Nelms et al, 1999).
1.5.9 Podocytes and B7-1
B7-1, also called CD80, is a transmembrane protein expressed on the surface of B
cells and other antigen presenting cells (Chambers & Allison, 1999). Its function in
the immune system as a co-stimulatory signal for T cells through the binding of T cell
receptors (TCR), CD28 and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4),
has been well characterized (Greenwald et al, 2005). Although increased expression
of B7-1 on glomerular inflammatory infiltrates in lupus GN, crescentic GN and anti-
GBM GN has been documented before (Li, Holdsworth & Tipping, 2000; Nishikawa
et al, 1994; Daikh et al, 1997), induced expression of B7-1 in podocyte, a resident cell
in the glomerulus, has only been reported in nephrotic syndrome recently (Reiser et
al, 2004). Mice injected with LPS, a component of the Gram-negative bacterial cell
wall, have been found to develop transient proteinuria, preceded by increased
expression of B7-1 on the podocytes. In-vitro study also showed that LPS increased
the gene expression of B7-1 through toll-like receptor (TLR)-4 signaling and leads to
reorganization of the podocyte foot process actin cytoskeleton and disruption of the
slit diaphragm. The induction of B7-1 in podocytes suggests that the podocyte is a
novel component of the innate immune system that is equipped with a danger
signaling machinery. This has led to the speculation that B7-1 may function as an
inducible modifier of glomerular permselectivity and the disruption of the glomerular
filter by TLR-induced B7-1 may help the innate immune system in clearing the
circulation from harmful agents by dumping them into the urine (Reiser & Mundel,
2004).
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1.6 Research hypothesis and scope of thesis
MCNS is the most common cause of significant morbidity amongst the childhood
glomerulonephritides in Singapore, though the pathogenesis is still unknown.
Although its pathogenetic mechanism remains unclear, studies have suggested that
MCNS is probably the result of a primary immune disturbance with a Th2 cytokine
bias (Mathieson, 2003; Cunard & Kelly, 2002). We have previously demonstrated that
gene expression of IL-13, a Th2 cytokine, was upregulated in both CD4+ and CD8+ T
cells during relapses in children with MCNS (Yap et al, 1999).  This was associated
with increased intracytoplasmic IL-13 production by CD3+ cells, as well as
downregulation of monocyte proinflammatory cytokines IL-8 and TNF-a (Chen et al,
2003). Recent studies indicate that the podocyte plays a key role in the development
and progression of glomerular diseases. In fact, podocyte foot process effacement is
the hallmark of nephrotic syndrome (Eddy & Symons, 2003), the mechanism of
which involves the slit diaphragm complex and its lipid rafts, the GBM-podocyte
interaction, the actin cytoskeleton and a-actinin-4 and the apical domains (Mundel &
Shankland, 2002). Recently, receptors for IL-13 have been demonstrated in
podocytes. We thus hypothesized that IL-13 may act directly on podocytes by
binding to the IL-13 receptors on the cell surface of podocytes, initiating certain
signaling pathways that lead to changes in the expression of podocyte-specific
proteins which are important in maintaining the structural integrity of the slit
diaphragm and the actin cytoskeleton. This will in turn result in podocyte foot
process effacement, subsequently leading to proteinuria and the nephrotic syndrome.
In this thesis, we attempted to overexpress IL-13 at the protein level in rats by
transfecting a mammalian expression vector cloned with the IL-13 gene into the
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quadriceps of rats using in-vivo electroporation. We then studied the effect of IL-13
on the development of proteinuria and the nephrotic syndrome by monitoring the level
of albumin excretion in the urine and the level of serum IL-13, albumin, cholesterol
and creatinine at regular intervals. The kidneys of the rats were harvested when they
were sacrificed and examined by light microscopy, immunofluorescence technique
and transmission electron microscopy for pathological changes in the glomeruli. In
order to study the effects of IL-13 in the kidney and, to be more specific, in the
glomeruli, we used a graded sieving technique to isolate glomeruli from the kidney
cortex tissue and studied the glomerular gene expression of the IL-13 receptor
subunits: IL-4Ra, IL-13Ra1 and IL-13Ra2; the downstream signaling molecule:
STAT6; and the podocyte-associated proteins: nephrin, podocin and dystroglycan
using real-time PCR with hybridization probes. Snap frozen tissue of the kidneys was
also collected to study their protein expression in the glomeruli using
immunofluorescence technique. In addition, we examined the gene and protein
expression of B7-1 in the glomeruli, to determine its relationship to IL-13 levels,
proteinuria and the glomerular expression of podocyte-associated proteins. Finally,
we studied the effects of IL-13 on the cholesterol metabolic pathway in order to
dissect the molecular mechanisms of hypercholesterolemia associated with nephrotic
syndrome.
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2.1 Cloning of rat IL-13 gene into mammalian expression vector
2.1.1 The pCI mammalian expression vector
The pCI mammalian expression vector (Promega, cat.#E1731) is designed to promote
constitutive expression of cloned DNA inserts in mammalian cells. It contains the
human cytomegalovirus (CMV) major immediate-early gene enhancer/promoter
region which allows strong, constitutive expression of the cloned DNA insert in many
cell types. Downstream of the enhancer/promoter region is a chimeric intron which is
able to increase gene expression level of the cDNA insert. It also contains a multiple
cloning region which provides 11 restriction enzyme sites for cloning of the DNA
insert. The SV40 late polyadenylation signal is found immediately downstream of the
multiple cloning sites. This polyadenylation signal causes the termination of
transcription by RNA polymerase II and signals the addition of approximately 200-
250 adenosine residues to the 3’ end of the RNA transcript. This will enhance RNA
stability and translation. (Figure 2.1)
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Figure 2.1 pCI mammalian expression vector and multiple cloning region maps
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2.1.2 Design of primers
The insert consists of the complete coding sequence of rat IL-13 (Gene accession no.
NM_053828) including the start codon, the leader sequence and the stop codon
(Appendix 2.1). An XhoI and a NotI restriction enzyme site was incorporated into the
PCR product at the 5’ and 3’ends respectively during primer design. This will
facilitate directional cloning of the insert into the pCI mammalian expression vector
through the multiple cloning sites. The forward primer begins with an XhoI restriction
enzyme site (C?TCGAG) followed by the first 20 (1-20) nucleotides of the rat IL-13
mRNA sequence. The reverse primer begins with a NotI restriction enzyme site
(GC?GGCCGC) followed by the complimentary base pair of the last 22 (375-396)
nucleotides of the rat IL-13 mRNA sequence reading from the 3’ end. (See below)
Primer Sequence Length(bp) Tm (
oC) GC%
Forward 5’–ctcgagatggcactctgggtgactgc–3’ 26 70.9 61.5
Reverse 5’–gcggccgctcagtggccatagcggaaaagt-3’ 30 74.2 63.3
2.1.3 RT-PCR using Taq polymerase
A polymerase chain reaction (PCR) using Taq polymerase was set up (Sambrook &
Russel, 2001) to generate PCR products which contained the rat IL-13 gene sequence
using primers designed in the previous section (Appendix 2.2). cDNA sample
reversed transcribed from mRNA extracted from rat PBMC was used as the template.
The PCR product (410 bp) contained the complete rat IL-13 gene sequence with an
XhoI restriction enzyme site at the 5’-end and a NotI restriction enzyme site at the 3’-
end. As both the XhoI and NotI restriction enzyme sites were located at the ends of
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the PCR product, these restriction enzyme sites would be cut with very low
efficiency. In order to facilitate the restriction digestion reaction, the PCR product was
first cloned into a TA cloning vector (Invitrogen, cat.#450641) (Appendix 2.3). The
plasmid vector (pCR®2.1-TOPO®) was supplied linearized with a single 3’- thymidine
(T) overhangs. PCR products generated using Taq polymerase would have an
additional hanging “A” nucleotide. This allowed the rat IL-13 PCR products to ligate
efficiently with the vector by the principle of TA cloning.
2.1.4 Restriction enzyme digestion of the XhoI and NotI sites
Two restriction enzyme digestion reactions were set up using XhoI and NotI
restriction endonucleases, one for the pCI mammalian expression vector, the other for
the TA cloning vector cloned with the rat IL-13 gene sequence. The restriction
enzyme digestion reaction was set up as follows (Sambrook & Russel, 2001):
XhoI (Promega, cat.#R616A) 0.5 ?l
NotI (Promega , cat.#R643A) 0.5 ?l
Buffer D, 10x (Promega, cat.#R004A) 2 ?l
Sterile ddH2O 15 ?l
Purified plasmid 2 ?l
The reaction mixture was incubated at 37oC for 2 hours and subsequently run on 1.5%
agarose gel.
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2.1.5 Agarose gel electrophoresis and gel extraction of DNA
A fast running and a slow running band could be seen from restriction enzyme
digestion reaction mixture of the TA cloning vector that was cloned with the rat IL-13
gene sequence after electrophoresis. The fast running band was about 410 bp and
consisted of the rat IL-13 gene sequence and the restriction enzyme sites at both ends.
The slow running band consisted of the linearized TA cloning vector that had been cut
apart at the respective restriction enzyme sites located at the ends of the rat IL-13
gene insert. A slow running band could be seen from restriction enzyme digestion
reaction mixture of the pCI mammalian expression vector after electrophoresis. This
represented the linearized pCI mammalian expression vector that had been cut apart at
the respective restriction enzyme sites of the multiple cloning sites. (Figure 2.2) The
bands consisting of the rat IL-13 gene sequence and the linearized pCI mammalian
expression vector were cut out from the agarose gel with the aid of a UV illuminator.
The DNA content within the gel were then extracted using the QIAquick® Gel
Extraction Kit (Qiagen, cat.#28704) (Appendix 2.4).
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Figure 2.2 DNA products of restriction enzyme digestion at the XhoI and NotI
sites separated by agarose gel electrophoresis. Lane 1: 100 bp DNA ladder. Brightest
band represents 500 bp. Lane 2-4: Restriction enzyme digestion products of TA
cloning plasmid cloned with the rat IL-13 gene. The slow running bands consisted of
the linearized TA cloning vector (3931 bp) that had been cut apart at the XhoI and
NotI sites located at the ends of the rat IL-13 gene insert. The fast running bands were
about 410 bp and consisted of the rat IL-13 gene sequence with the restriction enzyme
sites at both ends. Lane 5: Linearized pCI mammalian expression vector (4006 bp)
that had been cut apart at the XhoI and NotI sites of the multiple cloning region. Lane
6: Undigested supercoiled pCI mammalian expression vector with differing migration
characteristics.
 6       5      4       3      2       1
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2.1.6 Ligation of the rat IL-13 gene and the pCI mammalian expression vector
A DNA ligase reaction was set up to clone the purified rat IL-13 gene sequence into
the purified linearized pCI mammalian expression vector through the XhoI and NotI
restriction enzyme sites. Incubation was carried out at 4oC overnight. The DNA ligase
reaction was set up as follows (Sambrook & Russel, 2001):
Purified linearized pCI mammalian expression vector, 100 ng 0.5 ?l
Purified rat IL-13 gene, 17 ng 2 ?l
Ligase 10x buffer 1 ?l
T4 DNA ligase (Promega, cat.#M1801A) 0.2 ?l
Nuclease-free water to final volume of 10 ?l
2.1.7 Transformation of ligation product into E. coli
Five ?l of the ligation product was added to a vial of One Shot® Chemically
Competent TOP10 E. coli (Invitrogen, cat.#C4040-03), incubated at room
temperature for 15 minutes and put on ice before subjecting the cells to heat shock at
42oC for 30 seconds. SOC medium (250 ?l) was then added to the transformed E. coli
and incubated for 1 hour at 37oC with shaking at 200 rpm. After incubation, 50 ?l of
the incubation mixture was spread onto a LB (Luria-Bertani) plate containing 50
?g/ml ampicillin. The LB plate was then incubated at 37oC overnight. Transformed E.
coli are ampicillin resistant because the pCI vector carries the ampicillin resistant
gene. Therefore, E. coli that are not transformed cannot grow on the medium because
they are not ampicillin resistant. Theoretically, all the bacterial colonies on the LB
agar plate were transformed with cloned pCI vector because E. coli that were
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transformed with linearized pCI vector only would not translate the ampicillin
resistant gene protein and thus will not be able to grow on LB medium containing
ampicillin.
2.1.8 Extraction and purification of plasmid DNA
In order to confirm that the correct rat IL-13 gene sequence is successfully cloned into
the pCI vector, we needed to produce and extract enough of the cloned plasmid to
carry out a DNA sequencing reaction and a restriction enzyme digestion reaction.
Four bacterial colonies from the LB agar plate were picked up and transferred
separately to a 50 ml culture tube containing 10 ml of LB medium with 50 ?g/ml of
ampicillin. The culture tubes were then incubated at 37oC overnight with shaking at
250 rpm. There will be substantial growth of E. coli during the incubation and thus
amplification of the recombinant plasmid vector at the same time. Extraction and
purification of plasmid DNA was carried out using the QIAprep Spin Miniprep kit,
cat.#27104 from Qiagen. The QIAprep miniprep procedure is based on alkaline lysis
of bacterial cells followed by adsorption of DNA onto silica in the presence of high
salt. The procedure consisted of three basic steps: preparation and clearing of a
bacterial lysate, adsorption of DNA onto the QIAprep membrane, washing and elution
of plasmid DNA. The last 2 basic steps were performed on a spin column. (Appendix
2.5)
2.1.9 Restriction enzyme digestion reaction (for validation)
The restriction enzyme digestion reaction was set up as in Section 2.1.4. The reaction
mixture was incubated at 37oC for 2 hours and subsequently run on 1.5% agarose gel.
The expected size of the restriction enzyme digestion product was 410 bp.
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2.1.10 DNA sequencing (for validation)
DNA sequencing is the most direct and reliable approach to show whether the correct
sequence has been cloned into the plasmid DNA. The cycle sequencing reaction was
set up as follows using the “BigDye® Terminator v3.1 Cycle Sequencing Kit”
(cat.#4337457) purchased from Applied Biosystems:
BigDye 2 ?l
5x reaction buffer 4 ?l
T7 EEV promoter primer (Promega, cat.#Q6700)  3.2 pmol (0.32 ?l)
Purified plasmid 0.5 ?l
Sterile ddH2O Add up to 20 ?l
Cycle sequencing consisted of 25 cycles of denaturing at 96oC for 10 seconds,
annealing at 50oC for 5 seconds and elongation at 60oC for 4 minutes as shown below.
It was carried out using the GeneAmp® PCR System 9700 (PE Applied Biosystems).
Steps Temperature (oC) Time
Denaturation 96 10 seconds
Primers annealing 50 5 seconds
Extension 60 4 minutes
The extension products were precipitated and purified by an ethanol/sodium acetate
precipitation procedure (Appendix 2.6). The dried pellet was then reconstituted in 12
?l of Hi-Di formamide before loading to the sample tray for sequencing. Sequencing
was done on the ABI Prism 3100 genetic analyzer (PE Applied Biosystems) using a
DocumentsPDFComplete




50 cm capillary array and POP-6™ polymer. The results were analyzed using
“Sequencing Analysis v3.7” sequencing analysis software (PE Applied Biosystems).
The nucleotide base sequence was analyzed and compared to ensure 100% match to
that of rat IL-13 mRNA.
2.2 Large scale production of cloned plasmid
The cloned pCI mammalian expression vector was transformed into chemically
competent TOP10 E. coli by heat-shock at 37oC for 30 seconds. Large scale
production of cloned plasmid was carried out by overnight incubation in LB medium
containing 50 ?g/ml ampicillin with shaking at 250 rpm and 37oC. The bacteria
culture, harboring the rat IL-13 cloned pCI mammalian expression vector, was
harvested by centrifugation at 6000 x g for 15 minutes at 4oC using an ultra-centrifuge
(Sorvall RC-5C Plus). After discarding the supernatant, plasmid was extracted from
the bacterial pellet using the NucleoBond endotoxin-free plasmid DNA extraction kit
(Macherey-Nagel) according to the manufacturer’s instruction (Appendix 2.7). The
concentration and purity of the plasmid DNA was determined by spectrophotometry.
Each batch of plasmid DNA produced were checked by restriction enzyme digestion
and sequencing to ensure 100% match of the nucleotide sequence to that of rat IL-13
mRNA. The plasmid DNA was reconstituted to a final concentration of 2 ?g/?l with
1x PBS and stored at -20oC until use.
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Six-week old female Wistar rats weighing about 150-180 g were used. They were
kept in the animal holding unit with no restriction to food and water. All animal
studies were approved by the Institutional Animal Care and Use Committee of the
National University of Singapore.
In-vivo electroporation
In-vivo electroporation of plasmid DNA was carried out every 10 days. Rats were
anaesthetized by intraperitoneal injection of 0.6 ml CRC mixture composed of 1 part
of hypnorm, 1 part of dormicum and 2 parts of sterile distilled water. Two hundred ?g
of the purified plasmid, at a concentration of 2 ?g/?l, was injected into the quadriceps
of the rat, alternating between right and left thigh for each injection. The control rats
(n=17) received 200 ?g of the pCI mammalian expression vector while the test rats
(n=41) received 200 ?g of the pCI mammalian expression vector cloned with the rat
IL-13 gene. A 10 mm 2-Needle Array™ tip (BTX, Genetronics Inc), which was
connected to a 2-Needle Array™ electrode (BTX, Genetronics Inc), was inserted into
the muscle flanking the area of injection. An electric current, generated by the
“Electro Square Porator ECM830” (BTX, Genetronics Inc), was passed through the
muscles in 6 pulses of 20 milliseconds each at 160 V (Nickoloff, 1995) (Figure 2.4).
Collection of 24-hour urine sample
Rats were put in metabolic cages (Figure 2.5) for the collection of 24-hour urine
sample every 2 weeks. The volume of urine was recorded at the end of 24 hours.
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Collection of blood sample
Approximately 1 ml of heparinized blood was sampled at days 0, 30 and 60 from the
ventral artery of the tail by a 23G needle (Figure 2.6). Heparinized blood was also
collected by heart puncture technique (Figure 2.7) when the rats were sacrificed.
Serum was separated by centrifugation at 3000 rpm for 10 minutes.
The complete experimental protocol is also illustrated in the following figure:
I.M. In vivo Electroporation
Bleed
Blood: IL-13, albumin, cholesterol, creatinine, IgE
24-hour urine: albumin
Tissues from kidney and liver were collected for histology, electron
microscopy and gene expression studies when the rats were
sacrificed at day 70
Experimental protocol
DAYS0         10         20        30        40         50        60 70
Urine Collection
Figure 2.3 Experimental protocol of animal experiments
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Figure 2.4 In-vivo electroporation
A 10 mm 2-Needle Array™ tip connected
to a 2-Needle Array™ electrode (BTX,
Genetronics Inc).
The electric current was generated by the
“Electro Square Porator ECM830” (BTX,
Genetronics Inc).
Female Wistar rats weighing about 150-
180 g were used. 200 µg of the purified
plasmid was injected into the quadriceps of
rat.
The electrode was then inserted into the
muscle flanking the area of injection. An
electric current, generated by the
electroporator, was passed through the
muscles in 6 pulses of 20 milliseconds each
at 160 V.
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Figure 2.5 Metabolic cage
The metabolic cage is divided into an upper part and a lower part which is separated
by a metal grid. The animal is kept at the upper part which is also equipped with the
water and food inlet. The lower part consists of the collection chamber and the
collection tubes. Faeces and food particles will fall into the collection tube at the
centre. Urine will flow along the wall and drain into the collection tube at the side.
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Figure 2.6 Collection of blood from the tail
Rats were anaesthetized with CRC mixture and laid flat on their backs with the tail
hanging down. The site of insertion was sterilized by 70% ethanol. A 23G needle with
the plastic end removed was inserted into the ventral artery of the tail. Blood was
allowed to flow freely into an eppendorf tube containing 1 drop of 5000 I.U. heparin.
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Figure 2.7 Collection of blood by heart puncture technique
Rats were anaesthetized with CRC mixture and laid flat on their backs. A 23G needle
with handling flap was connected to a 10 ml syringe and rinsed with heparin before
insertion. The needle was inserted into the heart without opening the thoracic cavity.
Blood was drawn into the syringe by pulling the plunger. Multiple insertions should
be avoided. Up to 10 ml of blood could be collected by this technique.
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 2.3.2 Urine albumin ELISA
A direct sandwich enzyme linked-immuno-sorbent assay (ELISA) system was
developed (Crowther, 2001) to detect the concentration of albumin in 24-hour urine
samples. One hundred ?l of unconjugated rabbit antiserum vs. rat albumin (ICN,
Cappel, cat.#5711) diluted 1:2000 was used as the coating antibody and 50 ?l of a
horseradish peroxidase (HRP)-conjugated sheep monoclonal antibody vs. rat albumin
(ICN, Cappel, cat.#55776) diluted 1:7500 was used as the detecting antibody. o-
Diphenylenediamine (OPD), in citrate buffer pH 5.0, was used as the substrate for
color development. (Appendix 2.8) Rat albumin standards of known concentrations
were included in each assay. Each sample was measured in triplicates. Endpoint
absorbance was read at 490 nm by a microplate reader (BioRad Benchmark). The
total amount of albumin excreted in 24-hour urine was derived by multiplying the
concentration of albumin present (mg/ml) and the total 24-hour urine volume (ml).
2.3.3 Serum biochemistry
Serum albumin
Serum albumin level was determined by bromocresol purple (BCP) method (Pinnell
& Northam, 1978) using a reagent kit (Randox Laboratories, UK). Serum albumin
binds quantitatively to the indicator 5,5-dibromo-o-cresolsulphonphthalein
(bromocresol purple) to form a complex which absorbs maximally at 600 nm. Briefly,
10 ?l of samples (standard and serum samples) were added to 2 ml of BCP reagent
and incubated for 5 minutes at room temperature. Absorbance of the reaction mixtures
was read at 600 nm using a cuvette with 1 cm light path against the reagent blank.
(Appendix 2.9)
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Serum cholesterol level was determined by an enzymatic endpoint method (Allain et
al, 1974) using a reagent kit (Randox Laboratories, UK). Hydrogen peroxide is
released after enzymatic hydrolysis and oxidation of cholesterol. The indicative end
product, quinoneimine, is formed from hydrogen peroxide and 4-aminoantipyrine in
the presence of phenol and peroxidase. Briefly, 10 ?l of the samples (standard and
serum samples) were added to 1 ml of the reagent provided and incubated for 10
minutes at room temperature. Absorbance of the reaction mixtures was read at 500 nm
using a cuvette with 1 cm light path against the reagent blank. (Appendix 2.10)
Serum creatinine
Serum creatinine was determined by the alkaline picrate method (Archibald, 1962).
Creatinine in alkaline solution reacts with picrate to form a colored complex which
absorbs maximally at 490-520 nm. The amount of complex formed is directly
proportional to the creatinine concentration. Absorbance was read at 490 nm using a
microplate reader. (Appendix 2.11)
2.3.4 Serum IgE ELISA
Serum IgE level was determined by an indirect sandwich ELISA method (Crowther,
2001) using a 96-well microtiter plate for blood samples collected when the rats were
sacrificed. Purified mouse anti-rat IgE monoclonal antibody (Pharmingen,
cat.#553914) diluted 1:200 in carbonate buffer was used as the capturing antibody.
Fifty ?l of serum samples and purified rat IgE standards (Pharmingen, cat.#558691)
were added in duplicates and incubated at 37oC for 1½ hours. Biotin-conjugated
mouse anti-rat IgE monoclonal antibody (Pharmingen, cat.#553916) diluted 1:200
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was used as the detecting antibody.  ExtrAvidin – Alkaline Phosphatase (Sigma,
cat.#E2636) diluted 1:3000 was then added to bind to the biotin-conjugated detecting
antibody. p-Nitrophenyl phosphate (Sigma, cat.#N2770) was used as the substrate for
color development. Absorbance was read at 405 nm using a microplate reader after
incubation in the dark for 15 minutes. (Appendix 2.12)
2.3.5 Serum IL-13 ELISA
Serum IL-13 level was measured by a rat IL-13 ELISA kit (BioSource International,
Belgium) which has a sensitivity freshhold of 7.8 pg/ml. The rat IL-13 kit is a solid
phase sandwich ELISA. A monoclonal antibody specific for rat Il-13 had been coated
onto the wells of the microtiter strips provided. Fifty ?l of samples, including IL-13
standards of concentrations ranging from 7.8-500 pg/ml, control specimens, and
unknowns, were pipetted into the wells followed by 150 ?l of a biotinylated second
monoclonal antibody. During the first incubation, the IL-13 antigen bond
simultaneously to the immobilized (capture) antibody on one site, and to the solution
phase biotinylated antibody on a second site. After removal of excess second antibody
and washing, 100 ?l of streptavidin-peroxidase (enzyme) was added. This bond to the
biotinylated antibody to complete the four-member sandwich. After a second
incubation and washing to remove all the unbound enzyme, a substrate solution was
added, which was acted upon by the bound enzyme to produce color. The intensity of
this colored product was directly proportional to the concentration of IL-13 present in
the original specimen. Each sample was done in duplicates. Absorbance was read at
450 nm by a microplate reader. (Appendix 2.13)
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2.3.6 Sacrificing of animals
Rats were sacrificed at day 70 after collection of the last 24-hour urine sample. The
animals were anaesthetized by intraperitoneal injection of 0.8 ml CRC mixture. They
were examined physically for signs of oedema and the body weight was recorded.
Blood was taken by heart puncture technique as described in Figure 2.7. The kidneys,
spleen and liver were harvested and the weights of the organs were recorded after
removal of the overlying fat.
2.4 Pathological examination
2.4.1 Histology
Tissue from the kidneys was harvested for histology when the rats were sacrificed.
They were fixed immediately in 10% neutral buffered formalin and processed into
paraffin blocks. Three ?m sections were cut from the kidney tissue and stained with
haematoxylin and eosin (H&E) (Appendix 2.14) and periodic acid-Schiff (PAS) stain
(Appendix 2.15). The sections were examined by light microscopy for pathological
changes in the glomeruli.
2.4.2 Immunofluorescence study
Direct immunofluorescence technique was used to detect the presence of immune
complex deposits for IgA, IgG, IgM and C3 in the glomeruli. A small piece of the
kidney tissue was snap-frozen in liquid nitrogen when the rats were sacrificed. Frozen
sections were cut at 8 ?m using a cryostat, dried briefly in the air and fixed in acetone
for 10 minutes at 4oC. Primary antibodies for the detection of rat IgA and IgM are
fluorescein isothiocyanate (FITC)-conjugated goat polyclonal IgG antibody purchased
from US Biological (Swampscott, Massachusetts). Primary antibodies for the
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detection of rat IgG and C3 are FITC-conjugated goat polyclonal IgG antibody
purchased from ICN, Cappel (Costa Mesa, California). The list of primary antibodies
and their usage are summarized in Table 2.1. Frozen sections were incubated with the
FITC-conjugated primary antibodies, diluted with 1x PBS to a concentration of 5
?g/ml, for 30 minutes in the dark. Control sections were stained in parallel on the
same slide and incubated with 1x PBS only. The sections were then washed with 1x
PBS for 3 times of 5 minutes each, mounted with fluorescence mounting medium, and
kept at 4oC in the dark before examination under the immunofluorescent microscope.
(Appendix 2.16)
2.4.3 Electron microscopy
A small piece of the kidney cortex was fixed in 2.5% glutaraldehyde in 0.1 M
phosphate buffer, pH 7.4, overnight at 4oC and post-fixed in 1% aqueous osmium
tetroxide for 1 hour at room temperature. The staining and contrast of the tissue was
further enhanced by incubation for 30 minutes in 2% aqueous uranium acetate before
dehydrating through graded acetone. Araldite CY-212 resin was used for infiltration
and embedding. Resin blocks were polymerized at 60oC for 24 hours. (Appendix
2.17) Semi-thin sections were cut at 1 ?m and stained with 1% toluidine blue
(Appendix 2.18). Ultra-thin sections were cut at 100 nm and stained with saturated
aqueous uranium acetate for 20 minutes and Reynold’s lead citrate for 10 minutes to
enhance contrast (Appendix 2.19). Sections were examined by Philips EM208
transmission electron microscope.
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    Table 2.1
    List of primary antibodies used for immunofluorescence study
Primary antibody Type Isotype Conjugate Manufacturer Cat.# Concentration Working dilution
Goat anti-rat IgA Polyclonal IgG FITC US Biological 11890-05K 1 mg/ml 1:200
Affinity purified
Goat anti-rat IgM Polyclonal IgG FITC US Biological 11905-01R 1 mg/ml 1:200
Affinity purified
Goat anti-rat C3 Polyclonal IgG FITC ICN, Cappel 55751 6 mg/ml 1:1200
Affinity purified
Goat anti-rat IgG Polyclonal IgG FITC ICN, Cappel 55760 1 mg/ml 1:200
Affinity purified
    FITC = Fluorescein isothiocyanate
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2.5 Glomerular gene expression study
2.5.1 Isolation of glomeruli by graded sieving technique
Glomeruli were isolated from kidney cortical tissue using graded sieving technique
(Kreisberg et al, 1978). The graded sieving technique is based on partial mechanical
disaggregation of cortical tissue to form isolated glomeruli. The medullary portion
was removed and the cortical area was cut into small pieces before putting onto a
stainless steel sieve (W.S. Tyler, USA) with a bore diameter of 75 ?m. The tissue was
then pressed through the sieve with a spatula and rinsed off with ice-cold 1x Hank’s
balanced salt solution (HBSS) to a Petri dish placed underneath the sieve. The filtrate
collected in the Petri dish was then passed through a 70 ?m nylon sieve (BD
FalconTM, cat.#352350) placed on top of a 50 ml collection tube. Isolated glomeruli,
together with large tubular tissue fragments were retained on the nylon sieve while
red blood cells (RBC) and smaller tissue fragments passed through. The 70 ?m nylon
sieve was then placed upside down onto a new 50 ml collection tube and the
glomeruli were washed down to the collection tube with 1x HBSS. Glomeruli
obtained from the graded sieving technique were usually over 95% pure.
Contamination from tubular epithelial cells was minimal. (Figure 2.8)
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Step 1    The cortical areas of the rat kidney
were cut into small pieces. They were
pressed through a 75 ?m stainless steel sieve
with a spatula. A Petri dish was placed under
the sieve to collect glomeruli washed down
by 1x HBSS.
Step 2   The glomeruli collected were then
passed through a 70 ?m nylon sieve placed
on top of a 50 ml culture bottle.
Step 3   Most of the glomeruli were retained
on the nylon sieve while RBC and small
fragments passed through the nylon sieve.
Step 4   The 70 ?m nylon sieve was then
placed upside-down onto a new 50 ml
culture tube and washed down by 1x HBSS.
Figure 2.8 Graded sieving technique
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2.5.2 Extraction of total RNA from isolated glomeruli by TRIzol® reagent
Glomeruli isolated by the graded sieving technique were washed twice with ice cold
1x HBSS. The supernatant was discarded after the last wash. One ml of TRIzol®
reagent (Gibco BRL, cat.#15596-026) was added after dispersing the glomeruli pellet.
The glomeruli suspension in TRIzol® reagent was allowed to stand for 10 minutes at
room temperature before proceeding to total RNA extraction according to the
manufacturer’s instructions (Appendix 2.20). The concentration and the purity of
RNA were determined by UV spectrophotometry. Absorbance of 1 OD read at 260
nm in a 1 cm light path is equivalent to 40 ?g/ml of RNA. Pure RNA should have an
A260/A280 ratio of 2.0.
2.5.3 Plasmid standards for real-time PCR
Real-time PCR is able to quantitate the expression of a gene with the use of a standard
curve. The standard curve is created by cloned plasmid DNA standards of known
quantity, with which the unknown is compared with by the Cp (Crossing point) value.
Cp value is defined as the cycle number at detection threshold. The TA cloning vector
is an ideal template to prepare standards for quantitative PCR. PCR products can be
cloned readily into the TA cloning vector by the principle of TA cloning.
Amplification of the cloned plasmid is achieved by overnight culture after
transformation into E. coli. After the extraction and purification of plasmid DNA, the
concentration of plasmid DNA was determined by UV spectrophotometry.
Absorbance of 1 OD read at 260 nm in a 1 cm light path is equivalent to 50 ?g/ml of
DNA. Pure DNA should have an A260/A280 ratio of 1.8. The number of copies per ?g
of plasmid DNA was given by the following formula which depends on the size of the
cloned plasmid DNA:
DocumentsPDFComplete




copies per ?g of plasmid DNA
6.022 x 1023
---------------------------------------------
(Size of plasmid DNA x 662 x 106)
The number of copies of plasmid DNA per ?l can be derived by a simple calculation
if the concentration is known. Two ?l of the plasmid DNA was taken out and
reconstituted with Tris-EDTA (TE) buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA)
to 1 x 109 copies/?l to form the stock plasmid solution. A 10x serial dilution was then
made from the stock plasmid solution with TE buffer to form standards ranging from
1 x 108 to 10 copies/?l. Plasmid standards were created for all the genes being
examined. Standard curve was created in every PCR run with at least 5 standards.
(Reference: Online document: Creating standard curves with genomic DNA or
plasmid DNA templates for use in quantitative PCR. Website:
www.appliedbiosystems.com/support/apptech/)
2.5.4 Reverse transcription and real-time PCR
One ?g of total RNA from each sample was reversed transcribed into cDNA using M-
MLV (Moloney murine leukemia virus) reverse transcriptase (Promega, cat.#M1701)
in a total volume of 40 ?l reaction mixtures (Appendix 2.21). Glomerular gene
expression of the IL-13 receptor subunits: IL-4Ra, IL-13Ra1 and IL-13Ra2; the
downstream signaling molecule: STAT6; and the podocyte-associated proteins:
nephrin, podocin, dystroglycan and B7-1, were determined by quantitative real-time
PCR using LightCycler (Roche) with hybridization probes (Appendix 2.22, 2.23 &
2.24). Primers and probes were designed and synthesized by Proligo, Singapore. A
standard curve was created for each gene being studied using serial dilutions of at
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least 5 plasmid standards that were cloned with the PCR products generated by their
respective primers. All the standard curves have a regression coefficient of -1 and an
error of less than 0.1. Each sample was run in duplicates. Results were expressed as
an index of the housekeeping gene, b-actin. The nucleotide sequence of primers and
probes are summarized in Table 2.2.
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Table 2.2 Nucleotide sequence of primers and probes used in real-time PCR for
rat glomerular gene expression study
Gene/Accession # Primers & Probes Nucleotide sequence 5' - 3' bp
Rat nephrin Forward primer GGCGTAGCTTAGGGAC 231
AF161715 Reverse primer CCTAGCCGCCAATCAC
Probe 1 TATAGAGACAGAAAAGGGTAAGCTCAGAC-Fa
Probe 2 LC Red-AAATGTTGACACTGGATGTGGTT-Pb
Rat podocin Forward primer CTAAGCAGTCTAGCTCATG 271
NM_130828 Reverse primer CAATCACCCGCACTTT
Probe 1 CTCCTGGAAAGGAAGAGCATTG-F
Probe 2 LC Red-CAAGATGTAAAGGTTGCCTTGGAC-P
Rat dystroglycan 1 Forward primer ATGAAAACGGGAAGCC 213
XM_343483 Reverse primer CTGTGTGCAAGTAAACGTC
(Predicted) Probe 1 TGTCGGCACCTCCAATTTATCC-F
Probe 2 LC Red-GTGGCACCACCCTCTCC-P
Rat CD80 (B7-1) Forward primer CCACTCCTCGGGTTTC 184
NM_012926 Reverse primer TTTGCCAGTAGATTCGGT
Probe 1 AGGTATTGTCGGCCAAGTGT-F
Probe 2 LC Red-AAGTCGGTGAGAGAAAAGGCAT-P
Rat IL-4Ra Forward primer TCCACCCAATAGACCGT 265
AB015747 Reverse primer GCAATCAAGTTTGCGTTC
Probe 1 TTGAGTTAAGGGAGGGTAGATACTGC-F
Probe 2 LC Red-CAAGGAGGCTATTCATTGAACAGC-P
Rat IL-13Ra1 Forward primer TTGGCACAACCTGAGCT 330
AY044251 Reverse primer TGCACGAATAAGGCACC
Probe 1 TTCCTGGCTCCCTGGAAAGAA-F
Probe 2 LC Red-CAAGCCCGGACACCAACT-P
Rat IL-13Ra2 Forward primer GGAATGCTGGGAAGGT 190
NM_133538 Reverse primer AGTTTAGCAGAGCGTCT
Probe 1 AGGAAGACCCTGAACCCAC-F
Probe 2 LC Red-TGAGCCTCCATGTGGATTTGAACA-P
Rat STAT6 Forward primer TACTGGGTCTGCAGTTCC 155
XM_343223 Reverse primer CAGAGGTACAGTATTGTTCATGAT
(Predicted) Probe 1 AGCTGACATGGTGACAGAGAAAC-F
Probe 2 LC Red 640-GCCAGAGAACTAAGCCTGCC-P
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Rat b-actin Forward primer GCCCTAGACTTCGAGC 217
NM_031144 Reverse primer CTTTACGGATGTCAACGT
Probe 1 AGCTATGAGCTGCCTGACG-F
Probe 2 LC Red-CAGGTCATCACTATCGGCAATGAG-P
aFluorescein conjugate at the 3’ end
bPhosphate group at the 3’ end
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2.6 Glomerular protein expression study
Glomerular protein expression of nephrin, podocin, dystroglycan, B7-1 and IL-4Ra
were determined by indirect immunofluorescence technique. A small piece of the
kidney tissue was snap-frozen in liquid nitrogen when the rats were sacrificed. Frozen
sections were cut at 8 ?m using a cryostat, dried briefly in the air and fixed in acetone
for 10 minutes at 4oC. Primary antibody for the detection of nephrin is a guinea pig
polyclonal antibody purchased from Research Diagnostics Inc (Flanders, New
Jersey). Primary antibody for the detection of podocin is a rabbit polyclonal antibody
purchased from Alpha Diagnostic International (San Antonio, Texas). Primary
antibody for the detection of dystroglycan is a mouse monoclonal antibody purchased
from Upstate (Charlottesville, Virginia). Primary antibody for the detection of B7-1 is
a mouse monoclonal antibody purchased from eBioscience (San Diego, California).
Primary antibody for the detection of IL-4Ra is a rabbit polyclonal antibody
purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, California). FITC-
conjugated secondary antibodies were used to bind to the primary antibodies. The lists
of primary and secondary antibodies are summarized in Table 2.3A & 2.3B. Control
sections were stained in parallel on the same slide with the primary antibody being
omitted. Briefly, sections were incubated with the primary antibody for 30 minutes
and washed with 1x PBS for 3 times of 5 minutes each. This was followed by
incubation with the secondary antibody for 30 minutes in the dark and washed with 1x
PBS for 3 times of 5 minutes each. Sections were then mounted with fluorescence
mounting medium and kept at 4oC in the dark before examination under the
immunofluorescent microscope. (Appendix 2.25)
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List of primary antibodies used for glomerular protein expression study
Primary antibody Type Isotype Conjugate Manufacturer Cat. # Concentration Working dilution
Mouse anti-rat CD80 (B7-1) Monoclonal IgG1, K Unconjugated eBioscience 14-0800 0.5 mg/ml 1:10
Affinity purified
Guinea pig anti-rat nephrin Polyclonal IgG Unconjugated RDI RDI-PROGPN1 Unknown 1:50
Whole antiserum
Rabbit anti-rat podocin Polyclonal IgG Unconjugated Alpha Diagnostic PODO 11-A 1 mg/ml 1:50
Affinity purified
Mouse anti-rat ?-dystroglycan Ascites IgM Unconjugated Upstate 05-593 Unknown 1:50
Rabbit anti-rat IL-4R? Polyclonal IgG Unconjugated  Santa Cruz sc-686 0.2 mg/ml 1:50
Affinity purified
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List of secondary antibodies used for glomerular protein expression study
Secondary antibody Type Isotype Conjugate Manufacturer Cat.# Concentration Working dilution
Goat anti-mouse IgG1 Polyclonal IgG FITC Santa Cruz sc-2078 0.4 mg/ml 1:200
Affinity purified
Goat anti-mouse IgM Polyclonal IgG FITC Santa Cruz sc-2082 0.4 mg/ml 1:200
Affinity purified
Donkey anti-guinea pig IgG Polyclonal IgG FITC RDI RDI-706095148 unknown 1:100
Affinity purified
Donkey anti-rabbit IgG Polyclonal IgG FITC Chemicon AP182F 1 mg/ml 1:200
Affinity purified
FITC = Fluorescein isothiocyanate
DocumentsPDFComplete




2.7 Flow cytometric analysis of splenic mononuclear cells
Flow cytometry was used to determine the relative proportions of T cells, B cells and
macrophages in the spleen. A single cell suspension of the rat spleen was prepared by
pressing the tissue through a 40 ?m nylon sieve. Cell count of the mononuclear cells
was determined using hemacytometer. One million cells were used for staining in
each reaction. Primary antibody was used at a ratio of 1 ?g/million cells. Primary
antibody for the detection of T cells is a FITC-conjugated monoclonal mouse IgM
antibody directed against rat CD3 (Pharmingen, cat.#557354). Primary antibody for
the detection of B cells is a FITC-conjugated monoclonal mouse IgG1 antibody
directed against rat CD45RA (Pharmingen, cat.#554883). Primary antibody for the
detection of macrophage is a phycoerythrin (PE)-conjugated monoclonal mouse
IgG2a antibody directed against a rat macrophage subset (Pharmingen, cat.#554901).
The list of primary antibodies and their usage are summarized in Table 2.4. Isotype
controls were included for all the primary antibodies used. The reaction mixture was
set up as follows:
Tube Control/test Volume of cellsuspension used
Volume of
antibody used
1 Negative control 100 ?l -----
2 IgM-FITC isotype control 100 ?l 10 ?l
3 CD3-FITC (T cells) 100 ?l 2 ?l
4 IgG1-FITC isotype controlIgG2a-PE isotype control 100 ?l
10 ?l
10 ?l








The cells were incubated with the primary antibodies for 30 minutes in the dark
followed by lysis of RBC with 2 ml of RBC lysis buffer for 10 minutes. Cells were
washed with wash buffer for 3 times and resuspended in 300 ?l of wash buffer after
the last wash. Cell acquisition was performed using FACScan (Becton Dickinson),
and 3000 cells were acquired for each sample. (Appendix 2.26)
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List of primary antibodies used for flow cytometry
Primary antibody Type Isotype Conjugate Manufacturer Cat.# Concentration Suggested working dilution
Mouse anti-rat CD45RA Monoclonal IgG1, k FITC Pharmingen 554883 0.5 mg/ml Flow cytometry: 1?g/million cell
Affinity purified
Mouse anti-rat CD3 Monoclonal IgM, k FITC Pharmingen 557354 0.5 mg/ml Flow cytometry: 1?g/million cell
Affinity purified
Mouse anti-rat macrophage Monoclonal IgG2a, k PE Pharmingen 554901 0.2 mg/ml Flow cytometry: 1?g/million cell
Affinity purified
FITC = Fluorescein isothiocyanate, PE = Phycoerythrin
Isotype controls:
For B cells: Mouse IgG1, FITC (Dako, cat.#X0927)
For T cells: Mouse IgM, FITC (Dako, cat.#X0934)
For macrophage: Mouse IgG2a, PE (Dako, cat.#X0950)
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2.8 Hepatic gene expression study by real-time PCR using hybridization
probes
Two hundred mg of frozen liver tissue was homogenized in 2 ml of TRIzol® reagent
using a homogenizer (Heidolph Diax 600). Total RNA was extracted following the
manufacturer’s instructions (Appendix 2.20). The concentration and the purity of
RNA were determined by UV spectrophotometry. One ?g of total RNA from each
sample was reversed transcribed into single stranded cDNA using M-MLV reverse
transcriptase (Promega, cat.#M1701) in a total volume of 40 ?l reaction mixtures
(Appendix 2.21). Hepatic gene expression of IL-4Ra, IL-13Ra1, IL-13Ra2, STAT6,
SREBP2, HMG-CoA reductase, CYP7A1 and LDLR were determined by quantitative
real-time PCR using LightCycler (Roche) with hybridization probes (Appendix 2.22
& 2.23). Primers and probes were designed and synthesized by Proligo, Singapore. A
standard curve was created for each gene being examined using serial dilutions of
plasmid standards that were cloned with the PCR products generated by their
respective primers (Refer to “Plasmid standards for real-time PCR” in Section 2.5.3).
Each sample was run in duplicates. Results were expressed as an index of the
housekeeping gene, b-actin. The nucleotide sequence of primers and probes are
summarized in Table 2.5.
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Table 2.5 Nucleotide sequence of primers and probes used in real-time PCR for
rat hepatic gene expression study
Gene/Accession # Primers & Probes Nucleotide sequence 5’ - 3’ bp
Rat SREBP-2 Forward primer TCTTCTATGCCTGTAGAGCC 160
NM_001033694 Reverse primer AGCTGGACCACATGGTTA
(Predicted) Probe 1 TGTCATTGTGAGAGGGCCAGTG-Fa
Probe 2 LC Red 640-CACCTGTGGAGCAGTCTCAAT-Pb
Rat HMG-CoAR Forward primer CTGGTAGCATAGGAGGC 166
X55286 Reverse primer CACACAATTCGGGCAAG
Probe 1 CAGGATGCAGCACAGAATGTGG-F
Probe 2 LC Red-AGTTCAAACTGTATTACTTTAATGGAAGCAAG-P
Rat CYP7A1 Forward primer TGCCACCACTACATGATATTGA 210
NM_012942 Reverse primer CCAGCTATGTGAACACCC
Probe 1 TGCTCACTGATGCGCCCTAG-F
Probe 2 LC Red 640-ACTGGATTAGTGGGAAGAACTTTGTTC-P
Rat LDLR Forward primer CGCCATGAGGTACGTAAG 193
NM_175762 Reverse primer CACTGATGATGGCATCATAGGA
Probe 1 CCAACCTGAAGAATGTGGTGGC-F
Probe 2 LC Red 640-TGGACACTGAGGTGGCCAACAATA-P
Rat IL-4Ra Forward primer TCCACCCAATAGACCGT 265
AB015747 Reverse primer GCAATCAAGTTTGCGTTC
Probe 1 TTGAGTTAAGGGAGGGTAGATACTGC-F
Probe 2 LC Red-CAAGGAGGCTATTCATTGAACAGC-P
Rat IL-13Ra1 Forward primer TTGGCACAACCTGAGCT 330
AY044251 Reverse primer TGCACGAATAAGGCACC
Probe 1 TTCCTGGCTCCCTGGAAAGAA-F
Probe 2 LC Red-CAAGCCCGGACACCAACT-P
Rat IL-13Ra2 Forward primer GGAATGCTGGGAAGGT 190
NM_133538 Reverse primer AGTTTAGCAGAGCGTCT
Probe 1 AGGAAGACCCTGAACCCAC-F
Probe 2 LC Red-TGAGCCTCCATGTGGATTTGAACA-P
Rat STAT6 Forward primer TACTGGGTCTGCAGTTCC 155
XM_343223 Reverse primer CAGAGGTACAGTATTGTTCATGAT
(Predicted) Probe 1 AGCTGACATGGTGACAGAGAAAC-F
Probe 2 LC Red 640-GCCAGAGAACTAAGCCTGCC-P
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Rat b-actin Forward primer GCCCTAGACTTCGAGC 217
NM_031144 Reverse primer CTTTACGGATGTCAACGT
Probe 1 AGCTATGAGCTGCCTGACG-F
Probe 2 LC Red-CAGGTCATCACTATCGGCAATGAG-P
aFluorescein conjugate at the 3’ end
bPhosphate group at the 3’ end
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2.9 Gene expression study on hepatocyte cell culture incubated with
  recombinant IL-13
2.9.1 Incubation of hepatocyte cell line with recombinant IL-13
The mouse hepatocyte cell line (ATCC, cat.#CRL-2390) was propagated in 25 cm2
culture flask with 10% of heat inactivated FBS in F12K nutrient mixture, Kaighn’s
modification (Gibco BRL, cat.#21127-022) and penicillin/streptomycin as the
antibiotics. The culture medium was filtered with 0.22 ?m filter before use. The
hepatocytes were incubated with recombinant mouse IL-13 (R&D Systems, cat.#413-
ML) at 1, 10 and 50 ng/ml for 8 hours. Six 25 cm2 culture flasks were used for each
time point and dosage. Recombinant mouse IL-13 was added when cell growth
reaches 70-80% confluence. Fresh culture medium was added and cells were
incubated overnight before the addition of recombinant mouse IL-13. Cells were
collected in TRIzol® reagent at the end of incubation (Appendix 2.27).
2.9.2 Gene expression study
Total RNA was extracted following the manufacturer’s instructions (Appendix 2.20).
The concentration and purity of RNA were determined by UV spectrophotometry.
One ?g of total RNA from each sample was reversed transcribed into single stranded
cDNA using M-MLV reverse transcriptase (Promega, cat.#M1701) in a total volume
of 40 ?l reaction mixtures (Appendix 2.21). Gene expression of mouse IL-4Ra, IL-
13Ra1, IL-13Ra2, STAT6, SREBP2, HMG-CoA reductase, CYP7A1 and LDLR
were determined by quantitative real-time PCR using LightCycler (Roche) with
hybridization probes (Appendix 2.22 & 2.23). Primers and probes were designed and
synthesized by Proligo, Singapore. A standard curve was created for each gene being
examined using serial dilutions of plasmid standards that were cloned with the PCR
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products generated by their respective primers (Refer to “Plasmid standards for real-
time PCR” in Section 2.5.3). Each sample was run in duplicates. Results were
expressed as an index of the housekeeping gene, b-actin. The nucleotide sequence of
primers and probes were summarized in Table 2.6.
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Table 2.6 Nucleotide sequence of primers and probes used in real-time PCR for
mouse hepatocyte gene expression study
Gene/Accession # Primers/ Probes Nucleotide Sequence 5' - 3' bp
Ms SREBP-2 Forward primer AACCTGCTAGAAAGAGCG 155
NM_033218 Reverse primer GGTGAGGTCACAAATCCCA
Probe 1 GACCAGGAAGAAGAGAGCTGTGAATT-Fa
Probe 2 LC Red 640-CCAGTGCTCTAGAGTATTTGAAATTACTTCATT-Pb
Ms HMG-CoAR Forward primer CAGATTCTGGCAGTCAGTG 157
BC085083 Reverse primer CGTCAACCATAGCTTCCGTA
Probe 1 GACGAGGAAAGACTGTGGTTTGTGAA-F
Probe 2 LC Red-CGTCATTCCAGCCAAGGTGG-P
Ms CYP7A1 Forward primer GTCTACGCATGTTTCTCAACGA 158
L23754 Reverse primer TGCTTTCATTGCTTCAGGG
Probe 1 TGATCCTCTGGGCATCTCAAGC-F
Probe 2 LC Red-ACACCATTCCTGCAACCTTCTG-P
Ms LDLR Forward primer ACGAGGTCCGGAAGATGA 180
Z19521 Reverse primer TGGTGTCGTAGGACAAGTT
Probe 1 CCCAACCTGAAGAATGTGGTGG-F
Probe 2 LC Red 640-CTCGACACGGAGGTGACCAA-P
Ms IL-4Ra Forward primer TACGATGACAGATCACCATCC 218
BC012309 Reverse primer GCACACTCACTCACCTAAG
Probe 1 CACCAGAAGCCAACCTCATGTCA-F
Probe 2 LC Red-ACCCAAGACACCCTCAAACTTG-P
Ms IL-13Ra1 Forward primer CAACTTCTCCACCAAGGC 159
NM_133990 Reverse primer GCACAAGCTAGATACATAGTCAAA
Probe 1 AATGAGGTAGCATTCGAGTTGGAAC-F
Probe 2 LC Red-AGAAGACTCTAATGATGTATGCCCACC-P
Ms IL-13Ra2 Forward primer AGATGAAGGAAGTTTGGAAACTAA 150
BC003723 Reverse primer GCATGATCCAAGCCCTCATA
Probe 1 ATTTGGTCTGCTCTTGGAAACCT-F
Probe 2 LC Red-CAAGACAGTATATTCTGATACCAACTATACCATGTTT-P
Ms STAT6 Forward primer ATCGTGCATGGTAACCAAGA 155
NM_009284 Reverse primer CCCACCTCAACCATAAACT
Probe 1 GTGCCCTTTGTGGTGGGTGA-F
Probe 2 LC Red 640-GAGTGCCCTGGGAGAAGATGTG-P
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Ms b-actin Forward primer GCCCTAGACTTCGAGC 217
NM_007393 Reverse primer CTTTACGGATGTCAACGT
Probe 1 AGCTATGAGCTGCCTGACG-F
Probe 2 LC Red-CAGGTCATCACTATCGGCAATGAG-P
aFluorescein conjugate at the 3’ end
bPhosphate group at the 3’ end
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All the results were analyzed using Statistical Package for the Social Sciences (SPSS)
for Windows™ version 13.0. The medians of the control group and the IL-13
transfected group were compared by the non-parametric Mann-Whitney test.
Differences in group means were determined by the Student’s t-test and expressed as
mean±SEM (Standard error mean). Spearman’s coefficient of correlation (r) was used
to determine the correlation amongst different parameters. Results were considered to
be statistically significant at p<0.05.
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OVEREXPRESSION OF INTERLEUKIN-13 AND DEVELOPMENT OF
MINIMAL CHANGE NEPHROTIC SYNDROME
3.1 Introduction
Minimal change nephrotic syndrome (MCNS) is manifested with proteinuria,
hypoalbuminemia, hypercholesterolemia and oedema. Unlike other forms of
glomerulonephritis such as IgA nephropathy, membranous nephropathy or lupus
nephritis which also lead to nephrotic syndrome, MCNS is characterized by the
absence of inflammatory infiltrates or immune deposits in the glomeruli. The only
pathological change found in MCNS is the extensive effacement of podocyte foot
processes in which the GBM is covered by a thin and continuous layer of podocyte
cytoplasmic processes with the loss of the slit pore and the slit diaphragm
ultrastructurally.
Proteinuria is the hallmark of nephrotic syndrome and is the result of increased
glomerular permeability, leading to marked hypoalbuminemia. The decreased oncotic
pressure subsequent to hypoalbuminemia leads to retention of water in the
extravascular compartment and clinical oedema. Although the cause of
hypercholesterolemia in nephrotic syndrome is still unknown, elevation of serum
cholesterol has been associated with hypoalbuminemia during nephrotic relapses in
MCNS, and tends to resolve when the patient goes into remission. In patients with
steroid-resistant nephrotic syndrome, hypercholesterolemia is persistent, and is a
predisposing factor for atherosclerotic disease in the long-term.
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MCNS is the commonest form of nephrotic syndrome in children, although the
pathogenesis is still unknown.  There is strong evidence that proteinuria in MCNS is
mediated by cytokines (Schnaper, 1989). A Th2 cytokine bias which includes IL-4,
IL-10 and IL-13 has been described in idiopathic nephrotic syndrome (Le Berre et al,
2005; Stachowski et al, 2000). MCNS has been shown to be associated with both
atopy and Hodgkin lymphoma. The close relationship between IL-13 and atopy
(Fallon et al, 2001), as well as the discovery that IL-13 is an autocrine growth factor
in Hodgkin lymphoma (Kapp et al, 1999) where MCNS is a recognized complication,
rendered it a possible candidate responsible for increased glomerular permeability in
the nephrotic syndrome. We have previously demonstrated that IL-13 gene expression
was upregulated in both CD4+ and CD8+ T-cells in children with steroid-sensitive
nephrotic syndrome in relapse (Yap et al, 1999). This was associated with increased
intracytoplasmic IL-13 production by CD3+ cells (Cheung et al, 2004), as well as
downregulation of gene expression of the monocyte proinflammatory cytokines IL-8
and IL-12 (Chen et al, 2003). Our findings were consistent with Kimata’s study where
IL-13 was shown to be important for the spontaneous production of IgE and IgG4 by
PBMC from nephrotic patients, in contrast to asthmatic patients where IL-4 was
shown to be the primary cytokine involved (Kimata et al, 1995). Additionally, we
were able to demonstrate that genetic polymorphisms in the 3’ untranslated region
(3’UTR) of the IL-13 gene correlated with long-term outcome of MCNS in Singapore
Chinese children, rather than disease susceptibility (Wei et al, 2005). Moreover,
PBMC IL-13 mRNA expression in patients with the haplotype AAT (haplotype of the
three SNPs: 4738 (G/A), 4793 (C/A) and 4926 (C/T), found in the 3’UTR region of
the IL-13 gene), associated with continuing relapses 5 years from onset, was
significantly higher than those with the haplotype GCC, associated with long-term
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remission. Unfortunately, the exact role of IL-13 in the pathogenesis of MCNS is not
clear.
In the studies described in this chapter, we attempted to overexpress IL-13 in rats by
transfecting a mammalian expression vector cloned with the rat IL-13 gene into the
quadriceps of rats using in-vivo electroporation. In-vivo electroporation was carried
out every 10 days until day 70 when the rats were sacrificed. We then studied the
effect of IL-13 on the development of proteinuria and the nephrotic syndrome as well
as the histological changes in the glomeruli.
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There was a significant increase in body weight of the IL-13 transfected rats over the
course of the experiment, where the mean (±SEM) body weight of the IL-13




























* p = 0.04
#
p = 0.02
Figure 3.1 Mean body weight of control rats (n=17) and IL-13 transfected rats
(n=41) measured at 10-day intervals. Results are expressed as mean±SEM.
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3.2.2 24-hour urine albumin excretion
Urine albumin excretion in the rats was measured in mg/24hr (Urine albumin
concentration [mg/ml] x urine volume [ml/24hr]). The individual results are tabled in
Appendix 3.1, 3.2 & 3.3. The 24-hour urine albumin excretion of the IL-13
transfected rats increased progressively from day 14 onward, reaching a peak of
3.45±0.89 mg/24hr at day 70 prior to sacrifice compared to 0.36±0.04 mg/24hr in






































Figure 3.2   Mean 24-hour urine albumin excretion (mg/24hr) of control rats (n=17)
and IL-13 transfected rats (n=41) measured at 14-day intervals. Results are expressed
as mean±SEM.
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While it was almost undetectable in the control rats, the level of serum IL-13 in the
IL-13 transfected rats varied from 21-1976 pg/ml. Compared to controls, the IL-13
transfected rats showed lower mean serum albumin level (p=0.078) and significantly
higher serum cholesterol level (Table 3.1). No significant difference was found in the
serum creatinine and serum IgE levels between the control rats and the IL-13
transfected rats. The serum biochemistry results are tabled in Appendix 3.4, 3.5, 3.6 &
3.7. Interestingly, in the IL-13 transfected rats, serum IL-13 correlated significantly
only with serum cholesterol levels (r=0.51, p=0.001), but not with serum or urine
albumin levels (Figure 3.3).
Table 3.1 Mean serum levels of IL-13, albumin, cholesterol, creatinine and IgE







(pg/ml) 7.1±1.8 321.1±76.0 <0.001
Serum albumin
(g/L) 42.7±1.8 38.1±1.5 0.078
Serum cholesterol
(mmol/L) 1.72±0.05 3.39±0.34 <0.001
Serum creatinine
(mmol/L) 76.0±3.5 75.1±1.8 0.878
Serum IgE
(ng/ml) 24.7±7.1 29.1±4.9 0.542
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Figure 3.3 Correlation between serum IL-13 and serum cholesterol levels in IL-13
transfected rats (n=41).
Of the 41 IL-13 transfected rats with proteinuria, 34 had serum albumin levels >30
g/L (mean±SEM, 40.7±1.3 g/L) (Group I), whereas 7 had nephrotic syndrome with
serum albumin ?30 g/L (mean±SEM, 25.5±2.2 g/L) (Group II). Gross ascites was
noted in 3 of the 7 rats in group II. The serum levels of IL-13 and cholesterol, as well
as 24-hour urine albumin excretion, were found to be significantly higher in the
nephrotic rats (group II) than in the proteinuric rats (group I) (Table 3.2).
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Table 3.2  Mean 24-hour urine albumin excretion and mean serum IL-13, albumin
and cholesterol levels of control rats, proteinuric rats (Group I) and nephrotic rats



















The IL-13 transfected rats were divided into Group I with proteinuria and Group II
with nephrotic syndrome defined by serum albumin ?30 g/L.  Results are expressed as
mean±SEM. ap<0.001 compared with controls, bp<0.001 compared with proteinuric
(Group I) rats, cp<0.03 compared with proteinuric (Group I) rats, dp=0.002 compared
with proteinuric (Group I) rats.
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3.2.4 Light microscopy & transmission electron microscopy
Histological examination of the kidneys in IL-13 transfected rats showed no
significant glomerular changes on light microscopy, similar to control rats (Figure
3.4A). No inflammatory infiltrates was found in the glomeruli. The GBM showed
even and normal thickness. There was no mesangial proliferation or increase in the
number of mesangial cells. Immunofluorescence study revealed small amounts of
IgM in the mesangium of the glomeruli only from IL-13 transfected rats in group II.
No staining was observed for IgG, IgA and C3. However, transmission electron
microscopy (TEM) showed up to 80% of podocyte foot process effacement in rats
over-expressing IL-13, especially in Group II nephrotic rats (Figure 3.4B), whereas no
podocyte foot process effacement was seen in the control rats (Figure 3.4C). No
electron deposits were seen in the mesangium or the GBM. No splitting or lamination
of GBM was noted.
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Figure 3.4 LM and TEM study of the glomeruli
(A) Glomerulus of IL-13 transfected
rat showing no significant histological
changes. (PAS Magnification = x400)
(B) Glomerulus of IL-13 transfected
rat showing effacement of podocyte
foot processes covering the GBM
(arrows). (TEM Magnification =
x7100)
(C) Glomerulus of control rat
showing normal individual podocyte
foot processes along the GBM
(arrows). (TEM Magnification =
x11000)
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3.2.5 Flow cytometric analysis of splenic mononuclear cells
The mean net weight of the spleen was significantly higher in the IL-13 transfected
rats (1.13±0.10 g) than in the control rats (0.72±0.03 g), (p<0.01). When adjusted to
body weight (relative weight), the relative weight of the spleen was also significantly
higher in the IL-13 transfected rats (0.36±0.03 g/100g body weight) than in the





















Figure 3.5 Comparison on the weight of spleen expressed as net weight and
g/100g body weight between the control rats (n=17) and the IL-13 transfected rats
(n=41). Results are expressed as mean±SEM.
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The relative proportion of T cells in the spleen was significantly lower in the IL-13
transfected rats (41.0±1.1%) than the control rats (46.8±1.6%), (p=0.01). Conversely,
the relative proportion of B cells in the spleen was significantly higher in the IL-13
transfected rats (37.8±1.3%) than in the control rats (31.9±1.3%), (p=0.01). There was
no significant difference in the relative proportion of macrophages in the spleen













Figure 3.6 Relative proportions of T cells, B cells and macrophages in the spleen
between the control rats (n=17) and the IL-13 transfected rats (n=41). Results are
expressed as mean±SEM.
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Current evidence suggests that MCNS may be a primary T-cell disorder resulting in
glomerular podocyte dysfunction.  Immunological triggering factors, such as viral
infections or allergy, are associated with alterations in the permselectivity barrier of
the glomerular capillary wall, resulting in proteinuria and the nephrotic syndrome.  In
a recent review, Mathieson alluded to a Th2 cytokine bias in patients with MCNS
(Mathieson, 2003).  This was further supported by the findings obtained by screening
a cDNA library from T-cell enriched PBMC of patients with nephrotic relapse where
overexpression of truncated c-maf inducing protein (Tc-mip) induced c-maf,
transactivated the IL-4 gene and down-regulated IFN-g expression, characteristic of
Th2 commitment (Grimbert et al, 2003).  Our earlier work has shown a possible
correlation between upregulation of T-cell IL-13 in children with MCNS in relapse
(Yap et al, 1999).  Moreover, there is a well-recognized association between MCNS
and Hodgkin disease, and  IL-13 is known to be an autocrine growth factor for the RS
cell in Hodgkin lymphoma (Skinnider, Kapp & Mak, 2001), being highly expressed in
both the RS cells in biopsy samples and tumor cell-lines (Skinnider et al, 2001; Kapp
et al, 1999).  Our current study attempted to define the pathogenic relationship
between IL-13 and podocyte foot process effacement, with development of nephrotic
range proteinuria.
In-vivo electroporation, also called electro-gene transfer, is considered a safe and
simple approach in in-vivo expression of biological active protein. It has found many
successful applications in in-vivo gene expression for vaccination and gene therapy
purposes (Aurisicchio et al, 2001; Tomanin et al, 2002). There are a number of
advantages in using the pCI mammalian expression vector to express IL-13. Since the
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recombinant protein is produced in mammalian cells, the protein will undergo all the
post-translational modifications that occur in the mammalian system, and thus the
biological activities. It also saves time in terms of large-scale expression when
compared to bacterial culture system of recombinant protein production. Most
important of all, as the protein is produced constitutively in the rat, the rats are
continuously under the influence of elevated IL-13 level. This is a big advantage over
intra-peritoneal injection of recombinant rat IL-13 as the effect of such injection is
only intermittent and may decline long before the next injection. Furthermore, while it
may take months to set up a transgenic animal model, the cloning of the target gene
into the mammalian expression vector and the large scale production of the cloned
plasmid can be accomplished in two weeks. In-vivo electroporation is also safe to
perform, and the level of protein expression by mammalian expression vector is
comparable to transgenic animal models which overexpress cytokines at the germ-line
level. The serum IL-13 level can be monitored regularly using a commercially
available IL-13 ELISA kit.
While the serum level of IL-13 in the control rats was almost undetectable, serum
level of IL-13 in the IL-13 transfected rats ranged from 21-1976 pg/ml. IL-13
overexpression was also reflected indirectly by the increased percentage of B-cells
detected in the spleen of the IL-13 transfected rats as well as the increased glomerular
gene expression of IL-13Ra2, one of the subunits of the IL-13 receptor (refer to
Section 4.2.2). Previous studies have shown that prolonged intraperitoneal
administration of recombinant IL-13 in mice resulted in significantly enlarged spleen,
induction of extramedullary hemopoiesis and monocytosis (Lai et al, 1996). IL-13
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promotes B-cell proliferation and induces class switching to IgG4 and IgE in
combination with CD40/CD40 ligand (Cocks et al, 1993).
A small amount of protein (usually less than 100 mg) is normally excreted in the urine
of healthy subjects each day. In humans, clinical proteinuria is defined as a protein
excretion rate in excess of 150 mg/24hr. Albumin and other plasma-derived proteins
such as immunoglobulins account for >90% of the excreted protein.  Nephrotic range
proteinuria is defined as urinary protein loss in excess of 3.5 g/24hr and this is often
associated with generalized oedema, hypoalbuminemia and hypercholesterolemia
(Myers, 1997).
The reference range for normal rat urine albumin excretion varies between studies due
to the different rat species used, as well as the different methods of measurement. In
an experiment using Sprague-Dawley rat weighing 250-280 g, the mean baseline
urinary albumin excretion was 0.5 mg/24hr with an SD of ±0.2 mg/24hr (Luimula,
Aaltonen, Ahola et al, 2000).  The Wistar rats used in our experiment (n=58) showed
comparable values of baseline urinary albumin excretion with a mean of 0.26 mg/24hr
and an SD of ±0.12 mg/24hr.
In puromycin nephropathy, which is an animal model of MCNS, single intraperitoneal
injection of puromycin aminonucleoside (PAN) at 15 mg/100g resulted in a mean
urinary protein excretion of 373 mg/24hr with a SD of ±167 mg/24hr at day 6
(Luimula, Aaltonen, ahola et al, 2000).  In a well established animal model of diabetic
nephropathy using spontaneous diabetic GK rats, urine albumin levels reached a mean
value of 7.5 mg/24hr by 6 months and 29.8 mg/24hr by 12 months, accompanied by
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significant histological abnormalities such as focal glomerulosclerosis, mesangial
matrix expansion and thickening of basement membrane (Nobrega et al, 2004).
The 24-hour urine albumin excretion of the IL-13 transfected rats just before sacrifice
showed a mean of 4.4 mg/24hr with an SD of ±7.2 mg/24hr, which was comparable to
other rat models of nephrotic syndrome. The IL-13 transfected rats showed significant
albuminuria worsening over time, with development of frank nephrotic syndrome as
defined by generalized swelling and significant increase in body weight, low serum
albumin ?30 g/L and hypercholesterolemia. Of the 41 IL-13 transfected rats with
proteinuria, 34 had serum albumin levels >30 g/L (mean±SEM, 40.7±1.3 g/L) (Group
I), whereas 7 had nephrotic syndrome with serum albumin ?30 g/L (mean±SEM,
25.5±2.2 g/L) (Group II).  The serum levels of IL-13 and cholesterol, as well as 24-
hour urine albumin excretion were found to be significantly higher in the nephrotic
rats (group II) than in the proteinuric rats (group I). Gross ascites was noted in 3 of the
7 rats in group II and importantly, these rats had the most severe proteinuria and also
the highest levels of serum IL-13. Consistent with the clinical picture of MCNS, no
significant difference was detected in serum creatinine levels between the control rats
and the IL-13 transfected rats.
The serum IgE levels were similar in both the control group and the IL-13 transfected
group. This is in contrast to studies in transgenic IL-13 mice where substantially
elevated levels of circulating antigen-specific IgE, mast cell degranulation, and
histamine release have been demonstrated and which predispose the animal to fatal
analphylaxis following antigen sensitization (Fallon et al, 2001). Overproduction of
IL-13 has also been shown to induce many common features of the allergic diathesis,
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such as airway hyperresponsiveness, eosinophilic inflammation, IgE production,
mucus hypersecretion, and subepithelial fibrosis (Wills-Karp, 2001). Genetic
polymorphisms of the IL-13 gene such as C-1055T in the promoter region and the
Arg130Gln in exon 4 have been associated with increased IgE production and the
development of atopy or asthma in different populations (Howard et al, 2001; Liu,
Beaty, Deindl et al, 2003). The absence of elevated serum IgE levels in the IL-13
transfected rats in our experiment could explain why these rats did not show any
symptoms of asthma or atopy.
The serum cholesterol level was also positively correlated with the level of serum IL-
13 in the IL-13 transfected rats (r=0.51, p=0.001). Interestingly, in the IL-13
transfected rats, serum IL-13 correlated significantly only with serum cholesterol
levels, but not with serum or urine albumin levels.  This observation is consistent with
the hypothesis that a serum factor may be responsible for the marked
hypercholesterolemia seen in patients with idiopathic nephrotic syndrome, and not
related solely to the degree of albuminuria as shown in other experimental models of
nephropathy (Kaysen, 1991).  Previous studies in experimental rat models of
nephrotic syndrome (puromycin nephropathy and spontaneous FSGS) have
demonstrated abnormalities in hepatic cholesterol metabolism, resulting in the
generation and maintenance of hypercholesterolemia (Vaziri & Liang, 2002; Liang &
Vaziri, 2003), which were not related to the degree of hypoalbuminemia, as Nagase
hypoalbuminemic rats used as control in these experiments did not exhibit these
marked abnormalities.  Hence it was postulated that the marked proteinuria seen in
these rat models was responsible for the abnormalities in hepatic cholesterol
metabolism.
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MCNS, as the name implies, is characterized by the absence of significant glomerular
light microscopic changes. The absence of inflammatory infiltrates, the lack of
immune deposits, and the normal histological feature of the mesangium and the GBM
observed in the glomeruli of IL-13 transfected rats were in concert with the human
condition of MCNS in which no significant pathological changes can be seen.
Podocyte foot process effacement is seen in almost all forms of glomerulonephritis
that present with proteinuria, though the correlation between the extent of podocyte
foot process effacement and the severity of proteinuria has not yet been established
(van den Berg et al, 2004; McAdams et al, 1997). It is still controversial whether
podocyte foot process effacement is the cause of proteinuria or the consequence of
proteinuria. Since podocyte foot process effacement is the only histological change
found in MCNS, it is generally believed that this drastic change of podocyte
morphology is the cause of increased glomerular permeability and directly responsible
for proteinuria in this type of nephropathy. Most of the IL-13 transfected rats that
were proteinuric showed 20-40% of podocyte foot process effacement based on the
percentage in length of the capillary loop that was covered by the fused podocyte foot
processes. In contrast, about 70-80% of podocyte foot process effacement was
observed in the glomeruli of rats that were nephrotic, these rats also showed more
severe proteinuria among the IL-13 transfected rats.
In summary, our IL-13 overexpression rat model resembled the human condition of
MCNS with increased proteinuria, hypoalbuminemia, hypercholesterolemia, minimal
glomerular lesion on light microscopy and partial effacement of podocyte foot
processes viewed under electron microscopy.
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In order to determine whether the effect of IL-13 on the development of proteinuria
and nephrotic syndrome is specific, different treatment strategies are being considered
including i) cessation of transfection by in-vivo electroporation, ii) neutralization of
IL-13 by antibodies and iii) administration of steroid. It will be interesting to
determine if these treatments are able to reverse the effects induced by overexpression
of IL-13, such as proteinuria, hypoalbuminemia, hypercholesterolemia and podocyte
foot process effacement.
Secondly, since MCNS is believed to be a disease of immune dysregulation with a
Th2 cytokine bias, therefore, we will also try to develop overexpression models of
other Th2 cytokines, such as IL-4 and IL-10, and to determine if elevated serum levels
of these cytokines are able to induce proteinuria and the nephrotic syndrome in the
rat.
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MOLECULAR MECHANISM OF PROTEINURIA IN MCNS
INDUCED BY INTERLEUKIN-13
4.1 Introduction
The pathogenesis of MCNS, the commonest cause of nephrotic syndrome in
childhood, is unknown.  Recent studies indicate that podocyte foot process effacement
is the hallmark of nephrotic syndrome (Eddy & Symons, 2003). Podocytes are highly
dynamic cells with extensive cytoplasmic processes, which together with the
endothelium and the GBM, form the glomerular filtration barrier.  The selective
barrier for proteins resides in the slit diaphragm (Pavenstädt et al, 2003) which is
thought to be a modified adherens junction that is composed of a growing number of
proteins, including nephrin, P-cadherin, CD2AP, ZO-1, FAT, podocin, and NEPH1
(Asanuma & Mundel, 2003).  Nephrin is a transmembrane protein of the
immunoglobulin superfamily located to the slit pore of the podocyte (Holzman et al,
1999).  It is localized to signaling domains known as lipid rafts (Schwarz et al, 2001;
Simons et al, 2001), which through its association with podocin, has a critical role in
signaling pathways, promoting cell-cell adhesion through homophilic interactions
(Khoshnoodi et al, 2003).  Interference with any of the components of the slit
diaphragm may result in functional destabilization of the slit diaphragm and
consequent foot process effacement and proteinuria.
The podocyte tertiary foot processes are also linked to the GBM by a- and b-
dystroglycans, adhesion molecules which are encoded by the gene Dag1 (Ibraghimov-
Beskrovnaya et al, 1992). a- and b-dystroglycans are detected as a transmembrane
complex showing a granular staining pattern along the glomerular capillary wall by
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immunofluorescence (Raats et al, 2000). The transmembrane dystroglycan complex is
thought to link with the GBM through the binding of a-dystroglycan to agrin, and to
the actin cytoskeleton through the binding of b-dystroglycan to utrophin (Raats et al,
2000; Gesemann et al, 1998).  Since dystroglycan is the adhesion protein that anchors
and stabilizes the podocyte on the GBM, changes in the expression of dystroglycan in
the glomeruli may alter the binding properties of podocyte foot processes to the GBM.
IL-4 and IL-13 have been demonstrated to regulate cell morphology and induce
cytoskeleton rearrangement in B-cells (Davey et al, 1998), granulocytes (Girard et al,
1997), macrophages (DeFife et al, 1997) and cultured human umbilical vein
endothelial cells (Klein et al, 1993). In cultured podocytes, IL-4 and IL-13 have been
shown to alter protein sorting, ion transport and activity of lysosomal enzymes, such
as cathepsin L and heparanase (van den Berg et al, 2000; van den Berg et al, 2002).
Functional transmembrane receptor complexes for IL-4 and IL-13 were found to
express constitutively on podocytes. Stimulation of cultured monolayers of podocytes
with IL-13 resulted in phosphorylation of the signaling molecule STAT6 and a
decrease in transepithelial electrical resistance (van den Berg et al, 2000). This
indicates that podocytes are able to respond directly to immunological signals from
the environment through their cell surface cytokine receptors.
Since nephrin, podocin and dystroglycan are important protein molecules in
maintaining the integrity of the slit diaphragm and the attachment of podocyte foot
processes to the GBM, therefore, a loss of function or downregulation of these
structural proteins may disrupt the mechanical properties of the podocyte foot
processes, resulting in its effacement, and subsequent dysregulation of glomerular
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permeability. In fact, previous studies have demonstrated that inflammatory cytokines
such as IL-1b and TNF-a are able to modulate nephrin expression in human
embryonic kidney epithelial cells and podocytes (Huwiler et al, 2003).
We hypothesized that IL-13 or other Th2 cytokines may play an important role in the
development of proteinuria in MCNS by exerting a direct effect on podocytes, acting
through the IL-13 receptors on the podocyte cell surface, initiating certain signaling
pathways that eventually lead to changes in the expression of these podocyte-related
proteins. Therefore, the aim of this chapter was to study the effects of elevated
circulating IL-13 in the kidney, in particular the gene and protein expression of
nephrin, podocin and dystroglycan which were found to associate with nephrotic
syndrome. To study the effects of IL-13 in the kidney and to be more specific, in the
glomeruli, we used a graded sieving technique (Kreisberg et al, 1978) to isolate
glomeruli from the kidney cortex tissue and studied the glomerular gene expression of
the IL-13 receptors subunits: IL-4Ra, IL-13Ra1 and IL-13Ra2; the downstream
signaling molecule: STAT6; and the podocyte-associated proteins: nephrin, podocin
and dystroglycan using real-time PCR with hybridization probes. Snap frozen tissue
of the kidneys were also collected to study their protein expression in the glomeruli
using immunofluorescence technique.
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4.2.1 Quantitation of real-time PCR
Standard curve was created for each gene using serial dilutions of plasmid standards
that were cloned with the PCR products generated by their respective primers. The
higher the copy number of the plasmid (which is cloned with the target gene), the
lower the Cp (Crossing point) value will be. All standard curves created had a
regression coefficient of -1.0 and an error of less than 0.1 (Figure 4.1).
Figure 4.1 Example of a standard curve created by real-time PCR with
hybridization probes using serial dilutions of plasmid standards.
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The copy number of the target gene in the sample is automatically calculated if a
standard curve is included in the same run, by comparing the Cp value of the sample
with the standard curve (Figure 4.2).
Figure 4.2 Example of real-time PCR results showing the Cp value and the copy
number of target gene in each sample.
Gene expression index is then derived by the following formulae:
Copy number of target gene
Expression  index  =  - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Copy number of b-actin gene
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4.2.2 Glomerular expression of IL-13 receptors and STAT6
Glomerular gene expression of the IL-13 receptor subunits, IL-4Ra (0.010±0.0007 vs.
0.007±0.0009, p<0.005) and IL-13Ra2 (0.076±0.036 vs. 0.015±0.008, p<0.005), were
significantly increased in the IL-13 transfected rats compared to control rats.
However, there were no significant differences in the glomerular gene expression of































Figure 4.3 Glomerular gene expression of IL-4Ra, IL-13Ra1, IL-13Ra2 and
STAT6 in control rats (n=17) and IL-13 transfected rats (n=41), standardized against
b-actin.  Results are expressed as mean±SEM.
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Increased protein expression of IL-4Ra was also detected in the glomeruli of
nephrotic rats when compared to control rats. While no fluorescent signal was seen in
the glomeruli of control rats for IL-4Ra, some small, scattered fluorescent signal of
moderate intensity was seen in most of the glomeruli of nephrotic rats (Figure 4.4).
Figure 4.4 Immunofluorescence study on the expression of IL-4Ra in the
glomeruli. No fluorescent signal was detected in glomerulus of control rat for IL-4Ra.
Primary antibody = rabbit anti-rat IL-4Ra, diluted 1/50 (Santa Cruz cat.#SC-686).
Secondary antibody = FITC-conjugated donkey anti-rabbit IgG, diluted 1/200
(Chemicon cat.#AP182F). Magnification = x400. Compared to control rat, small
scattered fluorescent signal of moderate intensity for IL-4Ra was detected in








4.2.3 Glomerular expression of nephrin, podocin and dystroglycan
As described in the previous chapter, of the 41 IL-13 transfected rats with proteinuria,
34 had serum albumin levels >30 g/L (mean±SEM, 40.7±1.3 g/L) (Group I), whereas
7 had nephrotic syndrome with serum albumin ?30 g/L (mean±SEM, 25.5±2.2 g/L)
(Group II). Glomerular gene expression of the podocyte-associated proteins: nephrin,
podocin and dystroglycan, were significantly decreased in the IL-13 transfected rats
which were nephrotic (Group II) as compared to proteinuric rats (Group I) and




































Figure 4.5 Glomerular gene expression of nephrin, podocin and dystroglycan in
control rats (n=17), proteinuric IL-13 transfected rats (Group I, n=34) and nephrotic
IL-13 transfected rats (Group II, n=7), standardized against b-actin.  Results are
expressed as mean±SEM.
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Table 4.1  Glomerular gene expression of nephrin, podocin and dystroglycan in
control rats (n=17), proteinuric IL-13 transfected rats (Group I, n=34) and nephrotic








Nephrin 0.16±0.03 0.11±0.01 0.01±0.005b,c
Podocin 0.25±0.05 0.17±0.02 0.01±0.005b,c
Dystroglycan 0.020±0.003 0.012±0.002a 0.005±0.002b,d
ap<0.02 compared with controls
bp<0.002 compared with controls
cp<0.001 compared with proteinuric (Group I) rats
dp<0.04 compared with proteinuric (Group I) rats
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The protein expression of nephrin, podocin and dystroglycan in the glomeruli of
nephrotic rats was also significantly down-regulated when compared to the control
rats. Nephrin, podocin and dystroglycan were all stained strongly as a continuous
granular pattern along the glomerular capillary wall in the control rats. In contrast,
nephrin, podocin and dystroglycan staining in the nephrotic rats showed much weaker
fluorescent signal and also a discontinuous, sometimes segmental, granular pattern
along the glomerular capillary wall (Figure 4.6).
Figure 4.6 Immunofluorescence study on the expression of nephrin, podocin and










Figure 4.6 Immunofluorescence study on the expression of nephrin, podocin and
dystroglycan in the glomeruli. Glomerulus of control rat showing strong, continuous
and granular staining pattern of nephrin, podocin and a-dystroglycan along the
glomerular capillary wall. Compared to control rat, glomerulus of nephrotic rat
showed a much weaker, discontinuous, sometimes segmental, granular staining
pattern for nephrin, podocin and a-dystroglycan along the glomerular capillary wall.
Magnification = x400. For nephrin: Primary antibody = guinea pig anti-rat nephrin,
diluted 1/50 (RDI cat.#RDI-PROGPN2). Secondary antibody = FITC-conjugated
donkey anti-guinea pig IgG, diluted 1/100 (RDI cat.#706095148). For podocin:
Primary antibody = rabbit anti-rat podocin, diluted 1/50 (ADI cat.#PODO-11A).
Secondary antibody = FITC-conjugated donkey anti-rabbit IgG, diluted 1/200
(Chemicon cat.#AP182F). For dystroglycan: Primary antibody = mouse anti-rat a-
dystroglycan, diluted 1/100 (Upstate cat.#05-593). Secondary antibody = FITC-
conjugated goat anti-mouse IgM, diluted 1/100 (Santa Cruz cat.#sc-2082).
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Downregulation of the glomerular gene and protein expression of nephrin, podocin
and dystroglycan in this IL-13 transfected rat model of minimal change nephropathy
parallels the findings in other experimental models as well as human nephrotic
syndrome. Gene and protein expression of nephrin are known to be decreased both in
animal models such as puromycin nephropathy or mAB 5-1-6 nephropathy (Luimula,
Ahola, Wang et al, 2000; Kawachi et al, 2000), and in kidney biopsies of patients
with glomerular diseases, including membranous GN, MCNS and FSGS (Doublier et
al, 2001; Kim et al, 2002). An 80% decrease in mRNA expression of nephrin was
detected at the peak of proteinuria in puromycin nephropathy and this preceded the
onset of proteinuria (Luimula, Ahola, Wang et al, 2000). In many of these studies,
immunofluorescence showed extensive loss of staining for nephrin in the glomeruli,
with a shift from a linear to a granular pattern (Luimula, Ahola, Wang et al, 2000;
Kawachi et al, 2000; Doublier et al, 2001). This was always accompanied by
redistribution of nephrin protein from the filtration slit to the podocyte plasma
membrane as shown by immunoelectron microscopy (Luimula, Ahola, Wang et al,
2000; Kim et al, 2002; Huh et al, 2002).
Downregulation of podocin expression has been reported in puromycin nephropathy
(Luimula et al, 2002), as well as in children with primary nephrotic syndrome who
were having heavy proteinuria and foot process effacement at the time of kidney
biopsy (Guan et al, 2003). This was characterized by a change from a linear to a
discontinuous and granular pattern of staining on immunofluorescence, similar to our
IL-13 transfection model. Interestingly, in the puromycin nephropathy model, onset of
proteinuria and effacement of podocyte foot processes were found to parallel
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decreased protein expression rather than changes in mRNA expression of podocin
(Guan et al, 2004; Hosoyamada et al, 2005).
Expression of nephrin and podocin in the glomeruli has been shown to be
downregulated concomitantly in animal models of nephropathy e.g. puromycin
nephropathy (Guan et al, 2004; Hosoyamada et al, 2005; Luimula et al, 2002) and in
different acquired forms of nephrotic syndrome (Koop et al, 2003). In a number of
studies, decreased expression of podocin may downregulate the expression or alter the
distribution of nephrin in NPHS2 knockout mice (Roselli et al, 2004) and in kidney
biopsies of patients with different forms of glomerulonephritis (Guan et al, 2004;
Zhang et al, 2004). In fact, podocin accumulates in lipid rafts of the slit diaphragm as
oligomer, and binds to both CD2AP and nephrin (Schwarz et al, 2001). Recent studies
showed that recruitment of nephrin to the raft depends on the proper association of
podocin with specialized lipid raft microdomains of the plasma membrane (Huber,
Simons, Hartleben et al, 2003). Thus, the strong association between nephrin and
podocin may explain why expression of both nephrin and podocin are downregulated
concomitantly in our animal model as well.
Similarly, protein expression of dystroglycan is known to be reduced in both
experimental model of nephropathy and human kidney biopsies. Decreased protein
expression of dystroglycan has been found in adriamycin nephropathy (Raats et al,
2000), puromycin nephropathy and protamine sulfate perfusion (Kojima et al, 2004),
and this was accompanied by podocyte foot process flattening and heavy proteinuria.
In adriamycin nephropathy, immunofluorescence staining revealed a reduced staining
intensity for dystroglycan along the glomerular capillary wall while immunoelectron
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microscopy showed a redistribution of dystroglycan in proteinuric rats as compared to
controls. Disorders in the fibrillar components of the lamina rara externa of the GBM
have also been observed in both puromycin nephropathy and protamine sulfate
perfusion. Quantitative immunoelectron microscopic examination of human renal
biopsies has demonstrated a reduction in the density of a- and b-dystroglycan on the
podocytes’ soles in MCNS, whereas no difference was seen in normal kidneys and
FSGS. Expression of dystroglycan returned to normal in MCNS after steroid
treatment (Regele et al, 2000).
Podocytes are highly dynamic cells with an extensive network of actin cytoskeleton in
the cytoplasm. They are able to respond to stimuli in the microenvironment within the
glomeruli in different forms of glomerulonephritis (Andrews, 1988; Smoyer &
Mundel, 1998). These include retraction of foot processes, effacement of foot
processes and detachment of foot processes from the underlying GBM. These changes
in the shape and architecture of the podocyte have been shown to associate with
alterations in the actin cytoskeleton and its associated protein molecules e.g. a-
actinin-4 (Mundel & Shankland, 2002). Nephrin, podocin and dystroglycan have been
shown to link with the actin cytoskeleton in the podocyte foot processes. Nephrin
links the slit diaphragm to the actin cytoskeleton of the podocyte foot processes by the
adaptor protein, CD2AP (Yuan et al, 2002). Podocin was shown to associate with the
actin cytoskeleton together with nephrin (Saleem et al, 2002). Dystroglycan was
shown to associate with the actin filaments by its b-dystroglycan subunit through the
adaptor protein, utrophin (Raats et al, 2000). This implies that downregulation of
these podocyte-associated proteins may impair the proper organization of the actin
cytoskeleton, initiate changes in the shape and form of the podocyte foot processes
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and finally leads to the effacement of podocyte foot processes and detachment of
podocyte foot processes from the GBM as seen in this experiment.
Maintenance of the tertiary podocyte foot process structure is critical for the proper
functioning of the glomerular filtration barrier. This is best illustrated in MCNS where
the only pathological change demonstrable is the extensive effacement of podocyte
foot processes. The decrease in the expression of nephrin, podocin and dystroglycan
at both the transcriptional and translational levels in our IL-13 transfected rat model
were found to be associated with increased urinary albumin excretion and podocyte
foot process effacement, suggesting that these proteins are essential in maintaining the
filtration barrier, thus controlling glomerular permeability.
It will be difficult to establish whether podocyte foot process fusion is the cause or the
consequence of proteinuria. In-vitro study on the expression of nephrin, podocin and
dystroglycan in a podocyte cell line upon incubation with recombinant IL-13 may
help to determine whether IL-13 is able to act directly on podocyte and downregulate
the expression of these podocyte-associated proteins. This may, in part, help to
determine whether the downregulation of the podocyte-associated genes precedes
proteinuria in this IL-13 overexpression rat model.
As mentioned in the first chapter, IL-4 and IL-13 share a common receptor which is
made up of IL-4Ra and IL-13Ra1. This common receptor, which is called type II  IL-
4 receptor, is also the functional receptor for IL-13 (Hershey, 2003). Increasing
evidence has shown that IL-4Ra is the functional component of the IL-13 receptor
complex and is, in fact, the subunit responsible for intracellular signal transduction
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after stimulation by IL-13 (Zurawski et al, 1995), including phosphorylation of IL-
4Ra, insulin receptor substrate 2 (IRS-2), JAK1, and Tyk2 (Kelly-Welch et al, 2003).
Furthermore, disruption of IL-4Ra has been shown to impair IL-13-induced immune
responses (Urban et al, 1998).
Our knowledge on the signaling mechanisms of IL-4 and IL-13 through their
receptors is still limited. As both IL-4 and IL-13 transmit their signals through the IL-
4Ra, the mechanism by which IL-13 results in downstream effects that are not
observed with IL-4 is still unclear. The existence of other unidentified receptor
subunits for IL-13 cannot be excluded. Moreover, the function of IL-13Ra2 in IL-13
signaling is not yet fully understood. The short cytoplasmic tail of IL-13Ra2 contains
no box region that serves as the docking site for JAKs as compared to IL-13Ra1,
however, it contains a tyrosine residue that may have biologically important but not
yet identified function in IL-13 signaling (Donaldson et al, 1998).
In contrast, glomerular gene expression of STAT6, which is an important downstream
signaling molecule of the JAK/STAT signaling pathway utilized by IL-4Ra (Nelms et
al, 1999), showed no significant differences between the control group and the IL-13
transfected group despite an upregulation in the glomerular gene expression of IL-
4Ra. STAT6 exists as a latent cytoplasmic transcription factor in the family of signal
transducers and activators of transcription (STAT). They are recruited to IL-4Ra upon
phosphorylation of its cytoplasmic tyrosine residues. STAT6 then becomes tyrosine
phosphorylated, disengages from the IL-4Ra, dimerizes by reciprocal SH2 domain
interaction, migrates to the nucleus, and binds to consensus sequences found within
promoters of IL-4 and IL-13 regulated genes (Kelly-Welch et al, 2003). It was found
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that regulation of STAT6 activity is tightly controlled at the molecular level by
phosphorylation and dephosphorylation of its tyrosine residues (Hanson et al, 2003).
This may represent the major regulatory mechanism of STAT6 activity in the cell
when stimulated by IL-4 or IL-13. On the other hand, activation of IL-4Ra was
known to lead to other signaling pathways which do not involve the JAK/STAT, for
example, the insulin receptor substrate 1 and 2 pathways (Jiang et al, 2000). Taken
together, these may explain why the glomerular gene expression of STAT6 was not
affected in our IL-13 overexpression rat model.
Effacement of podocyte foot processes is reversible, for example, during remission
after steroid treatment in steroid-sensitive MCNS. Therefore, with a better
understanding of the pathophysiology of podocytes, in particular the mechanism by
which the podocyte foot processes fuse together, it may be able to stop the leakage of
protein in the glomerulus by maintaining the fine architecture of podocytes and by
preventing their detachment from the GBM.
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ASSOCIATION OF B7-1 WITH PROTEINURIA IN MCNS
INDUCED BY INTERLEUKIN-13
5.1 Introduction
The activation of lymphocytes and development of adaptive immunity require specific
antigen recognition by lymphocytes through TCR and additional signals (co-
stimulatory signals) that can be induced by microbes. This ‘two-signal’ concept
(Bretscher, 1999) explains why adaptive immunity is elicited by microbes and not by
self antigens, which do not induce second signals. B7-1, also known as CD80, is a cell
surface glycoprotein normally expressed on the surface of B cells and other antigen
presenting cells (Chambers & Allison, 1999). It acts as a co-stimulatory molecule
when it binds to CD28 or CTLA-4 expressed on T cells and helps to modulate and
fine-tune TCR signals (Greenwald et al, 2005). B7-1 is the first member of the B7
family to be discovered (Linsley et al, 1990) which also include B7-2, B7h and B7-
H1 (Swallow et al, 1999; Dong et al, 1999; Freeman et al, 1993). Upon binding with
B7-1, CD28 transduces a signal which enhances T cell proliferation and cytokine
secretion such as IL-2, and sustains the T cell response. Conversely, binding of B7-1
with CTLA-4 inhibits T cell responses (Abbas & Sharpe, 1999). Induced expression
of B7-1 in podocytes was found to link with nephrotic syndrome recently (Reiser et
al, 2004). Wild-type mice injected with low dose of LPS developed transient
proteinuria and showed partial effacement of podocyte foot processes in electron
microscopy without evidence of glomerular inflammation, similar to that seen in
human MCNS. Induced expression of B7-1 in podocyte was essential in the
development of proteinuria in these mice as B7-1 -/- mice were protected from
proteinuria. In antigen presenting cells, LPS is the strongest endogenous inducer of
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B7-1 expression through toll-like receptor (TLR)-4 signaling (Beutler & Rietschel,
2003). Toll-like receptors recognize specific patterns of microbial components,
especially those from pathogens, and regulate the activation of both innate and
adaptive immunity (Takeda et al, 2003). LPS treatment on podocyte cell culture also
upregulates the gene expression of B7-1 through TLR-4 signaling. This resulted in the
reorganization of podocyte actin cytoskeleton and redistribution of slit diaphragm
protein, including nephrin, CD2AP and ZO-1 (Reiser et al, 2004). These changes in
podocyte cell culture may help to explain the podocyte foot process effacement
observed in the in-vivo condition which will lead to increased glomerular permeability
and eventually proteinuria. Induced expression of B7-1 was found in genetic, drug-
induced, immune-mediated, and bacterial toxin-induced experimental kidney diseases
with nephrotic syndrome. Thus, induced expression of B7-1 in podocytes represents
not only a novel pathological mechanism in causing podocyte injury, but also a
common pathway by which different stimuli can lead to proteinuria. In the
experiments described in this chapter, we aimed to study the expression of B7-1 in the
glomeruli and to see how it is related to serum IL-13 level, proteinuria and the
glomerular expression of podocyte-associated proteins in our IL-13 overexpression rat
model of MCNS.
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5.2.1 Glomerular expression of B7-1
The glomerular gene expression of B7-1 was significantly upregulated in the IL-13
transfected rats compared to the control rats (Figure 5.1) (Appendix 4.1).
Control IL-13 transfected










Figure 5.1 Glomerular gene expression of B7-1 as shown by agarose gel
electrophoresis.  Lanes 1-6: Control rats.  Lanes 7-12: IL-13 transfected rats, where
Lane 8 represents a nephrotic rat in Group II.
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The control rats showed a B7-1 glomerular gene expression index of 0.005±0.001
(mean±SEM) compared to 0.009±0.001 in the proteinuric IL-13 transfected rats


































Figure 5.2 Glomerular gene expression of B7-1 in the control rats (n=17),
proteinuric IL-13 transfected rats (Group I, n=34) and nephrotic IL-13 transfected rats
(Group II, n=7).  Results are expressed as mean±SEM.
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While no fluorescent signal for B7-1 was seen in the glomeruli of control rats, the
glomeruli of nephrotic rats showed strong staining for B7-1 in a patchy pattern
(Figure 5.3).
Figure 5.3 Protein expression of B7-1 in the glomeruli by immunofluorescence
technique. While no fluorescent signal was seen in the glomeruli of control rats for
B7-1, the glomeruli of nephrotic rats showed strong staining for B7-1 in a patchy
pattern. Primary antibody = mouse anti-rat CD80 (B7-1), diluted 1/10 (eBioscience
cat#14-0800). Secondary antibody = goat anti-mouse IgG1, FITC-conjugated, diluted








5.2.2 Correlation between serum IL-13 levels and glomerular gene expression
  of B7-1
The glomerular gene expression of B7-1 also correlated significantly with serum IL-



































Figure 5.4 Correlation between serum IL-13 levels and glomerular gene
expression of B7-1 in IL-13 transfected rats (n=41).
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Our IL-13 overexpression rat model is the first study that has demonstrated a
significant correlation between serum IL-13 levels and B7-1 expression in the
glomeruli of nephrotic rats with a minimal change-like nephropathy. The strong
expression of B7-1 in the glomeruli of nephrotic rats, both in genetic and protein
level, in our experiment provides us further insights into the pathogenetic mechanism
of nephrotic syndrome. Expression of B7-1 has been implicated in different types of
glomerulonephritis (GN) including crescentic GN (Li, Holdsworth & Tipping, 2000;
Wu et al, 2003), anti-glomerular basement membrane (anti-GBM) GN (Nishikawa et
al, 1994; Reynolds et al, 2000), Lupus GN (Daikh et al, 1997) and IgA nephropathy
(Wu et al, 2004). Costimulation of B7-1 and B7-2 has been demonstrated to be
essential for the development of autoimmune disease in MRL-Faslpr mice, an animal
model of human lupus. MRL-Faslpr mice deficient in both B7-1 and B7-2 were
protected from proteinuria and survived far longer than the wild-type mice. There
were no leukocytic infiltrates or electron-dense immune deposits found in the
glomeruli. IgG and its isotypes as well as autoantibodies were also not elevated in the
serum (Kinoshita et al, 2000). Similarly, in a rat model of anti-GBM GN (a type of
autoimmune GN) characterized by deposition of IgG in GBM, infiltration of the
kidney by T cells and macrophages, severe crescent formation and renal failure
leading to death in 5-6 weeks, blockade of CD28-B7 co-stimulation by a soluble
CTLA-4 chimeric protein resulted in reduction of disease severity (Nishikawa et al,
1994; Reynolds et al, 2000). B7-1 has also been shown to enhance the survival and
proliferation of CD4+ T cells and exacerbating renal injury in anti-GBM GN
(Odobasic, Kitching, Tipping et al, 2005) and administration of anti-B7-1 was able to
attenuate glomerular accumulation of CD4+ T cells and macrophages, crescent
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formation, and proteinuria as well as renal mRNA levels of proinflammatory
cytokines IFN-g and migration inhibitory factor (MIF) (Odobasic, Kitching, Semple et
al, 2005). In addition, increased expression of B7-1 and B7-2 has been observed in
the kidneys of patients with IgA nephropathy (Wu et al, 2004) and crescentic GN
(Wu et al, 2003) when compared to controls. Mice treated with anti-B7-1 monoclonal
antibody also showed reduced crescent formation compared to controls in a murine
model of crescentic GN initiated by “planted” antigen (Li, Holdsworth & Tipping,
2000). However, in contrast to crescentic GN or lupus GN in which renal injury is
mediated by inflammatory cytokines secreted by Th1 cells upon binding with antigen
presenting cells such as monocytes and macrophages, there are no inflammatory
infiltrates such as monocytes, macrophages or CD4+ T cells in the glomeruli of
MCNS. Therefore, the pathway by which upregulation of B7-1 in the glomeruli
resulting in proteinuria in our IL-13 transfected rat model is probably different from
that in autoimmune GN.
Cytokines are able to regulate the expression of B7-1 on antigen presenting cells and
non-antigen presenting cells alone or in combination. IFN-g has been shown to
upregulate the expression of B7-1 in murine fibroblasts when combined with TNF-a
(Pechhold et al, 1997) and in human gastrointestinal carcinoma cell lines when
combined with IL-10 (Li et al, 1996) while IFN-b alone was able to upregulate the
expression of B7-1, B7-2 and CD40 on monocytes (Marckmann et al, 2004). IL-4,
which is another important cytokine secreted by Th2 cells, has also been found to
upregulate the expression of B7-1 in small splenic B cells (Stack et al, 1994) and
Langerhans cells (Kawamura & Furue, 1995). Similarly, IL-13 in combination with
IL-1a and IFN-g could induce B7-1 expression on human proximal tubular epithelial
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cells (Niemann-Masanek et al, 2002). These results suggest that cytokines may
function indirectly as a costimulatory factor by inducing the expression of
costimulatory molecules on different cell types.
In the kidney, tubular epithelial cells have been demonstrated to act as antigen
presenting cells and modulate renal immune responses. Coincubation of F1K cells
(primary renal tubular epithelial cell line) with IFN-g and LPS has led to decreased
expression of class II MHC and increased expression of B7-1 by flow cytometry and
Northern blot analysis (Banu & Meyers, 1999). In the glomerulus, expression of B7-1
has been demonstrated in podocytes and its expression is inducible by LPS (Reiser et
al, 2004). Since glomerular expression of B7-1 correlated significantly with the level
of serum IL-13 in our rat model, therefore, IL-13 may act directly on the podocyte
through the IL-13 receptors, transducing downstream signals which lead to increased
expression of B7-1. As induced B7-1 expression in the podocyte has been shown to
be essential for the development of proteinuria (Reiser et al, 2004), it provides a link
between IL-13 and the development of nephrotic syndrome in our IL-13
overexpression rat model of MCNS. On the other hand, the concurrent
downregulation of nephrin, podocin and dystroglycan in the glomeruli of IL-13
transfected rats may help to explain the mechanism by which induced expression of
B7-1 lead to reorganization of the actin cytoskeleton and redistribution of slit
diaphragm protein (Reiser et al, 2004). However, IL-13 may also downregulate the
expression of nephrin, podocin and dystroglycan in a B7-1 independent manner as IL-
13 may act directly on the podocyte by binding to the IL-13 receptors, transducing
downstream signals that lead to downregulation of these podocyte-associated proteins.
DocumentsPDFComplete




Further studies are necessary to understand the exact role of B7-1 in proteinuria and
nephrotic syndrome in MCNS. The use of B7-1 knockout animals in the IL-13
overexpression model may help to determine whether upregulation of B7-1 is
essential in the induction of proteinuria and downregulation of the podocyte-
associated proteins. Conversely, incubation of a podocyte cell line with recombinant
IL-13 may help to determine whether IL-13 is able to act directly on podocytes and
upregulate the expression of B7-1 in these cells.
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EFFECTS OF INTERLEUKIN-13 ON
CHOLESTEROL METABOLIC PATHWAY
6.1 Introduction
6.1.1 Nephrotic syndrome and hypercholesterolemia
Nephrotic syndrome is manifested with proteinuria, hypoalbuminemia,
hypercholesterolemia and oedema. In MCNS, hypercholesterolemia has been
associated with hypoalbuminemia during nephrotic relapses, and tends to resolve
when the patient goes into remission. Children with frequently relapsing nephrotic
syndrome have prolonged periods of hypercholesterolemia (Tsukahara et al, 1997),
and abnormal lipid profile during remission (Merouani et al, 2003). In patients with
steroid-resistant nephrotic syndrome, hypercholesterolemia is persistent, and is a
predisposing factor for atherosclerotic disease, resulting in increased risk of
cardiovascular and cerebrovascular morbidity and mortality in the long term
(D’Amico & Gentile, 1993). In addition, hyperlipidemia was also found to accelerate
the progress of renal diseases in patients with systemic lupus erythematosus (Luzar &
Ferluga, 2000) and IgA nephropathy (Hirano et al, 1999).
Elevation of plasma total cholesterol, or more specifically low density lipoprotein
(LDL) cholesterol, is the major lipid abnormality in nephrotic syndrome, although
hypertriglyceridemia may develop as the disorder progresses (Thabet et al, 1993). The
pathophysiology of nephrotic hyperlipidemia is complex. The prevailing view is that
both hepatic synthesis of lipids and of apolipoproteins is increased, and that the
clearance of chylomicrons and very low density lipoproteins (VLDL) is reduced
(Kaysen, 1991; Thabet et al, 1993; de Sain-van der Velden et al, 1998). Recent
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studies have shown that nephrotic hyperlipidemia is marked by elevations of plasma
cholesterol, triglycerides, LDL, VLDL, lipoprotein(a) [LP(a)], apolipoprotein-B
(Apo-B), and a depressed ratio of cardioprotective cholesterol-rich high density
lipoprotein (HDL)-2 to cholesterol-poor HDL-3 fraction (Kaysen & de Sain-van der
Velden, 1999; Sato et al, 2002; Vaziri, 2003). However, the precise contribution of
increased lipogenesis and decreased lipid catabolism to hyperlipidemia, and their
relationship to urinary protein loss, hypoalbuminemia and reduced serum oncotic
pressure remain controversial.
6.1.2 Cholesterol metabolism
Cholesterol is present in tissues and in plasma lipoproteins either as free cholesterol
or, combined with a long-chain fatty acid, as cholesterol ester. It is synthesized in
many tissues from acetyl CoA and is ultimately eliminated from the body in the bile
as cholesterol or bile acids. Cholesterol is an essential structural component of
membranes, and of the outer layer of plasma lipoproteins. It is the sole precursor of
bile acids and steroid hormones. Lipoproteins transport free cholesterol in the
circulation, where it readily equilibrates with cholesterol in other lipoproteins and in
membranes. Cholesterol ester is a storage form of cholesterol found in most tissues
and is also transported in the hydrophobic core of lipoproteins. The interchange
between these two compartments is facilitated by acyl-CoA cholesterol
acyltransferase (ACAT), a microsomal enzyme which esterifies free cholesterol with
long chain fatty acids and neutral cytosolic cholesteryl ester hydrolase (CEH), an
enzyme which hydrolyzes cholesterol esters. LDL is the mediator of cholesterol ester
and cholesterol uptake into many tissues. Free cholesterol is removed from tissues by
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HDL and transported to the liver for conversion to bile acids. (Figure 6.1) (Hylemon
et al, 2001)
The majority of the cholesterol in the body arises by synthesis, and the remainder is
provided by variable dietary intake. The liver is one of the major sites of cholesterol
synthesis, with the reactions from acetyl CoA to cholesterol occurring in the
cytoplasm and on the smooth endoplasmic reticulum of the cell. In the fed state, the
first unique reaction in cholesterol synthesis converts 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) to mevalonate and is catalyzed by HMG-CoA reductase. This latter
step is the rate limiting, regulated reaction in the cholesterol synthesis pathway, and is
targeted by drug therapy with statins to prevent atherosclerosis. (Figure 6.1)
(Hylemon et al, 2001)
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Figure 6.1 Cholesterol uptake, metabolism, and secretion in the hepatocyte.
Abbreviations: LDL, low-density lipoprotein; LDLR, low-density lipoprotein
receptor; HDL, high-density lipoprotein; SR-B1, scavenger receptor class B type 1;
VLDL, very low-density lipoprotein; HMG-CoAR, 3-hydroxy-methylglutaryl
coenzyme A reductase; S27, sterol 27-hydroxylase; C7a, cholesterol 7a-hydroxylase;
BS, bile salt; SCP, sterol carrier protein; C, cholesterol; PC, phosphotidylcholine;
SPGP, sister of P-glycoprotein; mdr2, multidrug resistance P-glycoprotein. (Adopted
from: The Liver - Biology and Pathobiology. 4th edition. Lippincott Williams &
Wilkins, Philadelphia, 2001, pp232.)
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The amount of HMG-CoA reductase can be downregulated acutely by the cholesterol
end product, which binds to a sterol sensing domain in the enzyme and activates its
proteolytic degradation. There is also a separate chronic mechanism whereby HMG-
CoA reductase enzyme concentration is modulated by cholesterol, the main product of
the pathway. The HMG-CoA reductase gene and the LDL receptor gene each contain
regulatory DNA sequences in their promoters that bind a control protein, sterol
regulatory element binding protein (SREBP), in order to be actively transcribed.
These genes work in tandem to increase intracellular cholesterol via de novo synthesis
through increased amounts of the reductase and through accelerated uptake into the
cell of LDL that is laden with cholesterol ester. In contrast, when cholesterol levels in
the cell are normal to high, the SREBP remains trapped in the endoplasmic reticulum
in its precursor form as pre-SREBP. In this way, cholesterol represses its own
synthesis and reduces the LDL receptor number to decrease uptake of cholesterol
ester into the cell. Only when cholesterol levels fall in the cell is there proteolytic
processing of pre-SREBP to SREBP, which then enters the nucleus to induce the
genes that code for the HMG-CoA reductase and the LDL receptor, thus increasing
both cholesterol synthesis and uptake of LDL (Figure 6.2) (Osborne & Rosenfeld,
1998; Hampton, 2002). There are 3 isoforms of SREBP, SREBP-1a, SREBP-1c and
SREBP-2. SREBP-1c is involved in fatty acid synthesis and insulin induced glucose
metabolism, whereas SREBP-2 is relatively specific to cholesterol synthesis. The
SREBP-1a isoform seems to be implicated in both pathways (Eberlé et al, 2004).
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Figure 6.2  The role of SREBP-1 in regulation of cholesterol biosynthesis.
Cholesterol is esterified by 2 pathways: either by acyl-CoA cholesterol acyltransferase
(ACAT) for intracellular storage or by lecithin cholesterol acyltransferase (LCAT) for
transport by HDL (Sturley, 1997; Dobiasova & Frohlich, 1999). Another major
enzyme in the cholesterol metabolic pathway is cholesterol 7a-hydroxylase (also
called CYP7A1), a smooth endoplasmic reticulum enzyme expressed exclusively in
the liver, which is the rate-limiting enzyme in the biosynthesis of bile acids.  Both
cholic acid and chenodeoxycholic acid are formed from a common precursor, 7a-
hydroxycholesterol, derived from cholesterol (Chiang, 1998). An important point
about the 7a-hydroxylase enzyme is that it is regulated both by induction and
repression. The enzyme is feed forward induced by cholesterol via binding of
cholesterol to the liver nuclear receptor, LXR. Its feedback repression is mediated by
bile acids via binding to the liver farnesoid receptor (FXR), which in turn represses
the 7a-hydroxylase promoter on the gene (Figure 6.3) (Handschin & Meyer, 2005).
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Figure 6.3  Induction and repression of cholesterol 7a-hydroxylase activities.
Non-hepatic cells transport cholesterol to the liver via HDL. Besides cholesterol ester,
HDL molecules contain lecithin, unique proteins and LCAT, for esterifying free
cholesterol from cells. Circulating HDL acquires cholesterol by employing LCAT to
extract cholesterol from the plasma membranes of peripheral cells. This process of
cholesterol removal by HDL is facilitated by an ATP-binding cassette transporter
called CERP (cholesterol efflux regulatory protein). CERP is activated by
apolipoprotein A1, which is associated with the HDL, pumps cholesterol across the
plasma membrane and delivers them as substrates for LCAT on HDL. HDL, now
containing cholesterol ester, is transported to the liver, where the cholesterol is
eliminated from the body via the bile acids. This is one of the crucial mechanisms by
which the body eliminates cholesterol. (Martinez et al, 2004; Lewis & Rader, 2005)
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The LDL receptor binds the LDL apoprotein B100, and the LDL with its receptor is
taken up intact by endocytosis. The receptor returns to the membrane, while LDL is
broken down in the lysosome/late endosome. The protein component is degraded to
amino acids, while the cholesterol ester is hydrolyzed. The free cholesterol is then
translocated into the free cholesterol pool in the Golgi apparatus. This influx of
cholesterol from LDL internalization causes the degradation of, and represses the
synthesis of HMG-CoA reductase to shut down cholesterol synthesis and represses
the formation of new LDL receptors. Internalized cholesterol also stimulates ACAT
activity to enhance cholesterol storage and, via binding to LXR, induces CERP
synthesis to promote cholesterol efflux (Brown & Goldstein, 1986). The LDL
receptor is "high-affinity" so that it is probably saturated under most circumstances.
Because of this saturation, if the capacity of the LDL receptor is exceeded, either
because of a genetic reduction in receptor amount or elevated circulating LDL, then
cholesterol esters will be deposited in artery walls instead of being taken up normally
by peripheral cells (Brown et al, 1981).
6.1.3 Hepatic enzymes and hypercholesterolemia in nephrotic syndrome
Although the pathogenesis of nephrotic hypercholesterolemia is incompletely
understood, in experimental rat models of nephrotic syndrome (puromycin
nephropathy and spontaneous FSGS), hypercholesterolemia has been shown to be
associated with alterations in the expression of hepatic enzymes and receptors
involved in cholesterol metabolism including (1) upregulation of hepatic HMG-CoA
reductase (Vaziri & Liang, 1995; Vaziri et al, 2003), the rate-limiting enzyme in
cholesterol biosynthesis; (2) upregulation of hepatic ACAT (Vaziri et al, 2003; Vaziri
& Liang, 2002), the enzyme responsible for esterification, intracellular storage and
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incorporation of cholesterol in Apo-B-containing lipoproteins; (3) downregulation of
hepatic LDL receptor and the HDL receptor, SR-B1 (Vaziri et al, 2003; Liang &
Vaziri, 1999), the main pathways of clearance of cholesterol-rich LDL and HDL
particles; (4) diminished plasma level of LCAT (Vaziri et al, 2003; Vaziri et al,
2001),  the enzyme responsible for extracellular esterification and optimal HDL
mediated uptake of cholesterol from peripheral tissues; (5) the absence of a
compensatory rise in hepatic CYP7A1 (Liang et al, 1996), the rate-limiting step in
cholesterol conversion to bile acids; (6) upregulation of hepatic Apo-B100 (de Sain-
van der Velden et al, 1998), the principal apolipoprotein of LDL and VLDL, and
finally, (7) increased plasma concentration of cholesterol ester transfer protein
(Moulin et al, 1992), a protein responsible for the transfer of cholesterol ester from
HDL to intermediate-density lipoprotein. These abnormalities in hepatic cholesterol
metabolism were not related to the degree of hypoalbuminemia, as Nagase
hypoalbuminemic rats used as control in these experiments did not exhibit these
marked abnormalities (Vaziri & Liang, 2002). Hence it was postulated that these
abnormalities in hepatic cholesterol metabolism were primarily due to the marked
proteinuria seen in these rat models (Vaziri & Liang, 2002; Davies et al, 1990).
6.1.4 Aim of chapter
As described in Chapter 3, rats overexpressing IL-13 developed hypercholesterolemia
and the serum levels of cholesterol correlated significantly with the serum levels of
IL-13 in the IL-13 transfected rats where r=0.51 and p=0.001 (refer to Figure 3.3).
Hence we hypothesized that IL-13 not only acted on podocytes to cause foot process
effacement and proteinuria, it can also act on the liver, affecting the cholesterol
metabolic pathways, resulting in hypercholesterolemia. This effect is probably
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additive to the effect of proteinuria per se on the hepatic enzymes of cholesterol
metabolism demonstrated in other experimental models of nephrotic syndrome. In this
chapter, we aimed to determine the role of IL-13 in the development of
hypercholesterolemia in nephrotic syndrome by studying i) the hepatic gene
expression of enzymes and proteins which are involved in cholesterol metabolism
including SREBP-2 (one of the 3 isoforms of SREBP which is more specific to
cholesterol synthesis), HMG-CoA reductase, CYP7A1 and LDL receptor and ii) the
hepatic gene expression of IL-13 receptor subunits: IL-4Ra, IL-13Ra1, IL-13Ra2
and the downstream signaling molecule STAT6 using real-time PCR with
hybridization probes. In addition, we also investigated the in-vitro effects of IL-13 on
cholesterol metabolism by incubating a mouse hepatocyte cell line with recombinant
mouse IL-13 at 1, 10 and 50 ng/ml for 8 hours and studying the gene expression of
SREBP-2, HMG-CoA reductase, LDL receptor, IL-4Ra, IL-13Ra1, IL-13Ra2 and
STAT6 by real-time PCR using hybridization probes.
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Fourteen of the IL-13 transfected rats with the highest level of serum cholesterol (>2.9
mmol/L) and eight control rats were included in this study. The biochemical data of
these rats are summarized in Table 6.1.
Table 6.1   Summary of biochemical data of control rats and IL-13 transfected rats








(pg/ml) 2.4±2.1 635.8±182.2 <0.001
Serum albumin
(g/L) 39.8±2.8 31.6±2.2 0.024
Serum cholesterol
(mmol/L) 1.67±0.05 5.53±0.68 <0.001
Serum creatinine
(mmol/L) 68.6±5.3 74.8±3.0 0.165
Urine albumin
(mg/24hr) 0.39±0.06 5.97±2.29 0.003
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Interestingly, the rise in the serum cholesterol levels in the IL-13 transfected rats
preceded the increase in proteinuria and fall in serum albumin (Figure 6.4). On day
30, the mean serum cholesterol levels were significantly higher (2.84±0.32 mmol/L)
than baseline (1.69±0.06 mmol/L) (p=0.002), whereas the mean urine albumin levels
(0.311±0.072 mg/24hr) did not change significantly from baseline (0.289±0.034
mg/24hr) (p=0.971). The urine albumin only increased significantly above baseline by
day 60 (2.385±0.706 mg/24hr) (p=0.001). Similarly, the serum albumin levels on day






















Figure 6.4 Time course study of the mean serum levels of albumin and cholesterol
and mean urine albumin excretion in IL-13 transfected rats with the highest levels of
serum cholesterol. Results are expressed as mean±SEM. * p<0.003 when compared to
baseline. #p<0.002 when compared to baseline, §p<0.005 when compared to baseline.
DocumentsPDFComplete




6.2.2 Effect of IL-13 on weight of liver
Both the net weight (gram) and the relative weight (which is expressed as g/100g
body weight) of the liver of the 14 IL-13 transfected rats with serum cholesterol levels
of ? 2.9 mmol/L (net: 15.60±0.86; relative: 5.09±0.33) were significantly higher than
the control rats (net: 12.40±0.54; relative: 4.06±0.18) (p=0.02 for net weight and

















Figure 6.5 Comparison of the net weight and the relative weight of the liver of
control rats (n=8) and IL-13 transfected rats (n=14). Results are expressed as
mean±SEM.
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6.2.3 Hepatic gene expression of enzymes and proteins associated with
cholesterol metabolism in IL-13 overexpression rat model
The hepatic gene expression of HMG-CoA reductase and CYP7A1 in the IL-13
transfected rats were significantly increased when compared to the control rats. No
significant differences were detected in the hepatic gene expression of SREBP-2 and
LDL receptor between the control rats and the IL-13 transfected rats (Table 6.2)
(Figure 6.6) (Appendix 6.1).
Table 6.2 Hepatic gene expression of SREBP-2, HMG-CoA reductase, CYP7A1
and LDL receptor in the control rats (n=8) and the IL-13 transfected rats (n=14),






SREBP-2 0.0018±0.0006 0.0013±0.0002 0.815
HMG-CoA reductase 0.039±0.005 0.056±0.005 0.035
CYP7A1 0.167±0.035 0.350±0.054 0.008
LDL receptor 0.036±0.008 0.038±0.011 0.402
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Figure 6.6 Hepatic gene expression of SREBP-2, HMG-CoA reductase, CYP7A1
and LDL receptor in the control rats (n=8) and the IL-13 transfected rats (n=14),
standardized against b-actin. Results are expressed as mean±SEM. The gene
expression index of SREBP-2 is multiplied by a factor of 100. The gene expression
index of HMG-CoA reductase and LDL receptor is multiplied by a factor of 10.
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6.2.4 Hepatic gene expression of IL-13 receptor subunits and STAT6 in IL-13
overexpression  rat model
The hepatic gene expression of IL-13Ra2 was significantly increased in the IL-13
transfected rats than in the control rats. No significant changes were detected for the
hepatic gene expression of IL-4Ra, IL-13Ra1 and STAT6 between the control rats
and the IL-13 transfected rats (Table 6.3) (Figure 6.7) (Appendix 6.1).
Table 6.3 Hepatic gene expression of IL-4Ra, IL-13Ra1, IL-13Ra2 and STAT6
in the control rats (n=8) and the IL-13 transfected rats (n=14), standardized against b-






IL-4Ra 0.0073±0.0008 0.0100±0.0010 0.082
IL-13Ra1 0.0021±0.0002 0.0030±0.0004 0.297
IL-13Ra2 0.00027±0.00004 0.00309±0.00033 <0.001
STAT6 0.00016±0.00008 0.00008±0.00001 0.525
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Figure 6.7 Hepatic gene expression of IL-4Ra, IL-13Ra1, IL-13Ra2 and STAT6
in the control rats (n=8) and the IL-13 transfected rats (n=14), standardized against b-
actin. Results are expressed as mean±SEM. The gene expression index of IL-13Ra1
and IL-13Ra2 is multiplied by a factor of 10. The gene expression index of STAT6 is
multiplied by a factor of 100.
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The serum cholesterol levels correlated significantly with both serum albumin levels
(r=-0.782, p=0.001) (Figure 6.8) and urine albumin levels (r=0.791, p=0.001) (Figure
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Figure 6.8 Correlation between serum albumin levels and serum cholesterol levels
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Figure 6.9 Correlation between urine albumin levels and serum cholesterol levels
in IL-13 transfected rats with the highest levels of serum cholesterol (n=14).
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It is also interesting to note that the hepatic gene expression of HMG-CoA reductase
(r=-0.742, p=0.002) (Figure 6.10) and CYP7A1 (r=-0.638, p=0.014) (Figure 6.11)
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Figure 6.10 Correlation between serum albumin levels and hepatic gene expression
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Figure 6.11 Correlation between serum albumin levels and hepatic gene expression
of CYP7A1 in IL-13 transfected rats with the highest levels of serum cholesterol
(n=14).
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In the 14 IL-13 transfected rats with the highest levels of serum cholesterol, the
hepatic gene expression of HMG-CoA reductase correlated significantly with the
hepatic gene expression of CYP7A1 (r=0.695, p=0.006) (Figure 6.12). However, only
the hepatic gene expression of HMG-CoA reductase (r=0.688, p=0.007) (Figure 6.13),
but not the hepatic gene expression of CYP7A1 (r=0.353, p=0.215), correlated
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Figure 6.12 Correlation between the hepatic gene expression of HMG-CoA
reductase and CYP7A1 in IL-13 transfected rats with the highest levels of serum
cholesterol (n=14).
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Figure 6.13 Correlation between the hepatic gene expression of HMG-CoA
reductase and serum cholesterol levels in IL-13 transfected rats with the highest levels
of serum cholesterol (n=14).
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6.2.6 Gene expression of enzymes and proteins associated with cholesterol
metabolism in mouse hepatocyte cell line incubated with recombinant IL-
13
When incubated with 50 ng/ml of recombinant mouse IL-13 for 8 hours, the gene
expression of HMG-CoA reductase in the mouse hepatocyte cell line was
significantly upregulated in the IL-13 treated group than in the control group, n=6 for
both the control group and the IL-13 treated group. No significant differences were
detected in the expression of SREBP-2 and LDL receptor between the control group
and the IL-13 treated group (Table 6.4) (Figure 6.14) (Appendix 6.2).
Table 6.4 Gene expression of SREBP-2, HMG-CoA reductase and LDL receptor,
standardized against b-actin, in mouse hepatocyte cell line incubated with 50 ng/ml of






SREBP-2 0.0103±0.0013 0.0112±0.0009 0.394
HMG-CoA reductase 0.0073±0.0002 0.0085±0.0003 0.015
LDL receptor 0.0076±0.0007 0.0092±0.0006 0.132
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50 ng/ml rMs IL-13, 8 hours
p=0.015
Figure 6.14 Gene expression of SREBP-2, HMG-CoA reductase and LDL receptor,
standardized against b-actin, in mouse hepatocyte cell line incubated with 50 ng/ml of
recombinant mouse IL-13 for 8 hours. Results are expressed as mean±SEM, n=6 for
both the control group and the IL-13 treated group.
No significant differences were detected between the control group (n=6) and the IL-
13 treated group (n=6) for the gene expression of SREBP-2, HMG-CoA reductase and
LDL receptor in the mouse hepatocyte cell line when incubated with 1 and 10 ng/ml
of recombinant mouse IL-13 for 8 hours.
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6.2.7 Gene expression of IL-13 receptor subunits and STAT6 in mouse
hepatocyte cell line incubated with recombinant IL-13
When incubated with 50 ng/ml of recombinant mouse IL-13 for 8 hours, the gene
expression of IL-4Ra and IL-13Ra2 in the mouse hepatocyte cell line was
significantly upregulated in the IL-13 treated group (n=6) than in the control group
(n=6). No significant differences were detected in the expression of IL-13Ra1 and
STAT6 between the control group and the IL-13 treated group (Table 6.5) (Figure
6.15) (Appendix 6.2).
Table 6.5 Gene expression of IL-4Ra, IL-13Ra1, IL-13Ra2 and STAT6,
standardized against b-actin, in mouse hepatocyte cell line incubated with 50 ng/ml of






IL-4Ra 0.0049±0.0003 0.0062±0.0003 0.009
IL-13Ra1 0.0054±0.0003 0.0062±0.0001 0.065
IL-13Ra2 0.00017±0.00001 0.00039±0.00002 0.002
STAT6 0.00035±0.00003 0.00040±0.00001 0.24
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50 ng/ml rMs IL-13, 8 hours
p=0.009
p=0.002
Figure 6.15 Gene expression of IL-4Ra, IL-13Ra1, IL-13Ra2 and STAT6,
standardized against b-actin, in a mouse hepatocyte cell line incubated with 50 ng/ml
of recombinant mouse IL-13 for 8 hours. Results are expressed as mean±SEM, n=6
for both the control group and the IL-13 treated group. The gene expression index of
IL-13Ra2 and STAT6 is multiplied by a factor of 10.
No significant differences were detected between the control group (n=6) and the IL-
13 treated group (n=6) for the gene expression of IL-4Ra, IL-13Ra1 and STAT6 in
the mouse hepatocyte cell line when incubated with 1 and 10 ng/ml of recombinant
mouse IL-13 for 8 hours.
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Similar to our clinical observations in some children with early relapse of MCNS
(defined by urine dipstix 2+ for 3 consecutive days), where we have documented
elevations of serum cholesterol levels prior to the development of oedema, severe
proteinuria (urine dipstix 3+ to 4+) and hypoalbuminemia, in our IL-13
overexpression rat model of MCNS, hypercholesterolemia also tended to precede the
development of heavy proteinuria, suggesting that some soluble factor in the serum
may be responsible for the elevated serum cholesterol level.  In addition, in this
experimental model of MCNS, we also demonstrated an increase in size of the liver,
similar to what we have observed in children with acute relapses of MCNS.
The strong correlation between the serum IL-13 levels and the serum cholesterol
levels in the IL-13 transfected rats suggested that IL-13 may be involved in the
metabolism of cholesterol. The increase in the size of the liver of the IL-13 transfected
rats may also imply that the liver is undergoing active metabolic processes. Direct
involvement of IL-13 in both synthesis and catabolism of lipid has not been
documented before. Since hypercholesterolemia is a common feature of nephrotic
syndrome, our in-vivo finding of elevated serum cholesterol level in IL-13 transfected
rats opens up an unexplored area on cholesterol metabolism, in which IL-13, a Th2
cytokine, may directly or indirectly induce the synthesis of cholesterol in the liver.
The mouse hepatocyte cell line used in this experiment constitutively expressed the
receptor subunits for IL-13, namely IL-4Ra, IL-13Ra1 and IL-13Ra2. The gene
expression of IL-4Ra and/or IL-13Ra2 were significantly upregulated in the liver of
IL-13 transfected rats as well as in the mouse hepatocyte cell line upon incubation
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with mouse recombinant IL-13 when compared to controls. This increase in the gene
expression of IL-4Ra and/or IL-13Ra2 paralleled the increase in the gene expression
of HMG-CoA reductase. Increase in the hepatic gene and protein expression of HMG-
CoA reductase as well as its enzyme activity has been reported previously in animal
models of puromycin nephropathy (Vaziri & Liang, 1995) and FSGS (Vaziri et al,
2003) associated with hyperlipidemia. It is therefore possible that IL-13 may act
directly on the liver by binding to the IL-13 receptors, inducing the expression of
HMG-CoA reductase, leading to increased synthesis of cholesterol in our IL-13
overexpression rat model.
The hepatic gene expression of CYP7A1 was also upregulated in the IL-13 transfected
rats when compared to the control rats. This is in contrast to results from other studies
in which reduced lipid catabolism is believed to play a part in the elevation of serum
cholesterol level in nephrotic syndrome (Garber et al, 1984; Staprans et al, 1987).
However, in view of the strong correlation between the hepatic gene expression of
HMG-CoA reductase and CYP7A1 (r=0.695, p=0.006) in the IL-13 transfected rats,
our results could indicate the animal’s physiological response to remove excess
cholesterol from the body in a positive feedback manner.
No alteration in the gene expression of LDL receptor was detected in the IL-13
transfected rats or IL-13 treated mouse hepatocyte cell line when compared to
controls. Previous reports on the study of hepatic cholesterol metabolism in
experimental nephrotic syndrome also showed no changes in the expression of LDL
receptor between the control group and the test group (al-Shurbaji et al, 1998). This is
in contrast to studies in rats with spontaneous focal glomerulosclerosis (Imai rats), in
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which the hepatic protein expression of LDL receptor was found to be downregulated
by three-folds when compared with normal rats (Vaziri et al, 2003). LDL receptor is
responsible for the intake of cholesterol carried in LDL into the liver cells when the
intracellular level of cholesterol is low. Therefore, the activity of LDL receptor may
not be altered if the intracellular level of cholesterol in the liver remained high or
normal, particularly in the IL-13 transfected rats in which the hepatic gene expression
of HMG-CoA reductase was found to be increased.
Both the in-vivo and in-vitro studies showed that the gene expression of SREBP-2
was not affected. SREBP-2, an upstream transcription factor in the cholesterol
synthetic pathway which promotes transcription of HMG-CoA reductase and LDL
receptor, is regarded as the master regulators of lipid homeostasis (Eberlé et al, 2004).
Our results indicated that the induced gene expression of HMG-CoA reductase in the
liver of IL-13 transfected rats as well as the hepatocyte cell line and the subsequent
hypercholesterolemia observed in the IL-13 transfected rats was not related to changes
in the gene expression of this upstream signaling molecule in the cholesterol synthetic
pathway. Since SREBP-2 also promotes the transcription of LDL receptor in the
nucleus, this may also help to explain why the gene expression of LDL receptor was
not affected in the liver as well as in the hepatocyte cell line in this study.
In summary, in the IL-13 transfected rats, IL-13 was able to act directly on the liver
and upregulate the gene expression of HMG-CoA reductase, the key enzyme
controlling the rate-limiting step in cholesterol synthesis, leading to increased serum
cholesterol levels. The constitutive expression of IL-13 and the high levels of serum
IL-13 in these rats could result in continuous stimulation of the hepatocytes to express
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HMG-CoA reductase and this may explain why the negative feedback mechanism of
cholesterol synthesis in the animal was overwhelmed. The increase in the hepatic
gene expression of CYP7A1 was likely to be a response to elevated cholesterol levels
rather than direct stimulation by IL-13.
Apart from the direct action of IL-13 on the liver which led to upregulation in hepatic
gene expression of HMG-CoA reductase and subsequently increased synthesis of
cholesterol, hypercholesterolemia could also be a complication of the minimal
change-like nephrotic syndrome induced by IL-13 in the IL-13 transfected rats. It is
still controversial whether hypercholesterolemia in nephrotic syndrome is the result of
hypoalbuminemia or proteinuria, although some studies have shown that both
hypoalbuminemia and proteinuria can have a distinct contribution, individually or in
combination (Joven et al, 1996; Shearer et al, 2001). The serum cholesterol levels
correlated inversely with the serum albumin levels (r=-0.782, p=0.001) in the 14 IL-
13 transfected rats that were being studied. This finding in our IL-13 overexpression
rat model supports the speculation that increased hepatic production of lipoproteins
could be secondary to elevated hepatic synthesis of albumin, probably through a
common or closely related pathway (Appel et al, 1985). The serum cholesterol levels
also correlated significantly with the urine albumin levels (r=0.791, p=0.001) in the
14 IL-13 transfected rats that were being studied. However, some of the proteinuric
IL-13 transfected rats developed hypercholesterolemia before there was a significant
decrease in serum albumin level, indicating that proteinuria alone is able to induce
hypercholesterolemia in nephrotic syndrome. Thus, hypercholesterolemia observed in
the IL-13 transfected rats of our IL-13 overexpression rat model is the result of the
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combined effects of hypoalbuminemia, proteinuria and the direct action of IL-13 on
the liver.
The relative contribution of IL-13, proteinuria and hypoalbuminemia to the induction
of hypercholesterolemia is not clear. In our current experiment, it is impossible to
create controls that develop nephrotic syndrome without any IL-13 elevations.  Hence
to study the spatial relationship between the onset of proteinuria, hypoalbuminemia
and the elevation of serum IL-13 and cholesterol levels, a series of time experiments
will be carried out to determine if elevation of serum cholesterol precedes the onset of
proteinuria.
It is unclear whether hypoalbuminemia or proteinuria contributed to the increased
hepatic expression of HMG-CoA reductase in the IL-13 transfected rats. Results from
other studies are often contradictory with regards to the hepatic expression of HMG-
CoA reductase in nephrotic syndrome associated with hyperlipidemia (Vaziri &
Liang, 1995; al-Shurbaji et al, 1998). However, our data showed that the hepatic gene
expression of HMG-CoA reductase correlated inversely with the serum albumin
levels (r=-0.742, p=0.002) but not with the urine albumin levels (r=0.455, p=0.102) in
the IL-13 transfected rats. Therefore, the mechanism by which hypoalbuminemia may
lead to hypercholesterolemia was associated with increased cholesterol synthesis
through the increase in the hepatic gene expression of HMG-CoA reductase, similar
to the direct effect of IL-13 on the liver. On the other hand, the mechanism by which
proteinuria may lead to hypercholesterolemia was not related to increased cholesterol
synthesis. This observation in our IL-13 overexpression model supports another
important hypothesis which attributed hyperlipidemia to reduced lipid catabolism due
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to the loss of liporegulatory protein molecules such as a1-acid glycoprotein in the
urine (Staprans et al, 1987). Studies are being carried out to determine the protein
expression and the enzyme activity of HMG-CoA reductase and CYP7A1, hepatic
enzymes that were found to be upregulated in our preliminary gene expression study.
This may help to better understand the role of IL-13 on the induction of
hypercholesterolemia in nephrotic syndrome.
Lowering cholesterol levels during childhood reduces the risk of atherosclerotic
changes. Furthermore, the beneficial effects of a reduction in serum lipids may
influence important intracellular pathways that are involved in the inflammatory and
fibrogenic responses, which are common components of many forms of progressive
renal injury (Buemi et al, 2005; Baigent et al, 2004). HMG-CoA reductase inhibition
by statin has been shown to improve hepatic LDL and HDL receptor deficiencies, and
ameliorate hyperlipidemia in puromycin-induced nephrotic rats (Vaziri & Liang,
2004). Therefore, an understanding of the pathogenesis of this cardinal manifestation
of nephrotic syndrome, especially in children with MCNS who have a prolonged
relapsing course, will enable us to identify potential pharmacological targets for the
management of nephrotic hyperlipidemia and its long-term complications.
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In this thesis, we have developed a novel strategy to express IL-13 constitutively in
rats using mammalian expression vector and in-vivo electroporation. IL-13 was found
to be highly expressed and present in significantly elevated levels in the blood stream
of the IL-13 transfected rats. It acts as a circulating factor mimicking a Th2 cytokine
bias as observed in patients with MCNS.
Rats overexpressing IL-13 developed proteinuria. The loss of protein in the urine
resulted in hypoalbuminemia and hypercholesterolemia which are consistent with the
clinical manifestations of MCNS. Rats with frank nephrotic syndrome showed the
highest level of 24-hr urine albumin excretion and serum IL-13, indicating that IL-13
was instrumental in the development of proteinuria and the nephrotic syndrome. The
absence of light microscopic histological changes and the presence of podocyte foot
process effacement also resembled pathological features in MCNS.
In this IL-13 overexpression rat model, we have demonstrated increased glomerular
IL-4Ra and IL-13Ra2 gene expression, as well as increased fluorescent signal for IL-
4Ra in most of the glomeruli of nephrotic rats. This implies that IL-13 was able to act
on the podocyte and alter the glomerular permeability by downregulating the
glomerular expression of nephrin and podocin, which are podocyte-associated protein
molecules important in the formation and proper function of the slit diaphragm, and
also dystroglycan, which is important in the attachment of the podocyte foot processes
onto the glomerular basement membrane. The ultimate effect is a disorganization of
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the actin cytoskeleton in the podocyte foot processes, resulting in their effacement and
subsequent loss of protein. The decreased expression of glomerular nephrin, podocin
and dystroglycan could either be due to a direct effect of IL-13 signaling on the
podocyte, or a consequence of IL-13-induced B7-1 danger signaling function in
podocytes since there was a concurrent upregulation in the glomerular expression of
B7-1. These results further strengthened the hypothesis that transient upregulation of
B7-1 could occur in MCNS resulting in nephrotic range proteinuria, and also provides
an explanation for the possible link between Th2 cytokine bias, atopy and MCNS.
In conclusion, our results suggested that IL-13 overexpression in the rat could lead to
podocyte injury with downregulation of nephrin, podocin and dystroglycan, and a
concurrent upregulation of B7-1 in the glomeruli, inducing a nephropathy
characterized by increased proteinuria, hypoalbuminemia, hypercholesterolemia and
minimal glomerular lesion on light microscopy with partial podocyte foot process
effacement on electron microscopy.
Our IL-13 overexpression rat model resembled more closely the human condition of
MCNS than other animal models of MCNS such as puromycin nephropathy and
adriamycin nephropathy. Unlike puromycin nephropathy and adriamycin
nephropathy, in which podocyte foot process effacement was caused by toxic reactive
oxygen radicals, podocyte injury in our IL-13 overexpression rat model was mediated
by elevated levels of circulating IL-13, a component of the immune system secreted
by Th2 cells.
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One of the drawbacks of our IL-13 overexpression model is that we could not control
the level of IL-13 being expressed, which depended on technical factors such as the
transfection efficiency of the plasmid constructs into the muscle cell and inherent
factors such as the adaptability of the plasmid construct in the host cell. Thus,
although all the IL-13 transfected rats showed increased levels of serum IL-13 than
the control rats, not all the IL-13 transfected rats developed nephrotic syndrome.
Instead, the IL-13 transfected rats showed varying degrees of proteinuria, with 17%
developing frank nephrotic syndrome. Moreover, the IL-13 transfected rats only
showed partial effacement of podocyte foot process, in contrast to human MCNS in
which the podocyte foot processes are found to be extensively fused. However, the
effect of IL-13 on the development of proteinuria may be more significant in
genetically susceptible individuals as genetic polymorphisms of the IL-13 receptors
have been identified.
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Nucleotide sequence of the rat IL-13 mRNA
LOCUS        NM_053828    443 bp    mRNA    linear    ROD 20-APR-2005
DEFINITION Rattus norvegicus interleukin 13 (Il13), mRNA.
ACCESSION    NM_053828
SOURCE       Rattus norvegicus (Norway rat)
/translation =  "MALWVTAVLALACLGGLATPGPVRRSTSPPVALRELIEELSNIT
QDQKTSLCNSSMVWSVDLTAGGFCAALESLTNISSCNAIHRTQ
RILNGLCNQKASDVASSPPDTKIEVAQFISKLLNYSKQLFRYGH"
     sig_peptide     1..21
     mat_peptide     22..393
ORIGIN
        1   atggcactct gggtgactgc agtcctggct ctcgcttgcc ttggtggtct tgccacccca
       61  gggccagtgc ggagatccac atctccccct gtggccctca gggagcttat cgaggagctg
      121 agcaacatca cacaagacca gaagacttcc ctgtgcaaca gcagcatggt atggagcgtg
      181 gacctgacag ctggcgggtt ctgtgcagcc ctggaatccc tgaccaacat ctccagttgc
      241 aatgccatcc acaggaccca gaggatattg aatggcctct gtaaccaaaa ggcctcggat
      301 gtggcttcca gccccccaga taccaaaatc gaagtagccc agtttatatc aaaactgctc
      361 aattactcca agcaactttt ccgctatggc cactgagggg agaccggccc tggacatctc
      421 agctgtggac ctcagttgtg gat
(Adopted from Entrez Nucleotide, NCBI, NLM, NIH.)
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Setup of Polymerase Chain Reaction (PCR)
Procedures:







PCR grade H2O 10.5 ?l
10x buffer 10x 2 ?l 1x
MgCl2 25 mM 1.2 ?l 1.5 mM
dNTPs 25 mM 0.2 ?l 0.25 mM
Forward primer 10 ?M 2 ?l 1 ?M
Reverse primer 10 ?M 2 ?l 1 ?M
Taq DNA polymerase 5 U/?l 0.1 ?l 0.5 U
Total 18 ?l
(Note: The Taq polymerase, 10x reaction buffer and MgCl2 are purchased
from Qiagen: HotStar Taq® DNA polymerase (Qiagen, cat.#203203). The 10x
PCR buffer contains 15 mM MgCl2, therefore, the final concentration of
MgCl2 in the reaction mixture is 3 mM. dNTPs are purchased from Promega,
cat.#U1240.)
2. Pipette 18 ?l of the master mix into a 0.2 ml PCR tube.








5. Run the PCR reaction on a thermocylcer (GeneAmp® PCR System 9700) with
the following parameters:
Steps Temperature Duration # of cycles
Activation 95oC 15 minutes 1
Amplification
Denaturation 95oC 30 seconds
Annealing 6 oC below
Tm of primers
30 seconds 35
Extension 72oC 20 bp/s
Final extension 72oC 7 minutes 1
Cooling 4oC Hold 1
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TA Cloning, transformation and amplification of plasmid DNA
Principle of TA cloning:
TOPO TA Cloning® (Invitrogen) provides a highly efficient, 5-minute, one-step
cloning strategy (“TOPO® Cloning”) for the direct insertion of Taq polymerase-
amplified PCR products into a plasmid vector. No ligase, post-PCR procedures, or
PCR primers containing specific sequences are required. The plasmid vector
(pCR®2.1-TOPO®) is supplied linearized with a single 3’- thymidine (T) overhangs
for TA cloning®. It is important that Taq polymerase is used in the above PCR
reaction because it has a non-template-dependent terminal transferase activity that
adds a single deoxyadenosine (A) to the 3’ends of PCR products. This allows PCR
inserts to ligate efficiently with the vector by the principle of TA cloning.
Procedures:
TA cloning
1. Set up the TA cloning reaction as follows:
Reagent Volume
Fresh PCR product 4 ?l
Salt solution 1 ?l
TOPO® vector 1 ?l
Final volume 6 ?l
2. Mix gently and incubate for 15 minutes at room temperature.
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1. Add 2 ?l of the cloning reaction mixture to a vial of One Shot® Chemically
Competent E. coli cells, incubate for 15 minutes in an ice bath.
2. Heat shock the cells at 42oC for 30 seconds. Put back on ice.
3. Add 250 ?l of SOC medium to the transformed E. coli and incubate for 1 hour
at 37oC with shaking at 250 rpm.
4. Spread 50 ?l of the incubation mixture onto a LB (Luria-Bertani) plate
containing X-Gal and 50 ?g/ml ampicillin.
5. Incubate the LB plates at 37oC overnight.
Blue/white screening
Positive clones are identified by the principle of blue/white screening. Transformed E.
coli are ampicillin resistant because the plasmid vector carries the ampicillin resistant
gene. The plasmid vector also carries a LacZa gene, the protein translated by this
gene is able to turn X-gal blue, this function will be lost if the PCR products are
successfully cloned into the vector. Therefore, E. coli that are not transformed cannot
grow on the medium because they are not ampicillin resistant. E. coli that are
transformed with the vector only will grow on the LB agar plate but appears as blue
colonies because there is no insertion and therefore no disruption of the LacZa gene.
E. coli that are transformed with the recombinant vector will grow on the LB agar
plate and appears as white colonies because the LacZa gene is disrupted by the
insertion of PCR products.
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Subculturing of bacterial colonies
In order to confirm that the correct rat IL-13 gene sequence is successfully cloned into
the TA cloning vector, we need to produce and extract enough of the cloned plasmid
to carry out a DNA sequencing reaction and a restriction enzyme digestion reaction.
Four white colonies from the LB agar plate are picked up and each transferred to a 50
ml culture tube containing 10 ml of LB medium with 50 ?g/ml ampicillin. The culture
tubes are then incubated at 37oC overnight with shaking at 250 rpm. There will be
substantial growth of E. coli during the incubation and thus amplification of the
recombinant plasmid vector at the same time.
(Reference: Invitrogen TOPO TA cloning® instruction manual.)
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Gel extraction and purification of DNA
Gel extraction and purification of DNA was carried out using the Qiagen QIAquick
gel extraction kit, cat.#28704. Protocol of this kit is designed to extract and purify
DNA of 70 bp to 10 kb from standard or low-melt agarose gels in TBE buffer. Up to
400 mg agarose can be processed per spin column.
Procedures:
1. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel
with the aid of a UV illuminator and weigh the gel slice.
2. Add 3 volumes of buffer QG to 1 volume of gel.
3. Incubate at 50oC for 10 minutes. Mix by vortexing the tube every 2-3 min
during the incubation until the gel slice has completely dissolved.
4. Add 1 gel volume of isopropanol to the sample and mix.
5. Place a QIAquick spin column in a 2 ml collection tube.
6. To bind DNA, apply the sample to the QIAquick column, and centrifuge for 1
minute.
7. Discard flow-through and place QIAquick column back in the same collection
tube.
8. Add 0.5 ml of buffer QG to QIAquick column and centrifuge for 1 minute.
Discard flow-through.
9. To wash, add 0.75 ml of buffer PE to QIAquick column and centrifuge for 1
minute.
10. Discard flow-through and centrifuge the QIAquick column for an additional 1
minute at ? 10000 x g or 13000 rpm.
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11. Place the QIAquick column into a clean 1.5 ml microcentrifuge tube.
12. To elute DNA, add 50 ?l of buffer EB (10 mM Tris-Cl, pH 8.5) or ddH2O to
the centre of the QIAquick membrane and centrifuge the column for 1 minute
at maximum speed.
(Reference: Qiagen QIAquick® spin handbook.)
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Extraction and purification of plasmid DNA using Qiagen QIAprep Spin
Miniprep kit
Principle:
Small scale extraction and purification of plasmid DNA are carried out using the
QIAprep Spin Miniprep kit from Qiagen (cat.#27104). The QIAprep miniprep
procedure is based on alkaline lysis of bacterial cells followed by adsorption of DNA
onto silica in the presence of high salt. The procedures consist of three basic steps:
preparation and clearing of a bacterial lysate, adsorption of DNA onto the QIAprep
membrane, washing and elution of plasmid DNA. The last 2 basic steps are performed
on a spin column.
Procedures:
Centrifugation note: all centrifugation steps are carried out at maximum speed
(³10000 x g or @ 13000 rpm) in a conventional, table-top microcentrifuge.
1. Centrifuge overnight bacterial culture at 3500 rpm for 10 minutes.
2. Resuspend pelleted bacterial cells in 250 ?l of Buffer P1 and transfer to a
microcentrifuge tube. (Ensure that Rnase A has been added to Buffer P1. No
cell clumps should be visible after resuspension of the pellet.)
3. Add 250 ?l of Buffer P2 and gently invert the tube 4-6 times to mix. (Mix
gently by inverting the tube. Do not vortex, as this will result in shearing of
genomic DNA. If necessary, continue inverting the tube until the solution
becomes viscous and slightly clear. Do not allow the lysis reaction to proceed
for more than 5 minutes.)
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4. Add 350 ?l of Buffer N3 and invert the tube immediately but gently 4-6 times.
(To avoid localized precipitation, mix the solution gently but thoroughly,
immediately after addition of Buffer N3. The solution should become cloudy.)
5. Centrifuge for 10 minutes. (A compact white pellet will form.) During
centrifugation, place a QIAprep spin column in a 2 ml collection tube.
6. Apply the supernatants from step 4 to the QIAprep column by decanting or
pipetting.
7. Centrifuge 30-60 seconds. Discard the flow-through.
8. (Optional): Wash QIAprep spin column by adding 0.5 ml of Buffer PB and
centrifuging 30-60 seconds. Discard the flow-through. This step is necessary
to remove trace nuclease activity when using endA+ strains such as the JM
series, HB101 and its derivatives, or any wild-type strain, which have high
levels of nuclease activity or high carbohydrate content. Host strains such as
XL-1 Blue and DH5aTM do not require this additional wash step.
9. Wash QIAprep spin column by adding 0.75 ml of Buffer PE and centrifuging
30-60 seconds.
10. Discard the flow-through, and centrifuge for an additional 1 minute to remove
residual wash buffer.
11. Place QIAprep column in a clean 1.5 ml microcentrifuge tube. To elute DNA,
add 50 ?l of Buffer EB (10 mM Tris-Cl, pH 8.5) or H2O to the center of each
QIAprep column, let stand for 1 minute, and centrifuge for 1 minute.
(Reference: QIAprep Miniprep Handbook July 1999 page 18-19.)
DocumentsPDFComplete





Extraction and purification of DNA after cycle sequencing
Procedures:
The extension products were precipitated and purified by an ethanol/sodium acetate
precipitation procedure as follows:
1. For each sequencing reaction, prepare a 1.5 ml microcentrifuge tube
containing 2 ?l of 3 M sodium acetate (NaOAc), pH 4.6 and 50 ?l of 95%
ethanol.
2. Pipette the entire contents of each extension reaction into a tube of sodium
acetate/ethanol mixture. Mix thoroughly.
3. Vortex the tubes and place on ice for 10 minutes to precipitate the extension
products.
4. Spin the tubes in a microcentrifuge for 20 minutes at 13000 rpm.
5. Carefully aspirate the supernatant with a pipette and discard.
6. Rinse the pellet with 250 ?l of 70% ethanol.
7. Spin for five minutes in a microcentrifuge at 13000 rpm.
8. Carefully aspirate the supernatant and discard.
9. Dry the pellet (but not over-dry).
(Reference: PE Applied Biosystems. ABI PrismTM BigDye® v3.1 cycle sequencing kit
instruction manual.)
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Extraction and purification of plasmid DNA using Macherey-Nagel NucleoBond
PC10000EF endotoxin-free giga scale plasmid DNA purification kit
Principle:
NucleoBond® EF kits employ a modified alkaline/SDS lysis procedure to prepare the
bacterial cell pellet for plasmid purification. Both chromosomal and plasmid DNA are
denatured under these alkaline conditions. Potassium acetate is then added to the
denatured lysate, which causes the formation of a precipitate containing chromosomal
DNA and other cellular compounds. The potassium acetate buffer also neutralizes the
lysate. Plasmid DNA, which remains in solution, can revert to its native supercoiled
structure. After equilibrating the appropriate NucleoBond® column with equilibration
buffer, plasmid DNA is bound to the anion-exchange resin and finally eluted after
efficient washing of the column. Endotoxins are removed by buffer N3-EF (<0.1
EU/mg). After precipitation of the eluted DNA it can easily be dissolved in TE-EF
buffer or water-EF for further use. Using the NucleoBond PC10000EF endotoxin-free
giga scale plasmid DNA purification kit (Macherey-Nagel), up to 10 mg of purified
plasmid can be extracted from each column. Yield and quality of plasmid DNA
depend on e.g. the type of growing media and antibiotics, the bacterial host, plasmid
type, size or copy number. As a general rule, 1 litre E. coli culture grown in LB
medium yields a pellet of about 3-20 g wet weight. The expected yield for a high-
copy-number plasmid is 1-3 mg per gram wet weight.
Endotoxins (lipopolysaccharide, LPS) are a major component of the Gram-negative
bacterial cell wall. The LPS molecule is an extremely potent stimulator of the
mammalian immune system. LPS is a common contaminant of plasmid DNA
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preparations grown in E. coli. The negative charges associated with lipid A and inner
core of LPS cause the LPS molecule to behave like DNA on anion exchange
chromatography resins. Therefore standard NucleoBond® procedures as well as other
chromatography techniques lead to slightly contaminated plasmid DNA.
Procedures:
(The following protocol is based on the application of up to 2000 ml of LB culture
and maximally 10 g pellet wet weight.)
1. Harvest bacteria by centrifugation at 6000 rpm for 10 minutes at 4oC.
2. Resuspend the pellet of bacterial cells in 120 ml of buffer S1-EF.
3. Add 120 ml of buffer S2-EF. Immediately mix the suspension by gently
inverting the tube 6-8 times. Incubate the mixture at room temperature for 4
minutes.
4. Add 120 ml of pre-cooled buffer S3-EF. Immediately mix the suspension
gently by inverting the flask 6-8 times until a homogeneous suspension is
formed.
5. Centrifuge the mixture at 12000 rpm for 1 hour at 4oC.
6. Equilibrate the NucleoBond AX cartridge with 100 ml of buffer N2-EF.
7. Load the cleared lysate onto the NucleoBond AX cartridge.
8. Wash the cartridge with 3 x 200 ml of buffer N3-EF.
9. Wash the cartridge with 2 x 200 ml of buffer N4-EF.
10. Elute the plasmid DNA with 100 ml of buffer N5-EF.
11. Precipitate purified plasmid DNA with 75 ml of isopropanol. Mix carefully
and centrifuge at 12000 rpm for 30 minutes at 4oC.
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12. Wash precipitated DNA with 10 ml of 70% ethanol prepared from endotoxin-
free water.
13. Centrifuge at 12000 rpm for 10 minutes at 4oC. Discard supernatant carefully.
Repeat washing step once.
14. Remove supernatant and air-dry the pellet.
15. Redissolve the DNA in an appropriate volume of 1x PBS.
16. Determination of DNA yield: Plasmid yield is measured by UV
spectrophotometry by using the following relationship: 1 OD at 260 nm (1 cm
path length) = 50 ?g plasmid DNA/ml.
17. Determination of DNA quality: Plasmid quality is checked by UV
spectrophotometry (quotient 260 nm/280 nm). A value of 1.80-1.95 is an
indication for pure plasmid DNA.
(Reference: Macherey-Nagel endotoxin free plasmid DNA user manual.)
Reagent preparation:
LB (Luria-Bertani)  medium
Sodium chloride    10 g
Bacto-peptone     10 g
Yeast extract     5 g
ddH2O      1000 ml
Mix until the components are completely dissolved, autoclave before use.
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Protocol for rat urine albumin ELISA
Principle:
A direct sandwich ELISA system was developed to detect the concentration of
albumin in urine samples using a “rabbit antiserum vs. rat albumin” (ICN, Cappel,
cat.#55711) as the coating antibody and a “HRP-conjugated sheep monoclonal
antibody vs. rat albumin” (ICN, Cappel, cat.#55776) as the detecting antibody. o-
Diphenylenediamine (OPD), in citrate buffer, pH 5.0, was used as the substrate for
color development. Standard curve was set up using serial dilutions of rat albumin
(ICN, Cappel, rat albumin fraction V cat.#55869) ranging from 31.25 to 2000 ng/ml.
Each sample was done in triplicate. Absorbance reading was taken at 490 nm by a
microplate reader.
Procedures:
1. Coating of 96 wells microtiter plate: 1/2000 of rabbit antiserum vs. rat albumin
in 0.1 M carbonate buffer, 4oC, overnight, 100 ?l in each well.
2. Pipette out the coating antibody and wash with 3 changes of 1x PBS.
3. Blocking: 100 ?l of 1% BSA in 1x PBS with 0.05% Tween 20, 1 hour, room
temperature.
4. Pipette out the blocking solution. Do not wash.
5. Add 50 ?l of standards and diluted urine samples to each well in triplicate.
Add 50 ?l of the diluent to the blank. Incubate for 1½ hours, 37oC.
6. Pipette out the samples and wash with 3 changes of 1x PBS.
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7. Incubate with 50 ?l of HRP-conjugated sheep monoclonal antibody vs. rat
albumin, diluted 1/7500 in 1% BSA in 1x PBS with 0.05% Tween 20, for 1
hour at 37oC.
8. Pipette out the detecting antibody and wash with 3 changes of 1x PBS.
9. Color development: add 50 ?l of OPD substrate in each well and incubate for
8 minutes at room temperature in darkness.
10. Stop reaction with 60 ?l of 4.5 N H2SO4.
11. Read the absorbance at 490 nm using a microplate reader.
Preparation of standards:
· Stock = 20 mg/ml
· Diluent = 0.05% Tween 20 in 1x PBS
· Dilute the 20 mg/ml stock solution 1/100 to 200 ?g/ml: 10 ?l of stock solution
+ 990 ?l of diluent
· Dilute the 200 ?g/ml rat albumin solution 1/100 to 2 ?g/ml: 50 ?l of 200 ?g/ml
rat albumin solution + 4950 ?l of diluent
· Make a 2x serial dilutions from the 2 ?g/ml rat albumin solution as standards
· Concentration of standards: 2000, 1000, 500, 250, 125, 62.5, 31.25 ng/ml
Dilution of urine samples:
· Dilute urine samples 1/500: 2 ?l of urine sample + 998 ?l of 1x PBS with
0.05% Tween 20
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0.1 M Sodium carbonate buffer, pH 9.6
0.2 M Sodium carbonate (Na2CO3)   8 ml
0.2 M Sodium bicarbonate (NaHCO3)  17 ml
ddH2O        25  ml
0.2 M Sodium carbonate (Na2CO3):
Sodium carbonate (Na2CO3)    21.2 g
ddH2O        1000  ml
0.2 M Sodium bicarbonate (NaHCO3):
Sodium bicarbonate (NaHCO3)   16.8 g
ddH2O        1000  ml
Blocking solution
1x PBS      50 ml
BSA       0.5 g
Tween 20      25 ?l
Diluent for standards and urine samples
1x PBS      500 ml
Tween 20      250 ?l
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Phosphate-citrate buffer, pH 5.0   6 ml
OPD (o-Diphenylenediamine)   300 ?l
30% H2O2      3  ?l
Mix OPD with citrate buffer first, add the hydrogen peroxide just before use.
Phosphate-Citrate buffer pH 5.0 for OPD substrate
0.1 M Citrate buffer     24.3 ml
0.2 M Phosphate buffer    25.7 ml
ddH2O        50  ml
0.1 M Citrate buffer:
Citric acid      3.84 g
ddH2O        200  ml
0.2 M Phosphate buffer:
Na2HPO4 (anhydrous)     5.68 g
ddH2O        200  ml
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Determination of serum albumin level
(Randox laboratories cat.#AB388)
Principle:
Serum albumin binds quantitatively to the reagent 5,5-dibromo-o-
cresolsulphonphthalein (bromocresol purple, BCP). The albumin-BCP complex
absorbs maximally at 600 nm.
Procedures:
1. Mix the standard (60 g/L), serum samples and reagent blank as follows:
Reagent blank Standard Sample
BCP reagent 2 ml 2 ml 2 ml
ddH2O 10 ?l --- ---
Standard --- 10 ?l ---
Sample --- --- 10 ?l
2. Incubate for 5 minutes at room temperature.
3. Measure the absorbance of the sample (Asample) and of the standard (Astandard)
against the reagent blank at 600 nm using a cuvette with 1 cm light path.
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Determination of serum cholesterol level
(Randox laboratories cat.#CH201)
Principle:
The cholesterol is determined after enzymatic hydrolysis and oxidation. The indicator
quinoneimine is formed from hydrogen peroxide and 4-aminoantipyrine in the
presence of phenol and peroxidase.
                                                        Cholesterol
Cholesterol-ester + H2O   ------------------>   Cholesterol + Fatty acids
                                                           Esterase
                                          Cholesterol
Cholesterol + O2   ------------------>   Cholestene-3-one + H2O2
                                             Oxidase
                                                                                     Peroxidase
2 H2O2 + phenol + 4-aminoantipyrine   ---------------------->   Quinoneimine + H2O
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1. Mix the standard (5.17 mmol/L or 200 mg/dL), serum samples and reagent
blank as follow:
Reagent blank Standard Sample
ddH2O 10 ?l --- ---
Standard --- 10 ?l ---
Sample --- --- 10 ?l
Reagent 1 ml 1 ml 1 ml
2. Incubate for 10 minutes at room temperature.
3. Measure the absorbance of the sample (Asample) and of the standard (Astandard)
against the reagent blank at 500 nm using a cuvette with 1 cm light path within
60 minutes.
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Determination of serum creatinine level
Principle:
Creatinine reacts with picric acid in alkaline conditions to form a color complex
which absorbs at 510 nm. The rate of formation of color is proportional to the
creatinine concentration in the sample. In the endpoint method the difference in
absorbance measurements after color formation and after acidification yields a
creatinine value corrected for interfering substances. (Unit conversion: mg/dL x 88.4
= ?mol/L)
         alkali
Creatinine + Sodium Picrate ------------------> Creatinine – Picrate complex
(yellow-orange)
Procedures:
1. Label microcentrifuge tube for standards 0.5, 1, 3, 10 mg/dL (Sigma), controls
(Sigma) and serum samples.
2. Pipette into each tube 50 ?l of standards/controls/serum samples, 50 ?l of
ddH2O, 50 ?l of 5% sodium tungstate and 50 ?l of sulphuric acid (2/3 N).
3. Mix well and stand at room temperature for 10 minutes.
4. Centrifuge at 6000 rpm for 2 minutes.
5. Pipette 100 ?l of the supernatant into a 96 wells microtiter plate in duplicate.
6. Add 20 ?l of saturated aqueous picric acid and 30 ?l of 1 N NaOH to each
well.
7. Mix well and stand for at least 20 minutes for color development to complete.
8. Read absorbance at 490 nm using a microplate reader.
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Sodium tungstate   5 g
ddH2O     100 ml
Saturated aqueous picric acid
Picric acid    6 g
ddH2O     500 ml
1 N Sodium hydroxide
Sodium hydroxide   2 g
ddH2O     50 ml
2/3 N Sulphuric acid
Concentrated sulphuric acid  1 ml
ddH2O     55 ml
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Protocol for rat serum IgE ELISA
Principle:
An indirect sandwich ELISA system was developed to detect the concentration of rat
serum IgE. An unconjugated purified mouse anti-rat IgE monoclonal antibody
(Pharmingen, cat.#553914) was used as the coating antibody and a biotin-conjugated
mouse anti-rat IgE monoclonal antibody (Pharmingen, cat.#553916) was used as the
detecting antibody. Avidine-conjugated alkaline phosphatase (Sigma, cat.#E2636)
was then added to bind to the biotin-conjugated secondary antibody. p-Nitrophenyl
phosphate (Sigma, cat.#N2770) was used as the substrate for color development.
Absorbance was taken at 405 nm using a microplate reader after incubation in
darkness for 15 minutes. Standard curve was set up using serial dilutions of rat IgE
(Pharmingen, cat.#558691) ranging from 5-100 ng/ml. Each sample and standard was
done in duplicate.
Procedures:
1. Coating of 96 wells microtiter plate: 1/200 of unconjugated purified mouse
anti-rat IgE monoclonal antibody (Pharmingen, cat.#553914) in 0.1 M
carbonate buffer, 4oC, overnight, 100 ?l in each well.
2. Pipette out the coating antibody and wash with 3 changes of 1x PBS.
3. Blocking: 100 ?l of 1% BSA in 1x PBS with 0.05% Tween 20, 1 hour, room
temperature.
4. Pipette out the blocking solution. Do not wash.
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5. Add 50 ?l of rat IgE standards and serum samples to each well in duplicate.
Add 50 ?l of the diluent for standards to the blank. Incubate for 1½ hours,
37oC.
6. Pipette out the samples and wash with 3 changes of 1x PBS.
7. Incubate with 50 ?l of biotin-conjugated mouse anti-rat IgE monoclonal
antibody (Pharmingen, cat.#553916), diluted 1/200 in 1% BSA in 1x PBS with
0.05% Tween 20, for 1 hour at 37oC.
8. Pipette out the detecting antibody and wash with 3 changes of 1x PBS.
9. Add 100 ?l of ExtrAvidin-Alkaline Phosphatase (Sigma, cat.#E2636) diluted
1/3000 in 1x PBS and incubate at room temperature for 1 hour.
10. Pipette out the enzyme and wash with 3 changes of 1x PBS.
11. Color development: add 100 ?l of p-Nitrophenyl phosphate substrate solution
(Sigma, cat.#N2770) and incubate for 15 minutes at room temperature in
darkness.
12. Read the absorbance immediately at 405 nm using a microplate reader.
Preparation of standards:
· Purified rat IgE, ? monoclonal immunoglobulin isotype standard
(Pharmingen, cat.#558691)
· Stock concentration = 0.5 mg/ml = 500 ?g/ml
· Diluent = 1x PBS + 0.05% Tween 20
· Dilute the stock solution 1/100 to 5 ?g/ml: 5 ?l of stock solution + 495
?l of diluent
· Dilute the 5 ?g/ml rat IgE solution 1/50 to 100 ng/ml: 100 ?l of 5
?g/ml rat IgE solution + 4900 ?l of diluent
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· Prepare the 50, 40, 30, 20, 10, 5 ng/ml standards according to the
following table:
Diluent (?l) 100 ng/ml standard (?l)
50 ng/ml 100 100
40 ng/ml 120 80
30 ng/ml 140 60
20 ng/ml 160 40
10 ng/ml 180 20
5 ng/ml 190 10
Reagent preparation:
0.1 M Sodium carbonate buffer, pH 9.6
0.2 M Sodium carbonate (Na2CO3)   8 ml
0.2 M Sodium bicarbonate (NaHCO3)  17 ml
ddH2O        25  ml
0.2 M Sodium carbonate (Na2CO3):
Sodium carbonate (Na2CO3)    21.2 g
ddH2O        1000  ml
0.2 M Sodium bicarbonate (NaHCO3):
Sodium bicarbonate (NaHCO3)   16.8 g
ddH2O        1000  ml
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PBS        50  ml
BSA       0.5 g
Tween 20      25 ?l
Diluent for rat IgE standards
PBS        500  ml
Tween 20      250 ?l
p-Nitrophenyl phosphate (pNPP) substrate solution
Add 1 pNPP tablet and 1 Tris buffer tablet (Sigma, cat.#N2770) to 20 ml of distilled
water. Mix until the tablets are completely dissolved. The solution should be used
within 1 hour.
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Protocol for rat serum IL-13 ELISA
Principle:
The rat IL-13 ELISA immunoassay kit (BioSource, cat.#KRC0132) is a solid phase
sandwich enzyme linked-immuno-sorbent assay (ELISA). A monoclonal antibody
specific for rat IL-13 has been coated onto the wells of the microtiter strips provided.
Samples, including standards of known IL-13 content, control specimens, and
unknowns, are pipetted into these wells followed by a biotinylated second monoclonal
antibody. During the first incubation, the IL-13 antigen binds simultaneously to the
immobilized (capture) antibody on one site, and to the solution phase biotinylated
antibody on a second site. After removal of excess second antibody, streptavidin-
peroxidase (enzyme) is added. This binds to the biotinylated antibody to complete the
four-member sandwich. After a second incubation and washing to remove all the
unbound enzyme, a substrate solution is added, which is acted upon by the bound
enzyme to produce color. The intensity of this colored product is directly proportional
to the concentration of IL-13 present in the original specimen. Concentration of the
known standards ranges from 7.8 – 500 pg/ml. The minimum detectable dose is 1.5
pg/ml.
Procedures:
1. Add 50 ?l of standard diluent buffer to zero wells.
2. Add 50 ?l of standards or controls to the appropriate microtiter wells.
3. For serum or plasma samples, add 25 ?l of standard diluent buffer to each well
followed by 25 ?l of sample.
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4. Pipette 150 ?l of biotinylated anti-rat IL-13 solution into each well. Mix by
gently tapping on the side of the plate.
5. Cover plate with plate cover and incubate for 2 hours at room temperature.
6. Thoroughly aspirate and discard the liquid. Gently wash wells 4 times with 1x
wash buffer.
7. Add 100 ?l streptavidin-HRP working solution to each well.
8. Cover plate with the plate cover and incubate for 30 minutes at room
temperature.
9. Thoroughly aspirate and discard the liquid. Gently wash wells 4 times with 1x
wash buffer.
10. Add 100 ?l of stabilized chromogen to each well. The liquid in the wells will
begin to turn blue.
11. Incubate for 30 minutes at room temperature and in the dark.
12. Add 100 ?l of stop solution to each well. Tap side of plate gently to mix. The
solution in the wells should change from blue to yellow.
13. Read the absorbance of each well at 450 nm. Read the plate within 2 hours
after adding the stop solution.
(Reference: BioSource Rat IL-13 ELISA, protocol booklet.)
Reagent preparation:
All necessary reagents are supplied within the kit. No reagent preparation is required.
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Haematoxylin & Eosin (H&E) stain
Procedures:
1. Bring sections to water.
2. Stain in Mayer’s haematoxylin solution (Merck, cat.#109249) for 10 minutes.
3. Wash in tap water.
4. Differentiate in 1% acid alcohol.
5. Wash in tap water.
6. Blue nuclei with Scott’s tap water.
7. Wash in tap water.
8. Stain in eosin solution for 15-30 seconds.
9. Wash in tap water.
10. Dehydrate clear and mount.
Results:
Nuclei – blue black
Cytoplasm – various shades of pink
Muscle fibres – deep pinky red
Red blood cell – orange/red
Fibrin – deep pink
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70% Ethanol    99 ml
Concentrated hydrochloric acid 1 ml
Scott’s tap water
Potassium bicarbonate  2 g
Magnesium sulphate   20 g
ddH2O     1 litre
1% Eosin solution
Eosin Y (CI45380)   1 g
Acetic acid (optional)   50 ?l
ddH2O     100 ml
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Periodic acid – Schiff (PAS) stain
Procedures:
1. Bring sections to water.
2. Incubate in 1% periodic acid for 30 minutes.
3. Wash in tap water.
4. Incubate in Schiff’s reagent (Merck, cat.#109033) for 3-5 minutes until the
section become slightly pink. (Bring the Schiff’s reagent to room temperature
before use.)
5. Wash in tap water for 10 minutes.
6. Counterstain nuclei with Mayer’s hematoxylin (Merck, cat.#109249) for 30
seconds.
7. Wash in tap water.
8. Blue in Scott’s tap water.
9. Wash in tap water.
10. Dehydrate, clear and mount.
Results:
Nuclei – Blue black
Glycogen, basement membrane – bright magenta
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Periodic acid    1 g
ddH2O      100 ml
Scott’s tap water
Potassium bicarbonate  2 g
Magnesium sulphate   20 g
ddH2O     1 litre
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Protocol for direct immunofluorescence technique
Principle:
Immunofluorescence technique is an antigen-antibody based method used for the
detection of protein molecules on fresh frozen tissue sections. Direct
immunofluorescence technique involves a single step incubation of the section with
the primary antibody that is conjugated with a fluorescent molecule, such as FITC. No
secondary antibodies are required. Sections are analyzed using a fluorescent
microscope.
Procedures:
1. Cut 8 ?m sections from frozen tissue and mount on poly-L-lysine coated
slides.
2. Fix sections in cold 100% acetone for 10 minutes at 4oC.
3. Air dry for 3 minutes.
4. Incubate sections in 1x PBS for 10 minutes at room temperature.
5. Incubate sections in FITC-conjugated primary antibody optimally diluted in
1x PBS for 30 minutes at room temperature in darkness. Omit primary
antibody and incubate with 1x PBS for negative control.
6. Rinse in 1 change of 1x PBS.
7. Incubate in 2 changes of 1x PBS, 5 minutes each.
8. Mount in fluorescent mounting medium (Dako, cat.#S3023).
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Processing of tissue for transmission electron microscopy
Procedures:
1. Fix tissue in 2.5% glutaraldehyde in cacodylate buffer, pH 7.4 at 4oC
overnight.
2. Wash in 2 changes of cacodylate buffer, 15 minutes each.
3. Post fix in 0.5% aqueous osmium tetroxide for 1 hour at room temperature.
4. Wash in 2 changes of distilled water, 15 minutes each.
5. Put in 2% uranium acetate for 20 minutes.
6. Wash in 2 changes of distilled water, 15 minutes each.
7. 70% ethanol, 5 minutes.
8. 95% ethanol, 10 minutes.
9. 100% ethanol, 10 minutes.
10. 100% ethanol, 15 minutes.
11. 100% Acetone, 10 minutes.
12. 100% Acetone, 10 minutes.
13. 1:1 acetone:resin, 2 hours.
14. 1:3 acetone:resin, 2 hours or until end of the day.
15. Pure resin, overnight.
16. Embed in fresh resin in a BEEM’s capsule with typed label.
17. Cure in 65oC oven for 48 hours.
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· All processing procedures are carried out in room temperature and on a rotator
unless otherwise stated.
· Phosphate buffer may be used in place of cacodylate buffer.
· Use of 2% uranium acetate helps to increase contrast of sections, but is optional.
· All used or unused resin must be cured before disposal.
Reagent preparation:
Cacodylate buffer pH 7.4
Stock A: 0.2 M Sodium cacodylate (M.W. 214)
Sodium cacodylate     42.8 g
ddH2O      1000 ml
Stock B: 0.2 M Concentrated hydrochloric acid (M.W. 36.46)
Concentrated hydrochloric acid   1.7 ml
ddH2O      1000 ml
Working cacodylate Buffer (pH 7.4):
250 ml stock A + 14 ml stock B + 736 ml ddH2O
(Store both the stock and working solution at 4oC)
2.5% Glutaraldehyde
Glutaraldehyde (25% solution)  10 ml
Cacodylate buffer, pH 7.4   90 ml
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0.5% Aqueous osmium tetroxide
Osmium tetroxide (crystal)   0.5 g
ddH2O       100  ml
2% Uranium acetate
Uranium acetate    2 g
ddH2O       100  ml
Filter into a brown bottle. Keep in dark at 4oC.
Araldite CY212 resin
Araldite CY212 resin     90 g
DDSA      80 g
DMP-30     2.5 g
DDSA (Dodecenyl Succinic Anhydride)
DMP-30 (2, 4, 6 – tridimethylamino methyl phenol)
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Sectioning and staining of semithin sections
Procedures:
1. Cut 1 ?m sections with glass knife using ultramicrotome.
2. Transfer the sections onto a drop of water on a glass slide.
3. Place the glass slide on a hotplate set at 90-100oC.
4. Leave slides on the hotplate until the drop of water dried up.
5. Cover the sections with working toluidine blue solution.
6. Leave to stain until the stain at the edge begin to dry up.
7. Rinse thoroughly with distilled water to remove background staining.
8. Put back onto the hotplate to dry.
9. Mount in DPX (BDH, cat.#361254D).
Reagent preparation:
Toluidine blue solution
Stock A: 0.25% Toluidine blue solution
Toluidine blue    0.25 g
ddH2O    100 ml
Stock B: 1% Sodium tetraborate solution
 Sodium tetraborate  1 g
 ddH2O    100 ml
Working toluidine blue solution:
Mix equal parts of stock A and stock B, filter before use. (Store the stock and working
solution at room temperature.)
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Sectioning and staining of ultrathin sections
Procedures:
1. Cut sections of about 100 nm in thickness (Light gold interference color as
observed through the stereo microscope) using diamond knife.
2. Place a piece of filter paper soaked in xylene or acetone closely on top of the
water surface to stretch the sections.
3. Put a copper grid under the water in the trough and pick up the sections.
4. Drain the excess water on a filter paper.
5. Dry at 40-50oC on a hotplate for 15 minutes.
6. Attach the grids onto a gridstick and insert the gridstick into a Pasteur pipette.
7. Pipette in working saturated aqueous uranium acetate solution, stain in dark
for 20 minutes.
8. Remove the stain and rinse in 2 changes of distilled water by pipetting in and
out of the Pasteur pipette.
9. Pipette in working lead citrate solution, stain for 10 minutes.
10. Remove the stain, rinse with 0.05 M sodium hydroxide by pipetting in and out
of the Pasteur pipette for 10 seconds.
11. Rinse in 2 changes of distilled water by pipetting in and out of the Pasteur
pipette.
12. Remove the grids from the gridstick, drain excess water on a filter paper.
13. Dry at 40-50oC on a hotplate for 15 minutes.
(Grids are ready for examination under the electron microscope.)
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Saturated aqueous uranium acetate
Stock solution:
Uranium Acetate  10 g
ddH2O    100 ml
Mix well and stand overnight before use. Store in a brown bottle, keep at 4oC and
inside a metal container.
Working solution:
Pipette out the upper layer of solution into a centrifuge tube. Centrifuge at 3000 rpm
for 10 minutes before use. Store at 4oC and keep away from light.
Reynold’s lead citrate
Stock solution:
1. Add 1.33 g of lead nitrate and 1.76 g of sodium citrate to 30 ml of distilled water
in a breaker and shake for 1 minute. A heavy white precipitate will be formed.
2. Put the breaker on a magnetic stirrer for 30 minutes to facilitate the conversion of
lead nitrate to lead citrate.
3. Add 8 ml of freshly prepared 1 N sodium hydroxide with agitation and dilute to
50 ml with distilled water. The white precipitate of lead citrate will dissolve
during this step.
4. Store at 4oC.
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Pipette out the stock solution into a centrifuge tube. Centrifuge at 3000 rpm for 10
minutes before use. Store at 4oC.
0.05 M Sodium hydroxide
Sodium hydroxide   1 g
ddH2O     500 ml
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Extraction of total RNA by TRIzol® reagent
Principle:
TRIzol® reagent (Invitrogen, cat#15596-026), a mono-phasic solution of phenol and
guanidine isothiocyanate, is a ready-to-use reagent for the isolation of total RNA from
cells and tissues. During sample homogenization or lysis, TRIzol® reagent maintains
the integrity of the RNA, while disrupting cells and dissolving cell components.
Addition of chloroform followed by centrifugation, separates the solution into an
aqueous phase and an organic phase. RNA remains exclusively in the aqueous phase.
After transfer of the aqueous phase, the RNA is recovered by precipitation with
isopropyl alcohol. Total RNA isolated by TRIzol® reagent is free of protein and DNA
contamination. The isolated RNA has an A260/280 ratio of 1.6-1.8 when diluted in




Homogenize tissue samples in 1 ml of TRIzol® reagent per 50-100 mg of tissue
using a power homogenizer. The sample volume should not exceed 10% of the
volume of TRIzol® reagent used for homogenization.
For cell grown in monolayer:
Lyse cells directly in a culture dish by adding 1 ml of TRIzol® reagent to a 3.5 cm
diameter dish, and passing the cell lysate several times through a pipette. The
amount of TRIzol® reagent added is based on the area of the culture dish (1 ml per
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10 cm2) and not on the number of cells present. An insufficient amount of
TRIzol® reagent may result in contamination of the isolated RNA with DNA.
2. Additional isolation
An additional isolation step may be required for samples with high content of
proteins, fat, polysaccharides or extracellular material such as muscles and fat
tissue. Following homogenization, remove insoluble material from the
homogenate by centrifugation at 12000 x g for 10 minutes at 2 to 8oC. The
resulting pellet contains extracellular membranes, polysaccharides, and high
molecular weight DNA, while the supernatant contains RNA. Transfer the cleared
homogenate solution to a fresh tube and proceed with chloroform addition and
phase separation.
3. Phase separation
Incubate the homogenized samples for 5 minutes at 15 to 30oC to permit complete
dissociation of nucleoprotein complexes. Add 0.2 ml of chloroform per 1 ml of
TRIzol® reagent. Cap sample tubes securely. Shake tubes vigorously by hand for
15 seconds and incubate them at 15 to 30oC for 2 to 3 minutes. Centrifuge the
samples at no more than 12000 x g for 15 minutes at 2 to 8oC. Following
centrifugation, the mixture separates into a lower red, phenol-chloroform phase,
an interphase, and a colorless upper aqueous phase. RNA remains exclusively in
the aqueous phase. The volume of the aqueous phase is about 60% of the volume
of TRIzol® reagent used for homogenization.
4. RNA precipitation
Transfer the aqueous phase to a fresh tube. Precipitate the RNA from the aqueous
phase by mixing with isopropyl alcohol. Use 0.5 ml of isopropyl alcohol per 1 ml
of TRIzol® reagent used for the initial homogenization. Incubate samples at 15 to
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30oC for 10 minutes and centrifuge at no more than 12000 x g for 10 minutes at 2
to 8oC. The RNA precipitate, often invisible before centrifugation, forms a gel-
like pellet on the side and bottom of the tube.
5. RNA wash
Remove the supernatant. Wash the RNA pellet once with 75% ethanol, adding at
least 1 ml of 75% ethanol per 1 ml of TRIzol® reagent used for the initial
homogenization. Mix the sample by vortexing and centrifuge at no more than
7500 x g for 5 minutes at 2 to 8oC.
6. Redissolving the RNA
At the end of the procedure, briefly dry the RNA pellet. Dissolve RNA in RNase-
free water by passing the solution a few times through a pipette tip, and incubating
for 10 minutes at 55oC. Partially dissolved RNA samples will have an A260/280
ratio of < 1.6. RNA samples can be stored at –70oC until use.
Reagent preparation:
DEPC treated ddH2O
DEPC (diethylpyrocarbonate)   1 ml
ddH2O       999  ml
Mix and incubate overnight, autoclave to destroy DEPC by causing hydrolysis of
DEPC.
75% Ethanol
Ethanol (analytical grade)   75 ml
DEPC treated ddH2O    25 ml
Prepared in DEPC treated bottle.
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Setup of reverse transcription (RT) reaction
Quantitation of RNA:
1. Yield of RNA in each sample was measured by UV spectrophotometry
(Pharmacia Biotech, Ultrospec 2000) using the following relationship: 1 OD at
260 nm (1 cm path length) = 40 ?g/ml RNA. The purity of RNA sample can
be checked by the A260/A280 absorbance ratio, pure RNA should have a ratio of
2.0.
2. 1000 ng of the total RNA is used in each reaction, amount of the RNA sample
used is based on the concentration of RNA in each sample as determined by
UV spectroscopy.
3. Maximum amount of RNA sample loaded is 10 ?l.
4. Dilution may be required if concentration of RNA in the sample is too high.
Setup of the reverse transcription reaction:





DEPC treated H2O 16 ?l
5x Buffer 1x 8 ?l
RNasin Ribonuclease Inhibitor 20U/20?l 1 ?l
Oligo T 2.5 ?M 2.5 ?l
dNTP 0.5 mM 2 ?l
M-MLV Reverse Transcriptase 40U/200ng RNA 0.5 ?l
Total volume 30 ?l
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2. Aliquot 30 ?l of the master mix into a 0.2 ml PCR tube (DEPC treated).
3. Add the appropriate amount of RNA sample (1000 ng) in each tube.
4. Top up with RNase free water to 40 ?l in each tube.
5. Mix briefly and put on a thermocycler.
6. Run the reaction on the thermocycler as follows:
Temperature Time
37 oC 60 minutes
95 oC 5 minutes
4 oC ?
Reagent preparation and their usage:
RNasin ribonuclease inhibitor (Promega, cat.#N2111)
Supplied: 40 U/?l
Usage: 1 U/?l
Therefore, add 1 ?l for every 40 ?l final reaction mixture.
M-MLV Reverse transcriptase (Promega, cat.#M170A)
Supplied: 200 U/?l
Usage: 200 U/?g mRNA
Therefore, add 1 ?l for every 1000 ng mRNA used.
Since mRNA only make up a small portion of the total RNA, therefore, may use less
reverse transcriptase.
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M-MLV RT 5x reaction buffer (Promega, cat.#M531A)
Supplied: 1 ml containing
250 mM Tris-HCl, pH 8.3 at 25oC
375 mM KCl
15 mM  MgCl2
50 mM  DTT
Usage: 5x dilution
Therefore, add 8 ?l for every 40 ?l of final reaction mixture.
dNTPs (Promega, cat.#U1240)
Supplied: 100 mM (for all dNTPs)
25 mM stock: mix equal volume of the 4 dNTPs to make up 25 mM
Usage: 0.5 mM (1/50 dilution)
Therefore, add 0.8 ?l for every 40 ?l of final reaction mixture.
Oligo T (Operon)
Supplied: refer to data sheet, reconstitute to 100 ?M as stock.
Usage: 2.5 ?M (1/40 dilution)
Therefore, add 1 ?l for every 40 ?l of final reaction mixture
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Programming of real-time PCR reaction on LightCycler
A LightCycler protocol that uses LightCycler FastStart DNA MasterPLUS HybProbe
(Roche, cat.#03 515 567 001) will contain the following parts:
· Pre-incubation (activation of FastStart DNA polymerase and denaturation of
the DNA)
· Amplification of the target DNA
· Melting curve for amplicon analysis (Optional; only needed for single
nucleotide polymorphism or mutation detection)
· Cooling the rotor and thermal chamber
The following table shows the PCR parameters that must be programmed for a normal
LightCycler PCR run with LightCycler FastStart DNA MasterPLUS HybProbe.
Steps Analysis mode Cycles Segment Target temperature Hold time
Pre-incubation None 1 95oC 15 min
Denaturation 95oC 10 s
Annealing Probes Tm – 5oC 5-20 sAmplification Quantification 45
Extension 72oC ? 25 bp/s
Denaturation 95oC 0 s
Annealing Probes Tm – 5oC 30 sMelting curve
analysis Melting curves 1
Melting 95
oC
Slope = 0.1oC/s 0 s
Cooling none 1 40oC 30 s
(Adopted from Roche LightCycler FastStart DNA MasterPLUS HybProbe instruction
manual.)
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Setup of real-time PCR reaction
Procedures:
LightCycler FastStart DNA MasterPLUS HybProbe (Roche, cat.#03 515 567 001)






PCR grade water 5 ?l
Forward Primer 20 ?M 0.25 ?l 0.5 ?M
Reverse Primer 20 ?M 0.25 ?l 0.5 ?M
Probe 1 8 ?M 0.25 ?l 0.2 ?M
Probe 2 8 ?M 0.25 ?l 0.2 ?M
Master Mix x5 2 ?l x1
Total 8 ?l
2. Depending on the total number of reactions, place the required number of
LightCycler capillaries in pre-cooled centrifuge adapters.
3. Pipette 8 µl of the reaction mixture into a capillary tube placing in a pre-
cooled adaptor.
4. Add 2 µl of PCR grade water, cDNA sample or plasmid DNA standards into
capillaries for control, tests and standards respectively.
5. Seal each capillary with a stopper and place the adapters, containing the
capillaries, into a standard benchtop microcentrifuge.
6. Centrifuge at 3000 rpm for 30 seconds.
7. Insert the capillaries into the LightCycler sample carousel and transfer to the
LightCycler PCR machine.
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Principle of quantitative real-time PCR using hybridization probes
Quantitative comparison of gene expression level using conventional thermocylcer
gives only semi-quantitative results because it measures the band intensity of
ethidium bromide-stained PCR products separated on an agarose gel by densitometry.
This is a major drawback in quantitative measurement of gene expression because
inconsistency in preparation of agarose gel, in running conditions of gel
electrophoresis and in image capturing may all affect the final intensity of the bands,
if comparison is not made on the same agarose gel. The procedures are also very
laborious and lack of sensitivity and specificity.
Quantitation of gene expression is possible with real-time PCR because it measured
the Cp (Crossing point) value of the PCR reaction. Cp value is measured during the
exponential growth phase of a typical PCR reaction and is directly related to the
amount of target in the sample. As no agarose gel electrophoresis is required, the
results will be much more reliable and reproducible, not only because it measures the
Cp value but also because it eliminates all the errors that may be introduced in gel
electrophoresis. Moreover, since the PCR reaction was carried out in a capillary tube
with large surface to area ratio, the time for denaturation and annealing was greatly
reduced when compared to conventional thermocylcer, and in turn resulted in a
shorter PCR run.
Specificity can be greatly improved on real-time PCR by using hybridization probes
for the detection of amplification products. In a typical real-time PCR reaction using
hybridization probes, the reaction mixture will contain 1 pair of primers, 1 pair of
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hybridization probes, 5x reaction mixture, PCR grade water and the sample cDNA.
The nucleotide sequence that the hybridization probes will bind to sits within the PCR
product that is being amplified by the primers. Both probes bind to the same strand of
DNA and will only emit signal when they are brought close together (usually
separated by 2 nucleotide base). There will be no contribution of signals from primer
dimers and other non-specific PCR products amplified by the primers because they do
not contain the nucleotide sequence for the hybridization probes to bind or the probes
may not be close enough to allow fluorescence resonance energy transfer (FRET)
even the hybridization probes are able to bind to the non-specific PCR products.
Therefore, the signal generated by hybridization probes is highly specific. It will be
much more desirable to use hybridization probes if the expression level of the target
gene is low.
The pair of hybridization probes consist of two different short oligonucleotides that
bind to an internal sequence of the PCR product amplified by the pair of primers
during the annealing phase of the amplification cycle. One probe is labeled at the 5’-
end with a LightCycler Red fluorophore (LightCycler Red 610, 640, 670 or 705); it is
also 3’- phosphorylated, so it cannot be extended. The other probe is labeled at the 3’-
end with fluorescein. When hybridized to the template DNA, the two probes are close
enough to allow fluorescence resonance energy transfer (FRET) between the two
fluorophores. During FRET, fluorescein (the donor fluorophore) is excited by the
light source of the LightCycler Instrument. Fluorescein transfers part of this excitation
energy to the LightCycler Red dye (the acceptor fluorophore). Then, the LightCycler
Red dye emits fluorescence, which is measured by the LightCycler instrument. (See
the following figure)
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Principle of real time PCR using hybridization probes (Adopted from Proligo)
Roche LightCycler supports two fluorescence-based methods for the detection of
amplification products: DNA binding dye SYBR Green I and hybridization probes.
The fluorescent dye SYBR Green I binds to the minor groove of the DNA double
helix. The unbound dye exhibits very little fluorescence in solution, however, DNA
binding results in a dramatic increase of the SYBR Green I molecules to emit light
upon excitation. Fluorescence measurement was made at the end of the elongation
step of every PCR cycle to monitor the increasing amount of amplified DNA.
Primer dimers will be formed in a PCR reaction when the copy number of the gene
being amplified is low. SYBR green I will emit signal when it binds to double strand
DNA, irrespective of whether it is the PCR product that is amplified by the primers or
the primer dimers. Therefore, signals emitted from SYBR green I are the combined
signal of the desired PCR product and the primer dimers. The contribution of signals
from primer dimers will be very significant if the expression level of the target gene is
low.
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Protocol for indirect immunofluorescence technique
Principle:
Immunofluorescence technique is an antigen-antibody based method used for the
detection of protein molecules on fresh frozen tissue sections. Indirect
immunofluorescence technique involves a 2-step incubation of the section with the
primary antibody and a FITC-conjugated secondary antibody which is raised against
the primary antibody. Sections are analyzed using a fluorescent microscope.
Procedures:
1. Cut 8 ?m sections from frozen tissue and mount on poly-L-lysine coated
slides.
2. Fix sections in 100% acetone for 10 minutes at 4oC.
3. Air dry for 3 minutes.
4. Incubate sections in 1x PBS for 10 minutes at room temperature.
5. Incubate sections in primary antibody diluted in 1x PBS for 30 minutes at
room temperature. Omit primary antibody and incubate with 1x PBS for
negative control.
6. Rinse in 1 change of 1x PBS.
7. Incubate in 2 changes of 1x PBS, 5 minutes each.
8. Incubate sections in FITC-conjugated secondary antibody diluted in 1x PBS
for 30 minutes at room temperature in darkness.
9. Rinse in 1 change of 1x PBS.
10. Incubate in 2 changes of 1x PBS, 5 minutes each.
11. Mount in fluorescence mounting medium (Dako, cat.#S3023).
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Flow cytometric analysis of splenic mononuclear cells
Procedures:
Preparation of single cell suspension
1. Place a 70 ?m nylon sieve (BD FalconTM, cat.#352350) onto a new 50 ml
sterile collection bottle.
2. Cut spleen into smaller pieces and transfer onto the nylon sieve.
3. Wet the tissue with 1x HBSS.
4. Press the tissue through the nylon sieve using the plunger from a 3 ml syringe.
5. Rinse with 1x HBSS intermittently.
6. Pass the filtrate through a 40 ?m nylon sieve (BD FalconTM, cat.#352340) to
remove cell clumps.
7. Count cells with a Neubauer chamber. Dilute the filtrate before counting if
necessary.
Counting of cell by Hemacytometer
1. Make appropriate dilutions of the cell suspension just prior to counting. The
optimal concentration of cells for counting is 5-10 x 105 cells/ml (50-100 cells
per large square).
2. Pipette the cell suspension to fill up the chamber, do not overflow (about 15
µl).
3. Count all of the cells contained in each of the 4 large squares (1-4) (See
diagram).
4. Some cells will be touching the outside borders. Count only those cells
touching two of the outside borders.
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5. A minimum of 200 cells should be counted.
6. Determine the average number of cells per large square. This is the number of
cells per 10-4 ml.
7. Therefore cells/ml = (average number per large square) x 104 x dilution factor.
Staining of cells for flow cytometry
1. Take out 5 million (5 x 106) cells, by calculation based on cell count.
2. Add wash buffer to 500 ?l and mix.
3. Divide equally into 5 tubes. Each tube should contain 1 x 106 cells.
4. Add primary antibody at a ratio of 1 ?g/million cells in 100 ?l of wash buffer.
Concentration of stock primary antibodies:
(FITC) Mouse anti-rat CD3 (T cells): 500 ?g/ml
(FITC) Mouse anti-rat CD45RA (B cells): 500 ?g/ml
(PE) Mouse anti-rat macrophage subset (Macrophage): 200 ?g/ml
DocumentsPDFComplete




Therefore, for every 1 x 106 cells, use
2 ?l of (FITC) Mouse anti-rat CD3 (T cells)
2 ?l of (FITC) Mouse anti-rat CD45RA (B cells)
5 ?l of (PE) Mouse anti-rat macrophage subset (Macrophage)
5. Setup the reaction mixture as follows:




1 Negative control 100 ?l -----
2 IgM-FITC isotype control 100 ?l 10 ?l
3 CD3-FITC (T cells) 100 ?l 2 ?l
4 IgG1-FITC isotype control
IgG2a-PE isotype control
100 ?l 10 ?l
10 ?l
5 CD45RA-FITC (B cells)
Macrophage-PE
100 ?l 2 ?l
5 ?l
6. Vortex the reaction mixture briefly.
7. Incubate for 30 minutes at room temperature in the dark.
8. Add 2 ml of RBC lysis buffer. Vortex briefly. Incubate at room temperature in
darkness for 15 minutes.
9. Centrifuge at 1800 rpm for 2 minutes. Discard the supernatant.
10. Add 2 ml of wash buffer. Vortex to mix.
11. Centrifuge at 1800 rpm for 2 minutes. Discard the supernatant.
12. Repeat washing 2 times with wash buffer.
13. Disperse cells. Resuspend in 300 ?l of wash buffer.
14. Do not fix the cell. Continue with cell acquisition immediately.
(Note: Fluorescent signal of CD45RA will be lost after fixation.)
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1x PBS     990 ml
FBS (1%)     10 ml
Sodium azide, NaN3 (0.1%)   1 g
RBC lysis buffer
155 mM NH4Cl
10 mM KHCO3 (omitted)
0.1 mM EDTA
NH4Cl (MW = 53.5)
1 M = 53.5 g in 1 litre
155 mM = 8.3 g in 1 litre = 4.15 g in 500 ml
EDTA (MW = 372.24)
1 M = 372.24 g in 1 litre
0.1 mM = 0.037 g in 1 litre = 0.0186 g in 500 ml
0.1 M EDTA = 1.86 g in 50 ml ddH2O
To prepare 500 ml of working RBC lysis buffer:
ddH2O         500 ml
0.1 M EDTA     0.5 ml
NH4Cl       4.15  g
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Harvesting of hepatocytes for gene expression study
Procedures:
1. At the end of incubation, remove the culture medium.
2. Rinse with 4 ml of sterile 1x PBS.
3. Incubate with 1 ml of 1x trypsin-EDTA (JRH, cat.#59418) in 1x PBS (sterile)
for 10 minutes at 37oC.
4. Neutralize trypsin with 4 ml of culture medium (10% FBS in DMEM).
5. Transfer the cell suspension into a 10 ml centrifuge tube.
6. Centrifuge at 2000 rpm for 5 minutes, decant the supernatant.
7. Disperse cells, resuspend in 10 ml of 1x HBSS.
8. Centrifuge at 2000 rpm for 5 minutes, decant the supernatant.
9. Disperse cells, add 1 ml of TRIzol® reagent, vortex briefly, stand at room
temperature for 10 minutes. Keep at -80oC.
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Preparation of common reagents
1x Hank’s balanced salt solution (HBSS)
Sterile ddH2O       450  ml
10x HBSS (Gibco BRL, cat.#14065-056)  50 ml
7.5% NaHCO3 solution    2 ml
Before adding of 7.5% NaHCO3 solution, pH of 1x HBSS = 6.52
After adding 2 ml of 7.5% NaHCO3 solution, pH of 1x HBSS = 7.4-7.5
7.5% NaHCO3 solution (MW = 84):
NaHCO3        7.5 g
Sterile ddH20       100  ml
Filtered by 0.22 ?m filter using a syringe.
10x Phosphate buffered saline (PBS)
NaCl        80  g
KCl        2  g
Na2HPO4      14.4  g
KH2PO4      2.4  g
Dissolve in 800 ml of ddH2O, adjust pH to 7.4, adjust volume to 1 litre with ddH2O
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10x PBS stock solution    100 ml
ddH2O        900  ml
Autoclave if necessary.
(When prepared with ddH2O in paediatrics lab, pH of 10x solution = 6.91, after
dilution with ddH2O to 1x PBS, pH = 7.45. Therefore, there is no need to adjust pH
after preparing the 10x solution.)
10x Tris buffered saline (TBS), 0.05 M, pH 7.6
Tris base      60.6 g
NaCl        87.7  g
Concentrated HCl     37 ml
Top up to 1 litre with ddH2O.
1x TBS, 0.05 M, pH 7.6
10x TBS stock solution    100 ml
ddH2O        900  ml
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Volume (ml) of 24-hour urine collected at regular intervals
 Sample Day 0 Day 14 Day 28 Day 42 Day 56 End
C1 16 17 30 33 22 26
C2 20 19 29 29 30 20
C3 30 26 26 27 29 34
C4 14 16 45 34 30 19
C5 15 21 12 17 24 13
C6 16 34 8.5 15 35 19
C7 8 17 10 19 17 23
C8 6 16 12 13 17 23
C9 24 31 18 21 29 25
C10 16 20 18 24 16 15
C11 24 24 27 22 23 25
C12 6 NA 7.5 17 17 33
C13 22 NA 13.5 12 18 20
C14 22 NA 34 45 26 29
C15 20 NA 43 36 48 66
C16 9 NA 16 16 26 38
C17 15 NA 38 20 30 35
J1 9 14 9 14 13 10
J2 15 18 17 38 10 10
J3 36 14 28 57 35 33
J4 24 19 34 20 18 24
J5 35 42 44 28 52 52
J6 14 24 27 30 18 28
J7 14 26 20 20 35 18
J8 22 66 65 30 33 30
J9 20 42 28 21 29 46
J10 30 37 24 21 58 42
J11 17 19 16 25 27 28
J12 8 11 24 21 25 28
J13 12 18 10 21 20 20
J14 16 24 40 28 35 13
J15 24 11 35 30 48 28
J16 12 21 10 20 10 18
J17 24 34 28 19 33 18
J18 13 15 24 21 23 19
J19 26 45 30 NA NA 30
J20 15 19 49 17 26 28
J21 8 21 16 27 42 22
J22 16 36 12 17 NA 17
J23 23 15 31 24 9 34
J24 16 NA 26 34 28 30
J25 18 NA 26 16 29 30
J26 18 NA 14 20 28 32
J27 11.5 NA 14 26 10 12
J28 6.5 NA 21 14 17 16
J29 15 NA 13 20 24 29
J30 10 NA 16 20 15 7
J31 23 NA 32 64 32 25
J32 8 NA 13 30 11 15
J33 16 NA 26 24 22 20
J34 18 NA 17 24 17 10
J35 5 NA NA 16 NA 16
J36 14 NA 22 32 44 27
J37 10.5 NA 18 26 22 22
J38 19 NA 40 37 33 30
J39 7.5 NA 12 38 18 27
J40 16 NA 26 62 40 41
J41 11 NA 16 36 20 15
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Concentration of albumin (?g/ml) in urine measured by ELISA
 Sample Day 0 Day 14 Day 28 Day 42 Day 56 End
C1 11.4 12.5 8.6 9.5 13.8 15.3
C2 16.6 14.4 10.5 9.9 9.0 10.9
C3 6.5 8.0 13.8 9.2 9.9 8.9
C4 28.5 10.1 7.4 8.9 9.9 10.2
C5 11.4 8.9 16.5 14.3 184.5 17.8
C6 11.6 7.7 24.3 13.6 8.4 8.7
C7 24.5 12.8 12.5 10.4 13.6 18.4
C8 26.9 10.5 11.8 12.4 14.8 23.0
C9 10.9 12.1 25.8 11.5 26.2 27.4
C10 14.1 10.8 13.4 12.4 15.3 23.5
C11 11.6 12.3 13.3 13.4 14.8 24.0
C12 14.9 NA 32.6 14.2 16.5 13.6
C13 11.4 NA 10.7 14.9 15.0 9.3
C14 9.7 NA 7.1 11.2 14.7 8.4
C15 11.0 NA 6.7 10.9 14.8 7.5
C16 29.7 NA 14.7 14.4 15.6 8.7
C17 16.7 NA 6.2 13.9 14.9 7.9
J1 14.5 11.1 12.9 10.3 10.5 15.1
J2 12.1 20.9 17.7 19.1 393.0 233.1
J3 8.0 13.2 9.3 1123.6 9.5 39.3
J4 12.6 13.6 20.9 204.0 210.5 129.1
J5 8.8 7.6 7.9 9.2 26.6 181.8
J6 12.0 11.8 10.8 123.8 30.3 136.0
J7 13.2 9.6 11.5 13.5 12.6 251.0
J8 9.4 8.4 11.9 358.4 104.3 253.0
J9 8.9 7.8 8.8 12.7 12.2 16.8
J10 8.6 12.4 9.5 20.1 16.1 44.4
J11 12.5 14.7 17.1 26.4 43.7 107.0
J12 54.6 119.0 198.7 383.4 179.6 174.7
J13 44.1 48.7 95.2 114.5 153.5 66.4
J14 16.0 10.5 9.2 19.2 25.7 119.9
J15 20.9 92.0 43.9 157.8 139.4 244.5
J16 23.8 14.9 33.6 27.4 42.5 104.6
J17 14.2 92.1 19.3 38.3 24.0 107.6
J18 12.0 23.8 20.7 36.0 42.5 158.5
J19 16.6 10.0 402.9 NA NA 402.9
J20 20.6 13.7 10.1 29.8 12.9 86.3
J21 69.8 130.8 126.0 306.5 117.5 83.2
J22 13.6 9.4 330.6 1932.0 NA 1932.0
J23 18.4 46.1 24.0 159.9 590.0 1000.0
J24 12.4 NA 12.5 20.8 48.1 35.1
J25 8.6 NA 8.8 17.6 15.9 35.4
J26 14.2 NA 13.7 44.8 45.5 46.1
J27 13.8 NA 12.3 15.6 22.1 24.5
J28 21.3 NA 10.8 40.2 54.1 72.4
J29 30.9 NA 62.5 151.7 162.8 150.4
J30 23.6 NA 16.0 22.5 28.6 343.5
J31 12.7 NA 7.9 12.6 17.1 56.1
J32 16.0 NA 51.1 37.1 415.7 178.6
J33 9.5 NA 8.7 11.4 20.3 17.4
J34 14.1 NA 17.1 18.7 25.0 147.8
J35 31.9 NA NA 13.7 NA 13.7
J36 17.3 NA 10.8 15.0 21.5 104.2
J37 23.9 NA 4.5 28.3 24.6 107.4
J38 13.4 NA 21.2 42.0 54.6 76.4
J39 21.7 NA 17.2 22.0 22.0 19.0
J40 45.6 NA 93.8 64.9 91.4 120.2
J41 32.6 NA 36.2 104.3 38.2 187.8
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24-hour urine albumin excretion (?g/24hr)
 Sample Day 0 Day 14 Day 28 Day 42 Day 56 End
C1 183 213 258 314 304 398
C2 332 274 305 287 270 218
C3 195 208 359 248 287 303
C4 399 162 333 303 297 194
C5 171 187 198 243 4428 231
C6 186 262 207 204 294 165
C7 196 218 125 198 232 424
C8 161 168 142 161 251 529
C9 262 375 464 242 761 685
C10 225 216 241 298 245 352
C11 278 295 358 295 340 600
C12 89 NA 245 241 280 448
C13 251 NA 144 178 271 186
C14 213 NA 241 503 382 242
C15 221 NA 286 392 710 495
C16 267 NA 235 231 406 332
C17 251 NA 234 278 446 275
J1 131 155 116 144 137 151
J2 181 376 301 726 3930 2331
J3 289 185 260 64045 333 1297
J4 301 258 711 4080 3789 3098
J5 308 319 348 258 1383 9454
J6 169 283 292 3714 545 3808
J7 184 250 231 270 442 4518
J8 206 554 776 10751 3440 7590
J9 178 328 248 268 353 773
J10 258 459 228 422 936 1863
J11 213 279 274 659 1180 2996
J12 437 1309 4770 8051 4490 4891
J13 529 877 952 2405 3071 1328
J14 256 252 368 538 901 1559
J15 501 1012 1537 4734 6693 6846
J16 285 313 336 548 425 1884
J17 341 3131 542 728 791 1937
J18 156 357 497 755 978 3012
J19 432 450 12087 NA NA 12087
J20 308 260 495 506 335 2417
J21 558 2747 2016 8276 4934 1831
J22 218 338 3967 32845 NA 32845
J23 424 692 744 3837 5310 34000
J24 199 NA 325 706 1345 1054
J25 154 NA 228 282 462 1062
J26 255 NA 192 897 1275 1474
J27 159 NA 172 406 221 294
J28 138 NA 226 562 920 1159
J29 464 NA 813 3033 3908 4361
J30 236 NA 257 450 429 2405
J31 292 NA 251 808 547 1404
J32 128 NA 664 1113 4572 2680
J33 152 NA 227 274 446 348
J34 254 NA 291 450 426 1478
J35 160 NA NA 219 NA 219
J36 242 NA 238 481 945 2813
J37 251 NA 81 737 541 2363
J38 254 NA 849 1555 1803 2293
J39 162 NA 207 834 396 512
J40 729 NA 2439 4025 3656 4927
J41 359 NA 579 3755 765 2818
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Serum biochemistry at day 0
Sample Serum albumin (g/L) Serum cholesterol (mmol/L) Serum creatinine (?mol/L)
C1 35.6 1.97 74.3
C2 40.4 1.81 61.9
C3 37.2 1.14 91.1
C4 40.0 1.81 83.1
C5 39.6 1.68 77.8
C6 43.2 1.71 68.1
C7 41.2 1.50 82.2
C8 39.1 2.05 63.6
C9 40.5 1.63 69.8
C10 36.6 1.71 56.6
C11 41.2 1.58 69.0
C12 44.1 1.76 73.4
C13 42.5 1.94 84.9
C14 NA NA NA
C15 41.9 1.76 87.5
C16 51.7 1.58 77.8
C17 50.5 1.97 87.5
J1 40.0 1.99 78.7
J2 36.4 1.74 84.0
J3 40.8 2.12 87.5
J4 40.8 1.71 103.4
J5 44.0 1.71 84.0
J6 43.2 1.99 84.0
J7 37.0 1.79 61.0
J8 40.8 1.40 76.0
J9 43.6 1.53 72.5
J10 42.2 1.53 57.5
J11 38.4 1.58 74.3
J12 44.7 1.76 84.9
J13 41.9 1.63 72.5
J14 44.0 1.97 74.3
J15 44.7 1.66 82.2
J16 42.9 1.63 67.2
J17 46.7 1.58 54.8
J18 46.4 1.63 72.5
J19 45.0 1.71 77.8
J20 41.5 1.63 71.6
J21 45.0 1.74 97.2
J22 41.2 1.48 62.8
J23 38.4 1.66 76.9
J24 44.4 2.05 76.9
J25 45.7 1.84 80.4
J26 53.3 2.02 83.1
J27 47.3 1.94 76.9
J28 47.9 1.81 73.4
J29 46.0 2.15 88.4
J30 47.0 1.89 65.4
J31 45.7 1.42 75.1
J32 45.1 2.10 79.6
J33 41.6 1.86 79.6
J34 48.3 1.76 70.7
J35 47.0 1.42 87.5
J36 48.9 1.45 76.9
J37 49.2 1.63 77.8
J38 NA NA NA
J39 46.3 1.71 84.9
J40 40.6 1.71 94.6
J41 42.2 1.71 69.8
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Serum biochemistry at day 30
 Sample Serum albumin (g/L) Serum cholesterol (mmol/L) Serum creatinine (?mol/L)
C1 40.8 1.71 93.7
C2 39.6 1.55 91.1
C3 38.8 1.24 86.6
C4 49.6 1.40 67.2
C5 45.2 1.14 76.0
C6 46.8 1.74 84.0
C7 NA NA NA
C8 NA NA NA
C9 NA NA NA
C10 NA NA NA
C11 NA NA NA
C12 44.7 1.66 63.6
C13 43.4 2.07 67.2
C14 47.2 2.15 59.2
C15 50.4 1.71 68.1
C16 50.4 1.27 66.3
C17 45.0 1.45 60.1
J1 36.8 4.20 117.6
J2 32.4 2.95 92.8
J3 35.2 2.43 84.0
J4 30.0 3.44 75.1
J5 41.6 1.48 95.5
J6 39.6 1.81 91.1
J7 NA NA NA
J8 NA NA NA
J9 NA NA NA
J10 NA NA NA
J11 NA NA NA
J12 NA NA NA
J13 NA NA NA
J14 NA NA NA
J15 NA NA NA
J16 NA NA NA
J17 NA NA NA
J18 NA NA NA
J19 NA NA NA
J20 NA NA NA
J21 NA NA NA
J22 NA NA NA
J23 NA NA NA
J24 42.4 1.99 66.3
J25 44.7 2.18 70.7
J26 50.7 2.87 69.8
J27 47.6 1.94 64.5
J28 44.4 2.59 63.6
J29 48.5 1.94 64.5
J30 46.9 2.25 61.0
J31 42.4 2.51 70.7
J32 52.0 1.97 76.9
J33 53.6 3.06 57.5
J34 46.6 1.35 69.8
J35 44.7 1.58 70.7
J36 48.2 1.84 81.3
J37 49.8 2.38 68.1
J38 50.4 1.76 71.6
J39 49.8 2.02 53.0
J40 49.8 1.97 76.0
J41 47.2 1.84 72.5
DocumentsPDFComplete





Serum biochemistry at day 60
 Sample Serum albumin (g/L) Serum cholesterol (mmol/L) Serum creatinine (?mol/L)
C1 40.0 1.24 86.6
C2 44.8 1.22 82.2
C3 NA NA NA
C4 48.4 1.24 84.0
C5 46.4 1.19 99.0
C6 47.2 1.66 103.4
C7 45.2 1.45 84.9
C8 38.0 1.24 84.0
C9 44.0 1.76 82.2
C10 49.6 1.42 103.4
C11 41.6 1.40 107.8
C12 41.2 1.55 61.0
C13 37.6 1.81 51.3
C14 45.2 2.51 63.6
C15 NA NA NA
C16 44.8 1.50 59.2
C17 47.2 1.55 54.8
J1 36.0 4.64 101.7
J2 35.2 3.26 80.4
J3 35.2 3.42 84.9
J4 NA NA NA
J5 45.6 1.50 84.0
J6 43.2 1.84 101.7
J7 42.0 1.97 84.0
J8 35.6 4.12 77.8
J9 45.6 2.15 80.4
J10 36.0 2.87 108.7
J11 35.2 3.86 112.3
J12 45.2 1.53 84.9
J13 40.8 1.76 84.0
J14 34.8 2.90 77.8
J15 34.4 3.44 107.8
J16 37.2 2.25 89.3
J17 38.4 1.86 82.2
J18 40.0 2.33 93.7
J19 NA NA NA
J20 39.6 2.33 86.6
J21 34.8 3.65 84.0
J22 NA NA NA
J23 32.8 3.11 91.1
J24 49.6 1.81 54.8
J25 45.6 2.10 74.3
J26 45.2 2.51 61.9
J27 43.2 1.68 71.6
J28 42.0 2.15 49.5
J29 43.6 1.45 51.3
J30 53.6 2.18 68.1
J31 32.4 3.24 57.5
J32 40.8 2.12 61.0
J33 51.6 3.11 63.6
J34 43.6 1.89 64.5
J35 33.6 1.66 61.0
J36 39.2 2.02 48.6
J37 44.0 2.10 63.6
J38 49.6 2.18 65.4
J39 39.2 2.31 61.9
J40 32.8 1.79 54.8
J41 45.6 2.05 64.5
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Serum biochemistry when the rats were sacrificed
Sample Serum IL-13  Serum albumin  Serum cholesterol  Serum creatinine  Serum IgE
(pg/ml) (g/L) (mmol/L) ??mol/L) (ng/ml)
C1 0 37.9 1.81 89.5 107.7
C2 0 41.0 1.94 88.2 74.4
C3 0 42.4 1.53 65.2 14.8
C4 0 56.9 1.63 67.2 3.3
C5 2 38.6 1.81 84.9 2.9
C6 8 49.7 1.97 88.2 10.4
C7 17 33.0 1.61 70.5 35.0
C8 0 32.4 1.58 66.2 4.1
C9 0 35.7 1.74 43.8 57.3
C10 2 39.1 1.55 57.5 18.1
C11 6 32.7 1.68 64.0 57.0
C12 25 47.7 1.58 71.6 8.7
C13 14 47.1 2.07 84.9 4.4
C14 12 46.4 2.10 102.5 10.7
C15 11 42.4 1.50 82.2 2.0
C16 15 56.4 1.55 76.0 7.1
C17 8 46.7 1.55 82.2 11.6
J1 12 40.0 5.91 89.5 46.1
J2 1578 27.9 7.80 69.7 22.6
J3 1073 35.5 5.65 75.7 3.9
J4 376 29.3 5.83 89.5 100.0
J5 167 35.5 4.07 91.5 41.7
J6 32 44.1 2.43 103.3 5.9
J7 62 35.4 1.66 77.8 101.7
J8 232 28.3 4.82 53.1 5.7
J9 33 40.4 2.12 62.6 100.0
J10 90 38.8 3.26 69.1 7.4
J11 28 29.0 4.30 70.5 72.5
J12 21 36.1 1.92 63.3 7.2
J13 61 32.7 2.12 85.0 31.1
J14 54 32.0 3.76 80.7 14.8
J15 336 29.3 4.45 67.6 29.3
J16 31 31.0 2.28 76.4 9.5
J17 57 31.0 2.49 61.2 100.0
J18 37 33.0 2.90 75.7 25.2
J19 1753 18.9 8.78 79.3 57.8
J20 48 38.1 2.62 72.8 12.2
J21 298 33.4 4.01 71.3 37.8
J22 657 15.5 12.20 56.8 32.1
J23 41 30.7 3.60 66.9 8.4
J24 109 51.7 1.86 73.4 20.1
J25 646 53.4 2.07 65.4 5.7
J26 178 49.4 2.90 78.7 9.7
J27 141 50.7 1.89 78.7 6.9
J28 78 34.1 2.25 66.3 37.0
J29 44 48.1 1.68 78.7 37.9
J30 837 43.8 2.41 90.2 9.6
J31 198 32.8 3.32 78.7 3.1
J32 738 49.1 2.28 79.6 10.9
J33 419 58.3 2.82 76.0 37.5
J34 24 39.1 2.07 87.5 10.4
J35 2015 38.1 3.37 74.3 2.4
J36 44 39.4 1.84 78.7 97.0
J37 141 40.4 2.07 70.7 7.7
J38 138 42.4 1.66 89.3 2.2
J39 51 53.0 1.86 57.5 10.1
J40 158 43.8 1.58 61.0 5.1
J41 130 49.1 2.25 92.8 40.5
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Body weight and weight of kidneys, spleen and liver when sacrificed
Sample Body wt Kidney Spleen Liver Kidney Spleen Liver
(gram) (net wt) (net wt) (net wt) (g/100g body wt) (g/100g body wt) (g/100g body wt)
C1 236 0.66 0.57 12.5 0.280 0.242 5.30
C2 266 0.71 0.57 12.0 0.265 0.214 4.51
C3 285 0.82 0.83 15.1 0.288 0.291 5.30
C4 261 0.76 0.66 12.4 0.291 0.253 4.75
C5 273 0.87 0.58 13.3 0.317 0.213 4.87
C6 277 0.72 0.67 14.7 0.258 0.242 5.31
C7 342 0.99 0.97 14.1 0.289 0.284 4.11
C8 299 0.89 0.74 11.3 0.296 0.248 3.78
C9 316 0.90 0.72 10.5 0.284 0.228 3.31
C10 332 0.87 0.64 11.3 0.261 0.193 3.40
C11 320 0.88 0.81 10.7 0.274 0.253 3.33
C12 270 0.97 0.63 8.6 0.360 0.233 3.19
C13 272 0.93 0.75 9.3 0.340 0.276 3.41
C14 241 0.89 0.68 8.9 0.370 0.282 3.69
C15 342 1.20 0.90 12.7 0.350 0.263 3.70
C16 266 0.81 0.72 8.3 0.310 0.271 3.11
C17 298 0.96 0.74 9.1 0.320 0.248 3.05
J1 284 0.83 0.84 18.0 0.292 0.296 6.34
J2 305 1.13 2.09 16.5 0.371 0.685 5.41
J3 259 1.05 1.16 18.3 0.405 0.448 7.07
J4 268 0.99 1.86 19.3 0.370 0.694 7.20
J5 253 0.72 0.56 13.2 0.283 0.221 5.22
J6 292 0.81 0.93 15.8 0.277 0.319 5.41
J7 302 0.84 0.68 11.5 0.277 0.225 3.82
J8 358 1.09 0.99 18.6 0.305 0.277 5.20
J9 321 0.90 4.07 12.2 0.281 1.268 3.80
J10 336 0.88 0.71 12.4 0.262 0.211 3.70
J11 382 1.08 1.17 16.8 0.283 0.306 4.39
J12 312 1.07 0.72 9.6 0.342 0.231 3.06
J13 332 0.98 0.84 13.0 0.294 0.253 3.93
J14 380 1.12 1.07 16.7 0.295 0.282 4.40
J15 336 1.02 1.31 18.1 0.304 0.390 5.40
J16 344 0.86 0.90 12.5 0.249 0.262 3.63
J17 354 0.96 0.97 12.5 0.272 0.274 3.54
J18 387 1.08 0.95 14.9 0.278 0.246 3.85
J19 314 1.29 2.03 9.0 0.411 0.647 2.86
J20 370 1.00 1.00 12.3 0.269 0.270 3.32
J21 353 1.01 0.97 17.3 0.286 0.275 4.91
J22 339 1.29 2.56 10.5 0.381 0.755 3.08
J23 369 1.22 0.85 15.2 0.329 0.230 4.13
J24 305 1.03 1.08 11.4 0.340 0.354 3.75
J25 284 0.96 1.11 10.8 0.340 0.391 3.81
J26 317 1.20 0.97 15.7 0.380 0.306 4.94
J27 262 1.00 0.80 8.4 0.380 0.305 3.19
J28 281 0.85 0.81 11.1 0.300 0.288 3.94
J29 299 0.96 1.02 11.7 0.320 0.341 3.92
J30 313 1.01 0.97 12.3 0.320 0.310 3.92
J31 341 1.14 1.20 15.2 0.330 0.352 4.45
J32 329 1.25 1.21 11.4 0.380 0.368 3.46
J33 258 0.97 0.84 11.2 0.370 0.326 4.35
J34 291 0.96 0.72 8.7 0.330 0.247 3.00
J35 252 0.94 0.95 12.0 0.370 0.377 4.76
J36 319 1.12 0.83 11.0 0.350 0.260 3.45
J37 281 1.00 0.91 12.1 0.360 0.324 4.30
J38 299 1.19 0.99 9.9 0.400 0.331 3.32
J39 261 0.92 0.78 9.4 0.350 0.299 3.61
J40 333 1.08 1.06 13.8 0.320 0.318 4.15
J41 299 1.19 0.88 10.3 0.400 0.294 3.44
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Summary of results on flow cytometric study of splenic mononuclear cells
Sample % T (CD3) % B (CD45RA) % Macrophage
C1 51.3 34.4 7.3
C2 55.8 36.4 6.6
C3 42.8 37.9 15.9
C4 35.6 35.1 16.8
C5 44.5 35.7 11.1
C6 51.7 30.3 7.9
C7 36.7 31.0 2.3
C8 40.4 37.2 3.9
C9 46.5 36.9 4.9
C10 40.4 38.8 7.0
C11 46.3 32.8 8.9
C12 50.9 24.5 8.2
C13 45.3 25.5 10.0
C14 46.5 27.7 3.6
C15 56.4 21.7 8.3
C16 55.8 26.8 5.4
C17 49.0 29.4 10.1
J1 37.3 45.9 7.5
J2 41.1 43.2 3.7
J3 22.7 53.0 8.1
J4 27.4 51.9 8.8
J5 32.3 44.9 12.7
J6 42.9 38.3 6.8
J7 42.3 43.7 4.4
J8 42.2 41.0 5.8
J9 40.3 30.4 8.5
J10 41.4 41.7 13.1
J11 36.7 44.2 3.2
J12 35.8 44.7 10.4
J13 43.7 41.6 3.7
J14 41.3 42.2 5.5
J15 32.8 49.8 8.3
J16 38.5 40.7 6.5
J17 52.3 32.7 5.8
J18 46.8 37.3 5.6
J19 30.7 47.8 5.9
J20 45.5 34.6 5.5
J21 38.7 44.4 8.6
J22 33.2 45.4 4.9
J23 37.3 40.3 9.5
J24 47.0 29.3 11.3
J25 48.3 26.6 8.8
J26 45.1 29.7 14.4
J27 43.4 34.7 8.7
J28 44.1 38.4 6.9
J29 44.3 29.9 6.9
J30 43.6 33.3 7.1
J31 37.1 40.8 6.3
J32 45.3 34.1 8.7
J33 45.3 36.2 6.5
J34 52.5 28.7 8.3
J35 49.8 27.1 9.0
J36 52.0 26.0 9.5
J37 45.5 32.9 9.5
J38 46.5 23.1 6.4
J39 28.1 49.2 6.6
J40 47.4 25.5 14.0
J41 31.8 26.1 9.2
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Glomerular gene expression index standardized against b-actin
Sample Nephrin Podocin Dystro B7-1 IL-4R? IL-13R?1 IL-13R?2 STAT6
C1 0.110 0.225 0.0194 0.0042 0.0104 0.0075 0.0003 0.0166
C2 0.130 0.261 0.0243 0.0059 0.0113 0.0102 0.0005 0.0206
C3 0.126 0.262 0.0338 0.0067 0.0107 0.0120 0.0004 0.0274
C4 0.148 0.202 0.0220 0.0028 0.0113 0.0061 0.0008 0.0128
C5 0.117 0.398 0.0407 0.0033 0.0105 0.0098 0.0022 0.0231
C6 0.143 0.278 0.0276 0.0025 0.0100 0.0075 0.0009 0.0163
C7 0.040 0.052 0.0052 0.0059 0.0019 0.0035 0.0001 0.0125
C8 0.052 0.078 0.0060 0.0001 0.0018 0.0028 0.1227 0.0147
C9 0.053 0.084 0.0074 0.0030 0.0031 0.0027 0.0232 0.0034
C10 0.064 0.076 0.0029 0.0001 0.0007 0.0017 0.0001 0.0323
C11 0.088 0.083 0.0105 0.0041 0.0045 0.0025 0.0290 0.0115
C12 0.198 0.278 0.027 0.0139 0.0087 0.0115 0.0001 0.0444
C13 0.189 0.299 0.021 0.0135 0.0071 0.0078 0.0590 0.0245
C14 0.338 0.026 0.010 0.002 0.0048 0.0065 0.0070 0.0121
C15 0.290 0.543 0.034 0.0049 0.0047 0.0098 0.0058 0.0241
C16 0.370 0.554 0.019 0.0028 0.0047 0.0097 0.0043 0.024
C17 0.306 0.621 0.028 0.0037 0.0039 0.0118 0.0002 0.0192
J1 0.103 0.231 0.0219 0.0034 0.0114 0.0075 0.0023 0.0151
J2 0.011 0.018 0.0071 0.0334 0.0115 0.0078 0.1294 0.0337
J3 0.012 0.025 0.0093 0.0093 0.0129 0.0059 0.0412 0.0291
J4 0.015 0.029 0.0174 0.0138 0.0150 0.0094 0.0089 0.0406
J5 0.112 0.199 0.0312 0.0071 0.0148 0.0097 0.0008 0.0291
J6 0.202 0.412 0.0350 0.0046 0.0130 0.0082 0.0018 0.0206
J7 0.029 0.055 0.0020 0.0046 0.0032 0.0016 0.0210 0.0073
J8 0.005 0.010 0.0016 0.0095 0.0044 0.0021 0.0461 0.0155
J9 0.062 0.112 0.0016 0.0097 0.0061 0.0035 0.0001 0.0216
J10 0.069 0.085 0.0110 0.0056 0.0085 0.0037 0.0457 0.0211
J11 0.031 0.033 0.0032 0.0077 0.0040 0.0022 0.0505 0.0107
J12 0.015 0.021 0.0021 0.0001 0.0052 0.0022 0.0757 0.01
J13 0.031 0.029 0.0045 0.0099 0.0048 0.0029 0.0189 0.016
J14 0.016 0.017 0.0049 0.0052 0.0055 0.0029 0.0786 0.0191
J15 0.001 0.003 0.0013 0.0108 0.0046 0.0019 0.1396 0.0126
J16 0.018 0.013 0.0017 0.0079 0.0042 0.0022 0.0865 0.0129
J17 0.018 0.015 0.0010 0.0063 0.0044 0.0020 0.0189 0.0091
J18 0.019 0.020 0.0046 0.0077 0.0071 0.0032 0.0069 0.0219
J19 0.001 0.004 0.0027 0.0273 0.0082 0.0021 1.4493 0.0216
J20 0.025 0.025 0.0066 0.0037 0.0053 0.0030 0.0195 0.0179
J21 0.007 0.007 0.0028 0.0067 0.0054 0.0024 0.0090 0.0116
J22 0.004 0.002 0.0018 0.0335 0.0044 0.0018 0.3250 0.0151
J23 0.014 0.016 0.0025 0.0059 0.0044 0.0023 0.0725 0.0141
J24 0.103 0.239 0.011 0.0122 0.0151 0.0065 0.0023 0.0341
J25 0.108 0.120 0.012 0.0106 0.0098 0.0044 0.0061 0.0303
J26 0.082 0.110 0.007 0.0085 0.0109 0.0049 0.0020 0.0208
J27 0.188 0.248 0.011 0.009 0.0118 0.0076 0.0040 0.0281
J28 0.167 0.276 0.013 0.0096 0.0183 0.0093 0.0260 0.0287
J29 0.212 0.290 0.034 0.0189 0.0184 0.0096 0.2122 0.0429
J30 0.170 0.232 0.015 0.0117 0.0147 0.0073 0.0041 0.0237
J31 0.095 0.129 0.011 0.0094 0.0113 0.0059 0.0129 0.0215
J32 0.102 0.155 0.008 0.0352 0.0108 0.0060 0.0584 0.0251
J33 0.135 0.105 0.009 0.0073 0.0101 0.0049 0.0032 0.0232
J34 0.173 0.355 0.018 0.0136 0.0151 0.0079 0.0325 0.0375
J35 0.285 0.367 0.015 0.0101 0.0195 0.0099 0.0174 0.0398
J36 0.114 0.157 0.007 0.0096 0.0127 0.0063 0.0053 0.0226
J37 0.234 0.302 0.011 0.0123 0.0152 0.0106 0.0160 0.0181
J38 0.219 0.279 0.018 0.006 0.0130 0.0095 0.0028 0.036
J39 0.269 0.466 0.030 0.0104 0.0145 0.0124 0.0156 0.0331
J40 0.147 0.214 0.010 0.0109 0.0133 0.0064 0.0047 0.0207
J41 0.147 0.496 0.009 0.0075 0.0131 0.0070 0.0234 0.0191
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Hepatic gene expression index standardized against b-actin
 SREBP-2 HMG-CoAR CYP7A1 LDLR IL-4Ra IL-13Ra1 IL-13Ra2 STAT6
C1 0.00614 0.0284 0.0297 0.0238 0.0084 0.00198 0.00044 0.00068
C2 0.00094 0.0384 0.0789 0.0204 0.0066 0.00198 0.00012 0.000117
C3 0.00136 0.022 0.2553 0.0489 0.0102 0.00168 0.00028 0.00018
C4 0.00065 0.0505 0.2642 0.0218 0.0074 0.00195 0.00039 0.00007
C7 0.00208 0.0517 0.2 0.0773 0.007 0.0016 0.00039 0.00005
C8 0.00155 0.0642 0.2753 0.059 0.0096 0.003 0.00021 0.000072
C9 0.00114 0.0296 0.0524 0.017 0.0037 0.00161 0.00013 0.000031
C10 0.00067 0.0242 0.1766 0.0211 0.0051 0.00315 0.00023 0.000036
J1 0.00136 0.0524 0.2253 0.0151 0.0107 0.00299 0.00094 0.000048
J2 0.00024 0.0626 0.3869 0.0148 0.0079 0.0025 0.00434 0.000059
J3 0.00086 0.0543 0.3773 0.0175 0.0108 0.00172 0.0039 0.000049
J4 0.00082 0.0692 0.4679 0.0179 0.0142 0.00195 0.00397 0.000153
J5 0.00077 0.0588 0.1093 0.0215 0.0142 0.00274 0.00205 0.000022
J8 0.00186 0.0552 0.2723 0.02 0.011 0.00319 0.0018 0.000064
J11 0.00103 0.0597 0.6084 0.0564 0.0193 0.00725 0.0019 0.000139
J15 0.00077 0.0408 0.3118 0.0244 0.0079 0.00425 0.00347 0.000161
J19 0.00199 0.1027 0.8432 0.0197 0.0095 0.00376 0.0035 0.000051
J21 0.00109 0.0541 0.3397 0.0301 0.0067 0.004 0.00276 0.000041
J22 0.00127 0.0742 0.2836 0.0121 0.0055 0.00305 0.00178 0.000043
J26 0.00136 0.018 0.0245 0.0407 0.0066 0.00131 0.00327 0.000068
J31 0.00294 0.0275 0.3728 0.1708 0.008 0.00106 0.00482 0.000048
J35 0.00188 0.0586 0.2735 0.0684 0.0079 0.00157 0.00469 0.000129
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Gene expression index of hepatocyte cell line incubated with recombinant IL-13
standardized against b-actin
SREBP-2 HMG-CoAR LDLR IL-4Ra IL-13Ra1 IL-13Ra2 STAT6
C1 0.00714 0.00707 0.00606 0.000478 0.000452 0.0000154 0.00278
C2 0.00833 0.00694 0.00680 0.000454 0.000514 0.0000136 0.00294
C3 0.00712 0.00727 0.00621 0.000479 0.000524 0.0000149 0.00286
C4 0.01209 0.00684 0.00796 0.000431 0.000556 0.0000150 0.00366
C5 0.01187 0.00732 0.00776 0.000482 0.000593 0.0000181 0.00384
C6 0.01518 0.00836 0.01099 0.000605 0.000626 0.0000219 0.00477
50ng (1) 0.00921 0.00811 0.00820 0.000536 0.000598 0.0000351 0.00362
50ng (2) 0.00942 0.00788 0.00723 0.000544 0.000601 0.0000319 0.00373
50ng (3) 0.01309 0.00834 0.01068 0.000631 0.000624 0.0000404 0.00426
50ng (4) 0.01318 0.00854 0.00972 0.000692 0.000616 0.0000411 0.00444
50ng (5) 0.01344 0.00977 0.01085 0.000675 0.000682 0.0000420 0.00421
50ng (6) 0.00894 0.00850 0.00865 0.000638 0.000590 0.0000412 0.00372
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